WO2005108429A1 - 新規可溶性cd14抗原 - Google Patents
新規可溶性cd14抗原 Download PDFInfo
- Publication number
- WO2005108429A1 WO2005108429A1 PCT/JP2005/008635 JP2005008635W WO2005108429A1 WO 2005108429 A1 WO2005108429 A1 WO 2005108429A1 JP 2005008635 W JP2005008635 W JP 2005008635W WO 2005108429 A1 WO2005108429 A1 WO 2005108429A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- fragment
- soluble
- antigen
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Definitions
- the present invention relates to a novel in vivo antigen that can be a diagnostic marker for sepsis.
- the present invention also relates to a method for diagnosing sepsis, which comprises measuring the antigen, a kit for measuring the antigen using a specific antibody, and a method for measuring the same. Further, the present invention relates to a recombinant soluble fragment useful as a standard substance of the measurement kit, an antibody binding to the fragment, a method for producing the fragment, and a method for screening an antibody using the fragment.
- the CD14 molecule was named at the 3rd Leukocyte Typing Conference in 1986 as a protein identified by a group of antibodies that recognize glycoproteins expressed on the membrane surface of mononuclear cells. 1990, revealed that Wright et al is a receptor of LPS is the CD14 molecule force endotoxin ( "Science (Science)” (the United States), 1990, 249 Certificates, p.l431 - 1433) 0 this CD14 Analysis of the cDNA revealed that the molecule is a glycoprotein with a molecular weight of 53-55 kDa and that the mRNA is approximately 1.4 kb in size and consists of 356 amino acids ("Nucleic Acids Research” (UK) ), 1988, Vol. 16, p.4173) 0
- Human CD14 molecules include soluble CD14 in addition to membrane-bound CD14, and it has been reported that there are multiple soluble CD14s having different molecular weights in blood (“Yoguchi Bian”). Journal of Immunology (Germany), 1993, Vol. 23, pp. 2144-2151). Landmann et al. Performed Western blot analysis of soluble CD14 in the serum of patients with sepsis, and found that soluble CD14 of approximately 55 kDa was high in patients with septic death and paroxysmal nocturnal hemoglobinuria (PNH).
- PNH paroxysmal nocturnal hemoglobinuria
- soluble CD14-ELISA kit power BL-Hamburg released by Medgenix, R & D Systems, has been used to measure soluble CD14 in many diseases including sepsis ("Tali-Cal Immunology and Immunopathology ( Clinical Immunology And Immunopathology) ”(USA), 1996, Vol. 80, pp. 307-310;“ Clinical Testing ”, 1994, Vol. 38, pp. 341-344).
- the soluble CD14 containing about 55 kDa and 49 kDa described above according to the degree of disease progression (reported, its molecular weight is different, so it is not limited to about 55 kDa and 49 ka.
- concentration increased and it became clear that soluble CD14 was not a marker specific to sepsis (“Infection and Immunity” (USA), 1999, Vol. 67). , P.417-420; “Clinical and Experimental Immunology” (UK), 2000, Vol. 120, p.483-487; “Tally and Experimental Immunology” Clinical Experimental Immunology) "(UK), 1994, Vol. 96, p.15-19).
- soluble CD14 does not show any correlation with severe septic shock, which was expected as a marker for the severity of sepsis (“Pediatric allergy and immunology” (Denmark)). 1997, Vol. 8, p. 194-199), because there is no correlation with the systemic inflammatory response syndrome (SIRS) ("Joichi Bian Journal of Cry-Rinore Investigation ( European Journal of Clinical Investigation) "(UK), 1998, Vol. 28, p.672-678), a powerful diagnostic agent for sepsis.
- SIRS systemic inflammatory response syndrome
- the amount of low-molecular-weight CD14 in blood is indirectly obtained by subtracting the amount of high-molecular-weight CD14 in blood from the total amount of soluble CD14 in blood ( International Publication No. WO01Z22085).
- kits and a method for measuring the antigen using a specific antibody are desired.
- a method for screening an antibody useful for measuring the antigen is desired.
- a recombinant soluble fragment having a similar immunological function to the antigen and a method for producing the fragment are desired.
- the present invention has invented a recombinant soluble fragment having immunologically similar properties to the antigen, a method for producing the fragment, and an antibody which specifically binds to the fragment.
- an antibody that specifically binds to a peptide consisting of a specific amino acid sequence of human full-length soluble CD14 or a fragment of the antibody;
- Invented are a kit and a method for measuring the antigen, which comprise, as a component, an antibody produced as a fragment or a fragment of the antibody, or an antibody that specifically binds to the fragment or a fragment of the antibody. did.
- soluble CD14 antigen can be referred to as “soluble CD14 protein”.
- fragment is used to mean that "recombinant soluble CD14 fragment” has a partial sequence of human full-length soluble CD14 that can be called “recombinant soluble CD14 protein”.
- “Fragment” is a general term I can do it. Also in the present invention, it is a part of the protein that also has partial sequence power of the amino acid sequence of the target protein, and the difference between the three-dimensional structure of the protein and the attached protein such as sugar chains or lipids is different from that of the target protein. Is not particularly questionable.
- the present invention provides the following (1) to (13).
- a method for measuring the soluble CD14 antigen of (1) contained in a specimen which comprises an antibody or a fragment of the antibody that specifically binds to at least one soluble CD14 antigen of (1) above
- a kit for measuring soluble CD14 antigen
- An antibody or a fragment thereof which specifically binds to at least one of the soluble CD14 antigens of the above (1) is specifically bound to the soluble CD14 antigen of the above (1).
- the antibody specifically bound to the fragment prepared in 2) is A step of selecting as an antibody useful for measuring the soluble CD14 antigen.
- a method for producing the recombinant soluble CD14 fragment of the above (2) which comprises the following steps: 1) A method for producing a recombinant soluble CD14 fragment having the following sequence of 1) to 4) About
- the C-terminus is any of positions 134 to 356 of SEQ ID NO: 3,
- the present invention provides the following novel soluble CD14 antigen, recombinant soluble CD14 fragment, and a novel method for diagnosing or detecting sepsis.
- a novel soluble CD14 antigen represented by the following (11) or (12):
- step (1) a recombinant soluble CD14 fragment having the following sequences (4) to (7) is prepared:
- N-terminus is a deviation from positions 1 to 17 of SEQ ID NO: 3
- the C-terminus is any of positions 134 to 356 of SEQ ID NO: 3, and
- step 7) of ⁇ 1> the predetermined protease is ProScission Protease, and the sequence of the cleavage site is Leu, Glu, Val, Leu, Phe, Gin, Gly, Pro.
- step 7) of step 1) the predetermined proteolytic enzyme is Thrombin and the sequence power of the cleavage site is SLeu, Val, Pro, Arg, Gly, Ser. Recombinant soluble CD14 fragment.
- step 5 of ⁇ 1>, the N-terminal is any one of positions 1 to 6 of SEQ ID NO: 3
- step 5 of ⁇ 1>! /,
- the N-terminus is the first position of SEQ ID NO: 3 (2-2) to (2-4)! , Some recombinant soluble CD14 fragments.
- step 7) of step 1) the sequence strength of the cleavage site of the predetermined protease is substituted or inserted after any of the positions 59 to 80 in SEQ ID NO: 3. Yes (2—
- step 7) of step 1) the sequence strength of the cleavage site of the predetermined protease is substituted or inserted after any of positions 64 to 75 of SEQ ID NO: 3 (2 —
- step 7) of step 1) the sequence strength of the cleavage site of the predetermined protease is substituted or inserted after position 64 of SEQ ID NO: 3!
- step 5) of ⁇ 1> the N-terminus is position 1 of SEQ ID NO: 3, and in 7) the sequence of the cleavage site of the specified protease is after position 64 of SEQ ID NO: 3.
- the C-terminus is any of positions 59 to 90 of SEQ ID NO: 3.
- the N-terminus is at position 1 to position 17 of SEQ ID NO: 3, and
- (4-1) A method for diagnosing or detecting sepsis, which comprises measuring the soluble CD14 antigen of the above (1).
- the present invention provides the following novel soluble CD14 antigen assay kit and assay method.
- the recombinant soluble CD14 fragment of (2) or (3) is prepared as an antigen.
- the soluble CD14 antigen of the above (1) is measured by a sandwich immunoassay shown in any one of the following (5-6-1) to (5-6-19).
- a kit for measuring the soluble CD14 antigen which is an antibody or a fragment of the antibody (5-6-2).
- the second specific binding substance that forms the second specific binding substance or the partner of the second specific binding substance binds to the insoluble carrier, and (5-6-11) to (5-6)
- the second specific binding substance that forms the second specific binding substance or the partner of the second specific binding substance is labeled (5-6-11) to (5-6-15). 6-13) !, a kit for measuring soluble CD14 antigen.
- (5-6-16) Contains a labeled soluble CD14 antigen of the above (1) or a labeled analog of the soluble CD14 antigen of the above (1), which is measured by a sandwich immunoassay by a competitive method (5-6-1)
- the label is a label with at least one of an enzyme, a dye, colloidal gold, colored latex, a chemiluminescent substance, a fluorescent substance, or an isotope (5-6-9), (5-6 6-10), (5-6-15) or (5-6-16) !, a kit for measuring soluble CD14 antigen.
- the labeled analogous substance of the soluble CD14 antigen of the above (1) is the labeled recombinant soluble CD14 fragment of the above (2). Measurement kit.
- the antibody of any of the above a) to c) or a fragment of the antibody is bound to an insoluble carrier, and the second binding substance is the antibody of the above d) or the antibody of the antibody.
- (6-1) at least one antibody or a fragment thereof which specifically binds to the soluble CD14 antigen of the above (1) is specifically bound to the soluble CD14 antigen of the above (1).
- the immunological method for measuring the soluble CD14 antigen according to the above (1) is specifically measured.
- An antibody that specifically binds to the soluble CD14 antigen of the above (1) or a fragment of the antibody may be any one of the following a) to d) or a fragment of the antibody: (6-1) an immunological assay method for the soluble CD14 antigen,
- the present invention provides a novel antibody and a method for screening an antibody useful for measuring the soluble CD14 antigen of the above (1).
- (9-1) An antibody that specifically binds to the recombinant soluble CD14 fragment of (3) above. (9-1) The antibody of (9-1), which does not substantially bind to the full-length soluble CD14 protein in human blood, but binds to the recombinant soluble CD14 fragment of (3).
- the antibody prepared in the above step 1) is selected from the amino acid sequences of SEQ ID NO: 3 in which the N-terminal amino acid sequence power from 1 to 314 is also selected.
- (10-1) The screening method according to (10-1), wherein the antibody is an antibody that specifically binds to a peptide having amino acid residues.
- the antibody prepared in the above step 1) is an antibody prepared using a peptide consisting of consecutive 8 to 30 amino acid residues selected from the amino acid sequence of SEQ ID NO: 3 as an antigen.
- (10-1) The screening method according to (1), wherein
- the screening method according to (10-1), wherein the liquid to be measured prepared in the step 2) is a normal human body fluid or a sample of human high molecular weight CD14.
- a labeled antibody for the antibody prepared in 1) is further prepared, and the antigen immobilization method composed in the step 3) is performed by binding the liquid to be measured to an insoluble carrier in 2). And (4) the screening method according to (10-6), wherein the antibody prepared in 1) and the labeled antibody are sequentially reacted with the measurement system based on the antigen immobilization method constituted in 3).
- the step of evaluating and selecting in 5) above is characterized by evaluating that the antibody prepared in 1) does not specifically bind to high molecular weight CD14 and selecting. (10-6) or the screening method of (10-7).
- the liquids to be measured prepared in the step 2) are a body fluid of a normal person and a body fluid of a sepsis patient.
- the immunoassay system composed of the above step 3) is a sandwich assay using the two antibodies prepared in 1) and 1) 1 (2).
- the step of evaluating and selecting the antibody in 5) above is a sandwich in which the measurement result of the body fluid of a normal person is compared with the measurement result of the body fluid of a sepsis patient, and the difference in the compared measurement results is a useful sandwich diagnosis for sepsis.
- This is a step of evaluating and selecting an antibody to be used for the immunoassay.
- the method according to the first aspect of the present invention which is a method for screening a combination of antibodies for use in a sandwich immunoassay method useful for measuring the soluble CD14 antigen (10-10) — 9) Screening method.
- the antibody prepared in 1) or 1)-(2) is bound to an insoluble carrier, and constituted. 9) or the screening method of (10-10).
- the antibody prepared in 1) or 1)-(2) is labeled and constituted (10-9) or (10 10) The screening method.
- the prepared antibody is specific to a protein having the amino acid sequence power of any of 6 to 356 selected from the amino acid sequence powers selected from SEQ ID NO: 3.
- the screening method according to (11) which is an antibody that binds specifically.
- the antibody prepared specifically binds to a protein containing at least 7 contiguous amino acid residues at which positions 53 to 68 described in SEQ ID NO: 3 are also selected.
- (11-1) The screening method according to (11-1),
- the system for evaluating the specific binding by reacting in the step (3) is the antigen immobilization method, wherein One Jung way.
- the system for evaluating specific binding by reacting in the step (11-5) 3) is a sandwich immunoassay, wherein Screening method of Jung.
- the system for evaluating specific binding by reacting in the step of (3) is an analysis method for interaction between biomolecules, which is characterized in that Screening method.
- the present invention provides a method for producing the following specific and soluble soluble CD14 fragment of the above (2).
- (12-1) a method for producing the recombinant soluble CD14 fragment of the above (2-3), comprising the following steps;
- the C-terminus is any of positions 134 to 356 of SEQ ID NO: 3
- the sequence of the cleavage site of the predetermined protease is substituted or inserted after positions 59 to 70 of SEQ ID NO: 3.
- step 4) of ⁇ 1> the predetermined protease is ProScission Protease, and the sequence of the cleavage site is Leu, Glu, Val, Leu, Phe, Gin, Gly, Pro. (12-1) The method for producing the recombinant soluble CD14 fragment according to the above (2-3).
- step 4) of ⁇ 1> the predetermined protease is Thrombin and the sequence power of the cleavage site is SLeu, Val, Pro, Arg, Gly, Ser. (2-3) The method for producing a recombinant soluble CD14 fragment.
- novel soluble CD14 antigen of the present invention is useful as a diagnostic marker for sepsis patients. Further, the soluble CD14 antigen can be a standard substance or a competitor used for measuring the soluble CD14 antigen.
- the recombinant soluble CD14 fragment of the present invention since the recombinant soluble CD14 fragment of the present invention has immunologically similar properties to the soluble CD14 antigen, it can be used as a standard substance or a competitor for measuring the soluble CD14 antigen, It can be used for screening for antibodies that can be used for the measurement.
- the immunologically similar properties to the soluble CD14 antigen means that the binding property to the known CD14 antibody and the binding property to the antibody binding to the soluble CD14 antigen are the recombinant soluble properties of the present invention.
- the CD14 fragment shows that the soluble CD14 antigen is almost identical to the recombinant soluble CD14 fragment of the present invention.
- kit and method for measuring the soluble CD14 antigen of the present invention include the soluble CD1 antigen.
- the antigen can be qualitatively or quantitatively determined with high sensitivity, easily and specifically, and is useful for diagnosis of sepsis patients.
- the screening method of the present invention is useful for searching for an antibody to be used for measuring the novel soluble CD14 antigen.
- the method for producing a recombinant soluble CD14 fragment of the present invention is a method for producing a recombinant soluble soluble CD14 fragment which has not been able to be expressed in prokaryotic cells or eukaryotic cells, particularly yeast cells. Enable production.
- FIG. 1 is a view showing the result of the result that only the S68 peptide inhibits the binding between the S68 peptide polyclonal antibody and the soluble CD14 antigen of the present invention.
- A shows the state of no binding in the serum of a normal human
- B shows the inhibition of binding of the S68 peptide in the serum of a sepsis patient.
- FIG. 2 is a diagram showing a standard curve of the EIA kit of Example 7- (1) using sCD14 (1-307) S286C protein.
- FIG. 3 is a diagram showing that soluble CD14 antigen derived from normal human serum has no effect on the measured value of the EIA kit of Example 7- (1) using sCD14 (1-307) S286C protein. .
- FIG. 4 shows the results obtained by analyzing the soluble CD14 antigen and the high molecular weight CD14 protein detected in the blood of a sepsis patient by gel filtration chromatography using the EIA kit of Example 7- (1), respectively.
- FIG. 7 is a diagram showing the results of analysis using the EIA kit and the commercial CD14-EIA kit (IBL-Hamburg).
- FIG. 5 shows that soluble CD14 antigen and high molecular weight CD14 protein detected by the EIA kit of Example 7- (1) in the serum of a sepsis patient by gel filtration chromatography were measured in Example 7- (1).
- FIG. 8 shows the results of analysis using an EIA kit and a commercial CD14-EIA kit (IBL-Hamburg). The upper black arrow indicates the position of the marker used for calibration. Left power and others are BSA, ovalbumin, chymotrypsinogen A, and ribonuclease A.
- Figure 6 shows the fraction obtained by passing the serum from a sepsis patient through an S68-Sepharose TM 4FF antibody column using F1024-1-3-3-Sepharos TM 4B as a pre-column, followed by gel filtration chromatography.
- the soluble CD14 antigen and the high molecular weight CD14 protein detected by the EIA kit of Example 7- (1) were respectively combined with the EIA kit of Example 7- (1) and the commercially available CD14-EIA kit (IBL-
- FIG. 7 is a diagram showing the results of analysis by Hamburg. The upper black arrow is the same as in FIG. [FIG. 7]
- FIG. 7 is a diagram showing the results of subjecting gel fractionation chromatography fractions 10-16 shown in FIG. 6 to individual freeze-drying and western blotting.
- Figure 8 shows that the fraction obtained after passing normal human serum through an S68-Sepharose TM 4FF antibody column using F1024-1-3-3-Sepharos TM 4B as a precolumn was fractionated by gel filtration chromatography.
- FIG. 4 is a diagram showing the results of fractions 10-16 individually subjected to lyophilization and subjected to western blotting.
- FIG. 9 is a view showing an image of purified rsCD14-ST (2ST64) and (PSP64) stained by silver staining after swimming by SDS-PAGE.
- FIG. 10 is a view showing a western blotting image of sCD14-ST and PSP64 stained with an S68 antibody.
- FIG. 11 is a view showing a standard curve of an EIA kit of Example 16 using rsCD14-ST (2ST64).
- FIG. 12 is a graph comparing the antibody titer of anti-sera of rabbits to which rsCD14-ST (PSP64) had been administered, compared to that of normal serum of normal rabbits.
- FIG. 13 is a diagram showing a standard curve of an EIA measurement system of Example 19 using rsCD14-ST (2ST64).
- the major soluble CD14 proteins present in human blood include the approximately 55 kDa and approximately 49 kDa soluble CD14 proteins described in Landmann et al., Described in the Prior Art section. These are human full-length soluble CD14 proteins and proteins that have a C-terminal length of 41 amino acids or less and are not deleted from human full-length soluble CD14 protein (hereinafter ⁇ human '' is abbreviated and described as high molecular weight CD14). Sometimes). In WO01Z22085, it has been confirmed that these high molecular weight CD14 specifically binds to the F1025-3-1 antibody.
- the present inventors differed from the high molecular weight CD14 described above and the CD14 having a molecular weight of 36 kDa described in WO01Z22085, and are present in the blood of septic patients more frequently than in normal persons. New soluble CD14 protein was found.
- soluble CD14 protein refers to a protein present in human plasma (or human serum), and can also be referred to as “soluble CD14 protein”. You. In particular, when used in the meaning of "membrane-bound CD14 protein" which is bound to cell membranes and does not exist in human plasma, it is described as “soluble CD14 protein”!
- the "antibody prepared using a peptide or fragment or the like as an antigen” or the “antibody prepared using a peptide or fragment or the like as an antigen” described in the present invention refers to a peptide or fragment used as an "antigen" These antibodies are produced or produced by immunizing various animals.
- the antibody comprises a peptide or fragment that serves as an "antigen” or a part of the epitope.
- the antibody specifically binds to a peptide or fragment that serves as an “antigen”.
- the "antibody produced as an antigen” or the “antibody produced as an antigen” may be added with a carrier or carrier protein to make the peptide to be an "antigen” immunogenic, or may have other amino acid residues. Even an antibody prepared as an immunogen using a peptide to which a group has been added is included in “an antibody prepared as an antigen” or “antibody prepared as an antigen” if it exhibits the above properties.
- the "specifically binding antibody” is an antibody that immunologically binds to a specifically binding target or an antibody that shows a normal antigen-antibody reaction with a specifically binding target.
- an antigen-antibody reaction can be confirmed by an agglutination method, a sandwich method, a solid-phase direct method or a solid-phase binding method, a competition method, or the like.
- the dissociation constant (KD) is usually less than 10 -7 M. If no dissociation constant measurement can be obtained in the binding test, state that there is substantially no binding.
- non-specific binding cannot be confirmed when the binding ability is 10 times or less, preferably 100 times or less, more preferably 1,000 times or less as compared with the case of "specifically bind". , In which case they are not substantially combined.
- Does not bind to LPS means that the recombinant soluble CD14 fragment has no or little binding ability to LPS.
- In vivo full-length CD14 or human full-length soluble CD14 protein described in SEQ ID NO: 3 has an ability to bind to LPS in vivo or in serum. And the complex activates the cells.
- the recombinant soluble CD14 fragment that does not bind to LPS has at most 1Z100 or less than the ability to bind LPS to full-length in vivo CD14 or human full-length soluble CD14 protein described in SEQ ID NO: 3. It is.
- a first embodiment of the present invention is a soluble CD14 antigen having the following properties 1) to 3).
- the soluble CD14 antigen according to the first aspect of the present invention has the above property 1). That is, a band derived from the soluble CD14 antigen according to the first aspect of the present invention is detected at a position having a molecular weight of 13 ⁇ 2 kDa by SDS-PAGE under non-reducing conditions.
- the soluble CD14 antigen according to the first aspect of the present invention has the above property 2).
- the amino acid sequence of SEQ ID NO: 1 is identical to the N-terminal amino acid sequence of human CD14 of SEQ ID NO: 3. This confirms that the soluble CD14 antigen of the first embodiment of the present invention is a kind of human CD14.
- the soluble CD14 antigen according to the first aspect of the present invention has the above property 3).
- the peptide having the amino acid residue power described in SEQ ID NO: 2 described in the above feature 3) corresponds to 16 amino acid residues from position 53 to position 68 of human CD14 described in SEQ ID NO: 3.
- other human proteins including the sequence of SEQ ID NO: 2 are not known except human CD14, and it can be said that this sequence is a sequence specifically contained in human CD14. This also confirms that the soluble CD14 antigen of the first embodiment of the present invention is a kind of human CD14.
- the soluble CD14 antigen of the first aspect of the present invention is further characterized by the following property 4).
- Soluble CD14 antigen (1-1) obtainable from human plasma.
- the soluble CD14 antigen according to the first aspect of the present invention which is characterized by the above property 4), is a protein present in human plasma.
- the soluble CD14 antigen of the first aspect of the present invention can be obtained with high purity.
- the soluble CD14 antigen of the first embodiment of the present invention has a high concentration in sepsis patients. This can be a marker for sepsis diagnosis or detection method.
- the soluble CD14 antigen of the first aspect of the present invention can be a standard substance or a competitive substance used in a kit for measuring the soluble CD14 antigen of the first aspect of the present invention, which is useful for diagnosis or detection of sepsis. .
- the soluble CD14 antigen of the first embodiment of the present invention can be purified from human plasma or human serum by a combination of human CD14-related antibody affinity column chromatography, gel filtration chromatography, and SDS-PAGE. .
- the kit for measuring the soluble CD14 antigen of the first embodiment of the present invention of the fifth embodiment of the present invention described below the soluble CD14 antigen of the first embodiment of the present invention of the elution fraction of the column chromatography can be obtained. Detection can be performed efficiently.
- the human CD14-related antibody is an anti-human CD14 antibody or an antibody against a peptide derived from the amino acid sequence of human CD14.
- the antibody can be separated from high-molecular-weight CD14 by using affinity chromatography of the F1025-3-1 antibody or the F1024-1-3 antibody as an anti-human CD14 antibody.
- the high molecular weight CD14 is adsorbed on the antibody, and the soluble CD14 antigen of the first embodiment of the present invention is fractionated in the first stream.
- the protein can be separated from other proteins in serum by using affinity chromatography of an antibody that specifically binds to the peptide having the amino acid residue described in SEQ ID NO: 2.
- the soluble CD14 antigen of the first embodiment of the present invention is adsorbed to the antibody and eluted by acidifying the solvent.
- the F1025-3-1 antibody and the hybridoma producing the F1024-1-3 antibody are respectively designated as Accession No.FERM BP-7296 and Accession No.FERM BP-7511 as described in WO01Z22085 and WO01Z72993. It is deposited internationally at the Patent Organism Depositary Center (IPOD), the 6th Independent Administrative Agency of the National Institute of Advanced Industrial Science and Technology, Tsukuba East, Ibaraki, Japan.
- the soluble CD14 antigen in serum can be separated from other proteins by affinity chromatography of an anti-human CD14 polyclonal antibody. Thereafter, the anti-human CD14 monoclonal antibody can be separated from high molecular weight CD14 by affinity chromatography.
- the soluble CD14 antigen of the first embodiment of the present invention can be further purified by gel filtration chromatography of human serum or the fraction partially purified by the above-mentioned affinity chromatography.
- the fraction in which the soluble CD14 antigen of the first embodiment of the present invention is detected may be collected using the measurement kit of the fifth embodiment of the present invention.
- a fraction having a molecular weight of 35 ⁇ 10 kDa may be collected by using a molecular weight marker.
- the fraction can be further purified by performing non-reducing SDS-PAGE of the fraction partially purified as described above and collecting the position of 13 ⁇ 2 kDa.
- the soluble CD14 antigen according to the first aspect of the present invention has been purified with high purity as a main protein.
- the soluble CD14 antigen of the first embodiment of the present invention is eluted at an ionic strength of around 0.3 M by anion exchange column chromatography at pH 8.5.
- a second embodiment of the present invention is a recombinant soluble CD14 fragment having the following properties 1) to 3).
- Examples of the recombinant soluble CD14 fragment according to the second embodiment of the present invention include a recombinant soluble CD14 fragment having the following sequences 5) to 7).
- the N-terminus is at position 1 to position 17 of SEQ ID NO: 3.
- Also preferred in 7) is a recombinant soluble CD14 fragment having a C-terminus at any of positions 59 to 80 of SEQ ID NO: 3, a group having a C-terminus at any of positions 64 to 75 of SEQ ID NO: 3.
- Recombinant soluble CD14 fragment is more preferred
- Recombinant soluble CD14 fragment having a C-terminus at position 64 of SEQ ID NO: 3 is more preferred.
- the N-terminal is position 1 of SEQ ID NO: 3
- the C-terminal is SEQ ID NO:
- the recombinant soluble CD14 fragment of any one of (2-3) to (2-5) at position 64 of 3 is preferred.
- a recombinant soluble CD14 fragment which is a fragment having a partial sequence of the amino acid sequence shown in SEQ ID NO: 3 in 5) is preferable.
- a method for producing the recombinant soluble fragment of the second aspect of the present invention by genetic engineering is described below, but is not particularly limited, and a conventional method can be used.
- the triplet (codon) of the gene encoding the amino acid sequence of the fragment of the present invention is known.
- the DNA base sequence is not limited to one type. Therefore, any gene may be used as long as it is a gene containing the nucleotide sequence encoding the fragment of the present invention.
- the gene is preferably a cDNA, which may be a cDNA, a chromosomal DNA and a combination thereof and a cDNA containing an intron which can be appropriately spliced, because of easy handling by genetic engineering.
- the gene may be one obtained by the V ⁇ method. For example, regardless of whether it is a chemically synthesized DNA or a suitable DNA library, PCR (Polymera) is performed using DNA containing the DNA of the gene encoding the entire length or part of CD 14 se Chain Reaction) method. Alternatively, the gene or fragment thereof obtained by these methods can be produced by annealing and ligation as necessary. Wear.
- the DNA of the gene can be chemically synthesized as follows. Specifically, the DNA of the gene is divided into fragments having a power of about 20 to 30 bases, and the fragments are synthesized as a plurality of fragments using a DNA chemical synthesizer (for example, Model 394, manufactured by Applied Biosystems). Then, if necessary, the 5 'end of each fragment is phosphorylated to anneal each fragment, and ligated to obtain the target DNA.
- a DNA chemical synthesizer for example, Model 394, manufactured by Applied Biosystems.
- the gene can also be obtained by a PCR method using a genomic library or a cDNA library, etc., as type III.
- a PCR method a known nucleotide sequence and a gene encoding a fragment into which a fragment or a cleavage site of a protease of the present invention is inserted or substituted (hereinafter, sometimes referred to as a fragment of the present invention) may be used.
- a sense primer and an antisense primer designed based on the base sequence of DNA or the like and, if necessary, a restriction enzyme recognition sequence or the like are prepared, and a known method (Michael AL Equivalent, Polymerase Chain Reaction, P and R Protocols, a guide to methods and applications ⁇ 1990, see Academic Press).
- the DNA library described above is not particularly limited as long as it contains the DNA of the gene or a part thereof. Therefore, appropriate cells such as lymphocytes, human cell lines, or hybridomas, which have been obtained by using a commercially available DNA library, can be used as appropriate activators.
- the cDNA may be prepared and used according to the method of Sambrook J. et al.
- nucleotide sequence of the DNA of the gene is not limited to one type. Therefore, as long as it is a gene containing a base sequence encoding the fragment or the like of the present invention, V may have a certain base sequence strength.
- the recombinant vector may be in any form, such as circular or linear, single-stranded or double-stranded, or a complex thereof, and may be appropriately selected depending on the intended purpose. From the viewpoint of ease of handling and ease of incorporation into a host, circular is preferred, and stability is preferred, and double-stranded is preferred.
- the "recombinant soluble CD14 fragment” is a soluble fragment produced by genetic recombination having a partial amino acid sequence of the human full-length CD14 protein shown in SEQ ID NO: 3.
- the recombinant soluble CD14 fragment according to the second embodiment of the present invention has the above property 1). That is, a band derived from the recombinant soluble CD14 fragment of the second embodiment of the present invention is detected at a position of a molecular weight of 13 ⁇ 2 kDa by SDS-PAGE under non-reducing conditions.
- the recombinant soluble CD14 fragment of the second embodiment of the present invention has the property of the above 2). That is, it does not specifically bind to 3C10 and MEM-18.
- recombinant soluble CD14 fragment does not immunologically bind to both 3C10 and MEM-18 antibodies, or Does not show an antigen-antibody reaction.
- the "recombinant soluble CD14 fragment of the second embodiment of the present invention” which does not specifically bind to 3C10 and MEM-18 is the in vivo full-length recombinant CD14 or human full-length recombinant soluble fragment described in SEQ ID NO: 3.
- the binding ability to each of 3C10 and MEM-18 is less than 1Z100. Preferably it is 1Z1,000 or less.
- the recombinant soluble CD14 fragment of the second embodiment of the present invention has the property of the above 3). In particular, it specifically binds to polyclonal antibodies.
- the peptide having the amino acid residue power described in SEQ ID NO: 2 described in the above feature 3) also corresponds to the 16 amino acid residues up to position 68 in the position 53 of human CD14 described in SEQ ID NO: 3.
- the polyclonal antibody recognizes a sequence having a length of 7 amino acids or more (see Example 4 described later)
- the recombinant soluble CD14 fragment of the second embodiment is a human CD14 fragment of SEQ ID NO: 3. At least a sequence having a length of 7 or more amino acids at any of the positions 53 to 68 has at least one.
- 3C10 and MEM-18 are very famous anti-CD14 antibodies, and the epitope on CD14 is recognized to be at positions 7-14 and 57-64, respectively. And conventional Recombinant soluble CD14 fragment derived from human CD14 is recognized as binding to 3C10 or MEM-18 as long as its sequence has the above-mentioned region of the epitope section!
- the recombinant soluble CD14 fragment according to the second aspect of the present invention has the properties described in 1) to 3) above, whereby the soluble CD14 antigen according to the first aspect of the present invention and the physical properties And have immunologically similar properties.
- the fact that the immunological properties are similar can be presumed that the soluble CD14 antigen of the first embodiment of the present invention has a similar tertiary structure of a sequence of amino acid residues that can serve as an epitope. Therefore, it is particularly useful as a standard substance when measuring the soluble CD14 antigen according to the first aspect of the present invention.
- human CD14 has an amino acid at the N-terminal position 1 to 307 of human CD14 and serine at position 286 was substituted with cysteine.
- the ability to use a recombinant polypeptide hereinafter referred to as rsCD14 (l-307) S286C
- the recombinant soluble CD14 fragment of the second embodiment of the present invention has a similar It is convenient when converting a chemical reaction into a substance amount.
- the reactivity of the recombinant soluble CD14 fragment of the second aspect of the present invention is similar to that of the soluble CD14 antigen of the first aspect of the present invention even when the state of the solvent changes.
- the immunity of the soluble CD14 antigen of the first embodiment of the present invention with rsCD14 (1-307) S286C with the soluble CD14 antigen of the first embodiment of the present invention is also used.
- the immunological reactivity is different, the immunological reactivity of the soluble CD14 antigen of the first aspect of the present invention and the recombinant soluble CD14 fragment of the second aspect of the present invention are identical. .
- the recombinant soluble CD14 fragment of the second aspect of the present invention has immunologically similar properties to the soluble CD14 antigen of the first aspect of the present invention.
- the antibody can be used as a target of specific binding.
- the soluble CD14 antigen according to the first aspect of the present invention is originally used as a target for specific binding, it is present only in a very small amount in the living body.
- Type soluble CD14 fragments It is particularly useful as a product.
- the recombinant soluble CD14 fragment of the second embodiment of the present invention has various utilities, because it has the properties described in 1) to 3) above. That is, the recombinant soluble CD14 fragment of the second aspect of the present invention having the above-mentioned properties 1) to 3) is not represented by the sequence, but has the physical properties and immunological properties t, Is represented by
- the recombinant soluble CD14 fragment of the second aspect of the present invention has the property of not binding to 4) LPS described above.
- WO96Z20956 does not disclose a specific peptide, but discloses a peptide having 8 to 60 amino acids including positions 57 to 64 of human CD14 and binding to LPS.
- the peptide and the recombinant soluble CD14 fragment of the second embodiment of the present invention are not identical, the recombinant soluble CD14 fragment of the second embodiment of the present invention has the above-mentioned property 4). It can be clearly understood that having
- the recombinant soluble CD14 fragment according to the second embodiment of the present invention is exemplified by a recombinant soluble CD14 fragment having the following sequences 5) to 7).
- N-terminus is at position 1 to position 17 of SEQ ID NO: 3.
- a recombinant soluble CD14 fragment having an N-terminus at any one of positions 1 to 6 of SEQ ID NO: 3 in 6) is preferable, and a recombinant soluble CD14 fragment having an N-terminus at position 1 of SEQ ID NO: 3
- the CD14 fragment is more preferred.
- the C-terminus is preferred to be a recombinant soluble CD14 fragment having a C-terminus at positions 59 to 80 of SEQ ID NO: 3, Recombinant soluble CD14 fragment at any of positions 64 to 75 is more preferred. Recombinant soluble CD14 fragment having a C-terminus at position 64 of SEQ ID NO: 3 is more preferred.
- the N-terminal is position 1 of SEQ ID NO: 3
- the C-terminal is SEQ ID NO:
- the recombinant soluble CD14 fragment of any one of (2-3) to (2-5) at position 64 of 3 is preferred.
- a recombinant soluble CD14 fragment which is a fragment having a partial sequence of the amino acid sequence of SEQ ID NO: 3 is preferable.
- the method for producing the fragment of the present invention by genetic engineering is described below, but is not particularly limited, and a conventional method can be used.
- the amino acid sequence of the fragment of the present invention is encoded.
- the nucleotide sequence of the DNA of the gene is not limited to one. Therefore, any gene may be used as long as it is a gene containing the nucleotide sequence encoding the fragment of the present invention.
- the gene is preferably a cDNA, which may be a cDNA, a chromosomal DNA and a combination thereof and a cDNA containing an intron which can be appropriately spliced, because of easy handling by genetic engineering.
- the gene may be one obtained by the method described in V ⁇ .
- the DNA containing the DNA of the gene encoding the entire length or a part of CD14 is used as a type III PCR (Polymerase) It may be obtained by the Chain Reaction) method.
- the gene or a fragment thereof obtained by these methods can be produced by annealing and ligation as necessary.
- the DNA of the gene can be chemically synthesized as follows. Specifically, the DNA of the gene is divided into fragments having a power of about 20 to 30 bases, and the fragments are synthesized as a plurality of fragments using a DNA chemical synthesizer (for example, Model 394, manufactured by Applied Biosystems). Then, if necessary, the 5 'end of each fragment is phosphorylated to anneal each fragment, and ligated to obtain the target DNA.
- a DNA chemical synthesizer for example, Model 394, manufactured by Applied Biosystems.
- the gene can also be obtained by a PCR method using a genomic library or a cDNA library, etc., as type III.
- a PCR method a known nucleotide sequence and a gene encoding a fragment into which a fragment or a cleavage site of a protease of the present invention is inserted or substituted (hereinafter, sometimes referred to as a fragment of the present invention) may be used.
- Sense primers and antisense primers were designed based on the nucleotide sequence of, and if necessary, in combination with restriction enzyme recognition sequences, etc. , Polymerase Chain Reaction, P and R Protocols, a guide to methods and applications ⁇ 1990, Academic
- the DNA library described above is not particularly limited as long as it contains the DNA of the gene or a part thereof. Therefore, appropriate cells such as lymphocytes, human cell lines, or hybridomas, which have been obtained by using a commercially available DNA library, can be used as appropriate activators.
- the cDNA may be prepared and used according to the method of Sambrook J. et al. In general, it is known that there are up to six types of triplets (codons) in the DNA of a gene encoding an amino acid, depending on the type of the amino acid.
- the nucleotide sequence of the DNA of the gene is not limited to one type. Therefore, as long as it is a gene containing a base sequence encoding the fragment or the like of the present invention, V may have a certain base sequence strength.
- the recombinant vector may be in any form, such as circular or linear, single- or double-stranded, or a complex thereof, and may be appropriately selected depending on the intended purpose. From the viewpoint of ease of handling and ease of incorporation into a host, circular is preferred, and stability is preferred, and double-stranded is preferred.
- the signal sequence to be connected can be selected as appropriate.
- a preferred example of the recombinant vector is one which transforms a eukaryotic cell such as an animal cell or yeast so as to express the fragment of the present invention from the viewpoint of a host. Therefore, the recombinant vector contains at least a translation initiation codon, a termination codon, a selection marker, a poly-A additional sequence in addition to one gene, and a promoter of SV40 that functions in animal cells.
- Preferred examples of the recombinant vector include an EF1 ⁇ promoter, an SRa promoter, an AOX1 promoter that functions in yeast, and an SV40 replication origin.
- the recombinant vector can be obtained by ligating the DNA of the gene with another DNA fragment having an arbitrary nucleotide sequence, or by introducing the DNA into an arbitrary vector (Sambrook J. et al., Molecular Cloning, a Laboratory Manual). 2nd ed., Cold spring Harbor Laboratory, New York, 1989).
- a transformant can be obtained by introducing the recombinant vector into a host cell or microorganism.
- the transformant is preferably a transformant that expresses the fragment or the like of the present invention, and particularly preferably expresses the fragment or the like of the present invention and is secreted into the culture supernatant. . This is because the use of such a transformant makes it easy to produce the fragment or the like of the present invention in large quantities.
- the transformant is cultured, and gene amplification and expression induction are performed as necessary. Next, the culture mixture is recovered, and if necessary, operations such as concentration, solubilization, dialysis, and various types of chromatography are appropriately combined to purify the fragment or the like of the present invention.
- the "culture mixture” refers to a transformant, a medium containing the transformant, or a culture supernatant or a lysate of cells.
- the transformant used in the production method is not limited as long as the transformant expresses the fragment or the like of the present invention.
- COS cells and mammalian cells such as CHO cells or yeast, or E. coli. It is preferably a transformant using a cell selected from any of the above as a host.
- the cells are pre-cultured in L-broth and then inoculated to a 1Z50 amount in M9-CA medium. Incubate at 37 ° C. A few hours after the start of the culture, when the OD550 value of the medium reaches 1 to 4 (that is, in the logarithmic growth phase), 3 ⁇ indoleacrylic acid is added to a final concentration of 10%. It is added to give ⁇ gZml to induce expression. By further culturing for about 1 to 2 days, a culture mixture containing the target protein can be obtained.
- the cells are pre-cultured in a BMGY medium for about 2 days, and after the medium is replaced, methanol is added to induce expression. . Furthermore, culturing is performed at 30 ° C for about 1 to 2 days to obtain a culture mixture containing the target protein.
- a transformant obtained by transforming a mammalian cell such as a CHO cell with a recombinant vector having an EF1a promoter is cultured in a DMEM medium containing 10% fetal calf serum.
- Cells are inoculated at a concentration of about 1 to 10 ⁇ 10 4 cells Zml, and cultured at 37 ° C., 5% carbon dioxide, and 95% air.
- the cells become confluent after 2-3 days, at which time the medium is replaced with serum-free D-MEM.
- a culture mixture containing the target protein can be obtained.
- the production amount of the target protein is small, it is possible to increase the production amount by amplifying the gene with methotrexate as described above.
- the above-mentioned culture mixture power is also appropriately selected from methods such as those generally used for purifying fragments, proteins or polypeptides.
- various affinity chromatography methods such as salting out method, ultrafiltration method, isoelectric point precipitation method, gel filtration method, electrophoresis method, ion exchange chromatography, hydrophobic chromatography and antibody chromatography, etc.
- An appropriate method may be appropriately selected from commonly used methods such as chromatofocusing, adsorption chromatography, and reversed-phase chromatography, and may be combined. If necessary, purification may be performed using an HPLC system or the like.
- the fragment or the like of the present invention may be expressed as a fusion protein with ⁇ -galactosidase of Escherichia coli or another polypeptide.
- any of the purification steps may be used.
- an operation of treating the fusion protein with a chemical substance such as bromocyan or hydroxylamine or an enzyme such as protease to cut out the protein is required.
- the transformant used is Escherichia coli, the fragment or the like of the present invention is not used.
- the protein is produced as an inclusion body, which is a fusion protein, during the purification, the steps of solubilizing, denaching, and refolding the inclusion body may be performed at an appropriate step of the purification (Thomas E). J. Molecular Biology, 87, 563-577, 1974).
- a solubilization buffer containing an appropriate amount of urea or guanidine hydrochloride, a surfactant, reduced daltathione, and oxidized daltathione for example, 5 M guadin hydrochloride, 0.005% Tween 80, 50 mM Tris hydrochloride (pH 8. Buffer solution containing 0), 5 mM EDTA, 2 mM reduced glutathione, and 0.02 mM oxidized glutathione
- 2-mercaptoethanol add 2-mercaptoethanol to the pellet, and degenerate.
- the solution is removed, dialyzed and refolded.
- unnecessary protein portions are cleaved with a chemical substance such as bromocyan or an enzyme such as protease, and then appropriate chromatography is performed.
- the fragment of the present invention can also be chemically synthesized by a general method, and a fragment prepared by chemical synthesis is also included in the fragment of the present invention.
- a fragment prepared by chemical synthesis is also included in the fragment of the present invention.
- it can be prepared by a commercially available peptide synthesizer.
- the book can also be prepared by synthesizing a fragment of a packed fragment with a peptide synthesizer and binding the fragments in a ligatory manner.
- a third embodiment of the present invention is a recombinant soluble CD14 fragment having the following properties 1) to 3) obtained by the following steps 1> to 3>.
- the inventors assumed the mechanism by which the soluble CD14 antigen of the first embodiment of the present invention exists in blood as described below, and used the same method as that for the assumed production process to produce the present invention. An attempt was made to produce the recombinant soluble CD14 fragment of the third aspect. However, the present invention is not restricted or limited by the assumed production process.
- the soluble CD14 antigen of the first embodiment of the present invention specifically increases in blood during sepsis. That is, it is found that the concentration increases due to an in-vivo phenomenon which can occur immediately after the initial stage of sepsis, particularly immediately after the living body comes into contact with endotoxin and the like.
- neutrophil activation an in vivo phenomenon that can occur immediately after a living body comes into contact with endotoxin and the like is neutrophil activation, and activated neutrophils may be proteases such as neutrophil elastase. Ze releases.
- high-molecular-weight CD14 such as soluble full-length CD14 and membrane-type CD14 (hereinafter sometimes referred to as full-length CD14) in the living body is decomposed by the elastase or the like, and the first embodiment of the present invention is described. It can be assumed that the soluble CD14 antigen is increased.
- the soluble CD14 antigen of the first embodiment of the present invention which is produced by the degradation of full-length CD14 by a protease such as elastase, is stable at least to the extent that it can be detected in vivo (in serum). Be there! /
- the soluble CD14 antigen of the first aspect of the present invention thus produced can be immunologically measured by distinguishing the soluble CD14 antigen of the first aspect of the present invention from full-length CD14. Is already different from the full-length CD14 in the three-dimensional structure.
- the recombinant soluble CD14 fragment of the third aspect of the present invention is a recombinant soluble CD14 fragment of the soluble CD14 antigen of the first aspect of the present invention. Fragment that is sterically similar to the soluble CD14 antigen of For a fragment having a similar epidemiological specificity, a production method of cleaving the C-terminus with a protease from a relatively large CD14 fragment was attempted, and the recombinant soluble CD14 fragment of the third embodiment of the present invention was produced. Successful separation and purification.
- step 1) a step of preparing a recombinant soluble CD14 fragment having the sequence of the following 8) to: L 1),
- N-terminus is !! of 1 to 17 of SEQ ID NO: 3
- the C-terminus is any of positions 134 to 356 of SEQ ID NO: 3, and
- Examples of the predetermined protease in step 11) of ⁇ 1> include ProScission Protease, Thrombin, Factor Xa, and the like. Then, when the predetermined protease is ProScission Protease, the sequence of the cleavage site is Leu, Glu, Val, Leu, Phe, Gin, Gly, Pro, and the eight amino acid residues are replaced with 59 of SEQ ID NO: 3. Substitution or insertion after any of the positions 70 to 70 is exemplified.
- the sequence of the cleavage site is Leu, Val, Pro, Arg, Gly, Ser, and the 6-amino acid residue is substituted with the amino acid residues 59 to 70 of SEQ ID NO: 3. Substitution or insertion after any of the positions is exemplified. Furthermore, when the predetermined protease is Factor Xa, the sequence of the cleavage site is lie, Glu, Gly, and Arg, and the four amino acid residues are located at any of positions 59 to 70 of SEQ ID NO: 3. Substitution or insertion is exemplified.
- step ⁇ 1> a recombinant soluble CD14 fragment produced by preparing a fragment having an N-terminus at any of positions 1 to 6 of SEQ ID NO: 3 in 9) and producing the fragment is preferred. . Furthermore, a recombinant soluble CD14 fragment produced by producing a fragment having an N-terminus at position 1 of SEQ ID NO: 3 is more preferable.
- step 1) a fragment which is substituted or inserted after any of positions 59 to 68 of SEQ ID NO: 3 in 11) was prepared. The recombinant soluble CD14 fragment produced is preferred.
- sequence power of the cleavage site of the predetermined protease was replaced or inserted after position 64 of SEQ ID NO: 3 to create a fragment, and the produced recombinant soluble CD14 fragment was produced. preferable.
- a fragment in which the N-terminus is any of positions 1 to 6 of SEQ ID NO: 3 and the sequence of the cleavage site of a given protease is substituted or inserted after position 64 of SEQ ID NO: 3 Even more preferred is the recombinant soluble CD14 fragment created and produced.
- a recombinant soluble CD14 fragment can be prepared as described in the section of the second embodiment of the present invention.
- Step 2) of the step of cutting the fragment into which the cleavage site of the predetermined protease has been inserted or substituted with the predetermined protease is performed by the usual reaction using the optimum conditions of the predetermined protease.
- the predetermined protease is ProScission Protease
- the predetermined protease is Thrombin
- the mixture is allowed to stand at 22 ° C. so that the enzyme: substrate ratio is 0.001 to 10: 1 (U: g), and the cutting reaction with thrombin is performed.
- the predetermined protease is Factor Xa
- the enzyme may be added so that the enzyme: substrate ratio is 0.0008 to 8: 1 (U: g), and the cleavage reaction may be performed.
- the step of recovering the N-terminal fragment of the cleaved fragment in 3> may be performed in the same manner as the above-described method of purifying the fragment or the like of the present invention.
- the fragments and the like of the present invention can be industrially mass-produced uniformly and with high efficiency.
- the specific sequence of the recombinant soluble CD14 fragment of the third embodiment of the present invention can be understood by the steps described above. Preferred fragments have the same sequence as the fragments described in the second aspect of the present invention.
- the recombinant soluble CD14 fragment according to the third embodiment of the present invention may have a part of the sequence of the cleavage site of a predetermined protease, added to the C-terminal thereof.
- the recombinant soluble CD14 fragment of the third embodiment of the present invention is particularly preferable because, as a preferable reason, it does not detect high molecular CD14 in blood and detects only the soluble CD14 antigen of the first embodiment of the present invention.
- the "recombinant soluble CD14 fragment” is a soluble fragment produced by genetic recombination having a partial amino acid sequence of the human full-length CD14 protein shown in SEQ ID NO: 3.
- the recombinant soluble CD14 fragment according to the second embodiment of the present invention has the above property 1). That is, a band derived from the recombinant soluble CD14 fragment of the second embodiment of the present invention is detected at a position of a molecular weight of 13 ⁇ 2 kDa by SDS-PAGE under non-reducing conditions.
- the recombinant soluble CD14 fragment of the second embodiment of the present invention has the property of the above 2). That is, it does not specifically bind to 3C10 and MEM-18.
- “Does not specifically bind to 3C10 and MEM-18” means that the recombinant soluble CD14 fragment does not immunologically bind to both 3C10 and MEM-18 antibodies, or Does not show an antigen-antibody reaction.
- the "recombinant soluble CD14 fragment of the second embodiment of the present invention” which does not specifically bind to 3C10 and MEM-18 is the in vivo full-length recombinant CD14 or human full-length recombinant soluble fragment described in SEQ ID NO: 3.
- the binding ability to each of 3C10 and MEM-18 is less than 1Z100. Preferably it is 1Z1,000 or less.
- the recombinant soluble CD14 fragment of the second embodiment of the present invention has the property of the above 3). In particular, it specifically binds to polyclonal antibodies.
- the peptide having the amino acid residue power described in SEQ ID NO: 2 described in the above feature 3) also corresponds to the 16 amino acid residues up to position 68 in the position 53 of human CD14 described in SEQ ID NO: 3.
- the polyclonal antibody recognizes a sequence having a length of 7 amino acids or more (see Example 4 described later)
- the recombinant soluble CD14 fragment of the second embodiment is a human CD14 fragment of SEQ ID NO: 3. At least a sequence having a length of 7 or more amino acids at any of the positions 53 to 68 has at least one.
- 3C10 and MEM-18 are very famous anti-CD14 antibodies, and the epitope on CD14 is recognized to be at positions 7-14 and 57-64, respectively.
- the conventional recombinant soluble CD14 fragment derived from human CD14 has been recognized to bind to 3C10 or MEM-18 as long as its sequence has the above-mentioned epitope region!
- the recombinant soluble CD14 fragment of the embodiment has the properties described in 1) to 3) above, whereby the physical properties and immunological properties of the soluble CD14 antigen of the first embodiment of the present invention are similar. Having.
- the soluble CD14 antigen of the first embodiment of the present invention has a similar tertiary structure of a sequence of amino acid residues that can serve as an epitope. Therefore, it is particularly useful as a standard substance when measuring the soluble CD14 antigen according to the first aspect of the present invention.
- human CD14 has an amino acid at the N-terminal position 1 to 307 of human CD14 and serine at position 286 was substituted with cysteine.
- the ability to use a recombinant polypeptide (hereinafter referred to as rsCD14 (l-307) S286C)
- the recombinant soluble CD14 fragment of the second embodiment of the present invention has a similar It is convenient when converting a chemical reaction into a substance amount.
- the reactivity of the recombinant soluble CD14 fragment of the second aspect of the present invention is similar to that of the soluble CD14 antigen of the first aspect of the present invention even when the state of the solvent changes.
- the immunity of the soluble CD14 antigen of the first embodiment of the present invention with rsCD14 (1-307) S286C with the soluble CD14 antigen of the first embodiment of the present invention is also used.
- the immunological reactivity of the soluble CD14 antigen of the first embodiment of the present invention and the recombinant soluble CD14 fragment of the second embodiment of the present invention are the same.
- the recombinant soluble CD14 fragment of the second aspect of the present invention has immunologically similar properties to the soluble CD14 antigen of the first aspect of the present invention.
- the antibody can be used as a target of specific binding.
- the soluble CD14 antigen according to the first aspect of the present invention is originally used as a target for specific binding, it is present only in a very small amount in the living body. Type soluble CD14 fragments are particularly useful as a substitute.
- the recombinant soluble CD14 fragment of the second embodiment of the present invention has various utilities, because it has the properties described in 1) to 3) above. That is, the recombinant soluble CD14 fragment of the second aspect of the present invention having the above-mentioned properties 1) to 3) is not represented by the sequence, but has the physical properties and immunological properties t, Is represented by
- the recombinant soluble CD14 fragment of the second aspect of the present invention has the property of not binding to the above-mentioned 4) LPS.
- WO96Z20956 does not disclose a specific peptide, but discloses a peptide having 8 to 60 amino acids including positions 57 to 64 of human CD14 and binding to LPS.
- the peptide and the recombinant soluble CD14 fragment of the second embodiment of the present invention are not identical, the recombinant soluble CD14 fragment of the second embodiment of the present invention has the above-mentioned property 4). It can be clearly understood that having
- the step of cleaving the fragment into which the cleavage site of the predetermined protease has been inserted or substituted by the predetermined protease is performed by applying the optimum conditions of the predetermined protease to the usual reaction. Just do it.
- the predetermined proteolytic enzyme is ProScission Protease
- the enzyme: substrate substrate
- the mixture may be allowed to stand at 22 ° C so that the ratio becomes 0.001 to 10: 1 (U: g), and the cutting reaction with thrombin may be performed.
- the predetermined protease is Factor Xa
- the enzyme may be added so that the enzyme: substrate ratio is 0.0008 to 8: 1 (U: g), and the cleavage reaction may be performed.
- the step of recovering the N-terminal fragment of the cleaved fragment may be performed in the same manner as in the above-described method of purifying the fragment or the like of the present invention.
- the fragment or the like of the present invention can be industrially mass-produced uniformly and with high efficiency.
- the fragment of the present invention can also be chemically synthesized by a general method, and a fragment prepared by chemical synthesis is also included in the fragment of the present invention.
- a fragment prepared by chemical synthesis is also included in the fragment of the present invention.
- it can be prepared by a commercially available peptide synthesizer.
- the book can also be prepared by synthesizing a fragment of a packed fragment with a peptide synthesizer and binding the fragments in a ligatory manner.
- a fourth aspect of the present invention is a method for diagnosing or detecting sepsis, comprising measuring the soluble CD14 antigen according to the first aspect of the present invention.
- the method includes the following steps 1) to 3).
- the blood collected from the subject may be blood collected from the subject, that is, whole blood may be used, or the blood collected from the subject may be prepared into plasma or serum.
- the step is a step of preparing the plasma or serum to measure the soluble CD14 antigen of the first embodiment of the present invention.
- Measure the soluble CD14 antigen of the first embodiment of the present invention refers to measuring the amount of the soluble CD14 antigen of the first embodiment of the present invention. That is, the concentration may be measured. The measurement result should be obtained in the unit corresponding to the standard value to be compared in step 2).
- step 1) measurement by a sandwich immunoassay is simple and easy. Is preferred.
- the measurement can be performed by a measurement method according to a sixth aspect of the present invention described later.
- it can be performed by using the measurement kit of the fifth aspect of the present invention.
- step 1) is not limited by this measurement method.
- a method in which the soluble CD14 antigen of the first embodiment of the present invention in blood, plasma or serum collected from a subject is separated by electrophoresis, and the concentration or width of the detected band is measured by densitometry. Is mentioned.
- the antibody is used in the assay kit according to the fifth aspect of the present invention, and the band is detected using Western Blott. It is.
- methods such as separation and detection by mass spectrum, HPLC, gas chromatography, TLC, etc. may be used.
- the measurement results of a plurality of normal persons are obtained in advance, and the values of the normal persons or the range of the values of the normal persons, which are standardized by taking the average value or the range of the measurement results, are corrected.
- This is a step of comparing with the value measured in step 1) as a standard value for ordinary people.
- the standard value of a normal person may be determined using the average value of a normal person + 2SD or 3SD as a cutoff value.
- a step of obtaining a reference value of the sepsis patient in advance and comparing the reference value with the value measured in the step 1) may be performed. This step may be performed instead of the step 2) of comparing with the standard value of normal subjects.
- the step 3) is a step for evaluating whether the subject has sepsis (positive) or not (negative) based on the result of the comparison in step 2).
- false positive evaluation or predictive diagnosis may be performed. For example, if the standard range for normal subjects is 0 to 0.1 gZmL and the value for sepsis patients is 0.2 gZmL or more and compared with the measured value, the subject value is 0 to 0.1 / z gZmL. If negative, 0.1-0.2 g ZmL, false positive; if 0.2 / z gZmL or more, evaluate as positive or more likely to develop sepsis within 24 hours, for example And so on.
- the stability of the soluble CD14 antigen of the first embodiment of the present invention in a sample may be an important factor in some cases. For example, when freeze-thawing is repeated or left at room temperature for a long time, the soluble CD14 antigen of the first embodiment of the present invention in serum is degraded, and In some cases, high-molecular-weight CD14 in serum may be decomposed into the soluble CD14 antigen of the first embodiment of the present invention or a structure similar thereto, resulting in erroneous measurement results.
- ethylene diamine tetraacetic acid (EDTA), heparin, and citric acid which are used for blood sampling of plasma, can be mentioned as a toner for adding blood when collecting blood.
- Antithrombm III 1-antitrypsin ⁇ aprotmin, leupeptm, 2- macrogloblm, peps tatin, antipain, chymostatin, amastatin, tripsin inhibitor ⁇ phenylmethyls ulfonyl fluoride (PMSF), EGTA, E-64, benzamidine in serum ⁇
- PMSF phenylmethyls ulfonyl fluoride
- EGTA EGTA
- E-64 benzamidine in serum ⁇
- Decomposition of proteins can be suppressed by adding various protease inhibitors such as 4-fluoro- (2-aminoethyl) benzenesulfonyl chloride (AEBSF).
- lactoce sucrose
- sucrose to improve the stability of Torehar o soluble in the first aspect of the present invention in the liquid in by addition of synthetic polymers of sugar and PEG such as se CD14 antigen and the high molecular weight CD14 You can also.
- the fifth aspect of the present invention relates to a method of the present invention contained in a sample, comprising at least one antibody that specifically binds to the soluble CD14 antigen of the first aspect of the present invention or a fragment of the antibody.
- 1 is a kit for measuring a soluble CD14 antigen for measuring a soluble CD14 antigen according to one embodiment.
- the kit of the present invention comprises at least one antibody that specifically binds to the soluble CD14 antigen of the first embodiment of the present invention or a fragment of the antibody, and the kit of the first embodiment of the present invention contained in the specimen. Measure soluble CD14 antigen. Further, in order to detect the objective soluble CD14 antigen of the first aspect of the present invention, the soluble CD14 antigen of the first aspect of the present invention can be directly measured. Further, a kit that detects only the soluble CD14 antigen of the first embodiment of the present invention and does not detect the human high molecular weight soluble CD14 antigen and the 36 kDa soluble CD14 protein is preferable.
- the measurement kit of the present invention does not detect human high molecular weight soluble CD14 protein and 36 kDa soluble CD14 protein when human serum is measured as a sample without any special treatment.
- the special treatment is a treatment in which a protein is added to human serum or a protein in human serum is denatured.
- the antibody fragment refers to the antibody fragment. Fab, Fab ', or F (ab') 2 of the antibody.
- the measurement kit of the present invention comprises at least one antibody specifically binding to the soluble CD14 antigen of the first embodiment of the present invention or a fragment of the antibody, and comprises the first kit of the present invention contained in a sample.
- the soluble CD14 antigen of the embodiment can be measured.
- the antibody or the antibody fragment specifically binding to the soluble CD14 antigen of the first embodiment of the present invention includes any of the following a) to d), or a fragment of the antibody: This is a kit for measuring soluble CD14 antigen.
- an antibody prepared using a peptide consisting of 16 amino acid residues of SEQ ID NO: 2 as an antigen d) a recombinant soluble CD14 fragment of the second embodiment of the present invention or a set of the third embodiment of the present invention An antibody that specifically binds to a recombinant soluble CD14 fragment.
- it is a measurement kit containing the antibody of the above a), c) or d) or a fragment of the antibody. More preferably, it is a measurement kit containing the antibody of d) or a fragment of the antibody. Particularly preferred is d) an antibody that binds to the recombinant soluble CD14 fragment of the second embodiment of the present invention or a measurement kit containing the antibody fragment.
- the antibody of d that is, the recombinant soluble CD14 fragment of the second aspect of the present invention or the recombinant soluble CD14 fragment of the third aspect of the present invention (hereinafter referred to as the second soluble type of the present invention)
- the recombinant soluble CD14 fragment of the embodiment or the recombinant soluble CD14 fragment of the third embodiment of the present invention may be collectively described as the recombinant soluble CD14 fragment of the present invention): a) An antibody that specifically binds to the peptide having the amino acid residue capability of SEQ ID NO: 2; b) any of 8 to 16 consecutive amino acid residues selected from the amino acid sequence of SEQ ID NO: 2 And c) an antibody prepared using a peptide having 16 amino acid residues as an antigen as described in SEQ ID NO: 2 as an antigen.
- the antibody of d) may include a part of the antibodies of a) to c) described above. Further, the antibody of d) and the above a) In order to clearly distinguish them from the antibodies of (c) to (c), the antibodies of (a) to (c) above may be excluded from the antibody of (d).
- the recombinant soluble CD14 fragment or the present invention of the second aspect of the present invention may be used as the antibody specifically binding to the soluble CD14 antigen of the first aspect of the present invention or a fragment of the antibody.
- An antibody prepared using the recombinant soluble CD14 fragment of the third aspect of the invention as an antigen or a fragment of the antibody is preferable.
- an antibody prepared using the soluble CD14 antigen of the first aspect of the present invention as an antigen or a fragment of the antibody is also preferable.
- An antibody prepared using the recombinant soluble CD14 fragment of the second embodiment of the present invention as an antigen or a fragment of the antibody is more preferable.
- a monoclonal antibody prepared using the recombinant soluble CD14 fragment of the second aspect of the present invention as an antigen or a fragment of the antibody is preferable. Particularly, it is substantially different from recombinant high molecular weight CD14 such as human high molecular weight CD14 or a soluble polypeptide having amino acids at positions 1 to 356 of the N-terminal of human CD14 (hereinafter referred to as rsCD14 (1-356)). Antibodies are preferred, and do not bind.
- the principle of measurement is not particularly limited as long as the antibody or a fragment of the antibody is used to immunologically measure the soluble CD14 antigen of the first aspect of the present invention.
- the antibody of a that is, the ⁇ antibody that specifically binds to the amino acid residue described in SEQ ID NO: 2 '' or the ⁇ recombinant soluble CD14 fragment of the second aspect of the present invention ''
- a sandwich immunoassay method hereinafter sometimes referred to as a sandwich immunoassay kit
- a known technique can be used for the sandwich immunoassay.
- Assay method see, for example, “Ultrasensitive Enzyme-Linked Immunoassay” by Eiji Ishikawa, Gakkai Shuppan Center (1993), “New Use Cases of Immunoassay and Diagnostic Reagents” Application to Development ”Immunoassay Development Study Group, Management Education Publishing, Enzyme Immunoassay (3rd edition), edited by Eiji Ishikawa et al., Medical School (1987).
- the sandwich immunoassay system kit of the present invention includes an antibody that specifically binds to a peptide consisting of the amino acid residues set forth in SEQ ID NO: 2.
- the amino acid residue of SEQ ID NO: 2 The characteristics of the antibody that specifically binds to the strong peptide, the method of preparation, and the like are as described in the first embodiment of the present invention.
- the antibody is not particularly limited, and may be a polyclonal antibody or a monoclonal antibody.
- the sandwich immunoassay is a method in which an antibody-antigen-antibody complex is formed by using two or more types of antibodies which usually recognize different proteins at different sites.
- an insoluble carrier to which the first antibody is bound is prepared, and is used as a solid phase or a reaction site.
- the sandwich method can be either a two-step method (two-step method) or a one-step method (one-step method) in which an antigen and a labeled antibody are simultaneously added.
- the ⁇ antibody which specifically binds to the peptide capable of amino acid residue described in SEQ ID NO: 2 '' or ⁇ the recombinant soluble CD14 fragment of the second embodiment of the present invention
- a monoclonal antibody prepared as an antigen, a "soluble CD14 antigen according to the first aspect of the present invention” -a "second binding substance that specifically binds to the soluble CD14 antigen according to the first aspect of the present invention” Measure by forming.
- the configuration of the sandwich immunoassay kit of the present invention includes "an antibody that specifically binds to a peptide capable of amino acid residue described in SEQ ID NO: 2" or "a set of the second embodiment of the present invention.”
- An insoluble carrier to which a ⁇ monoclonal antibody prepared using a recombinant soluble CD14 fragment as an antigen '' is bound, and a labeled second binding substance that binds to ⁇ the soluble CD14 antigen of the first embodiment of the present invention hereinafter simply referred to as , A second binding substance).
- an insoluble carrier to which a second binding substance has been bound and a ⁇ labeled antibody that specifically binds to the peptide having 16 amino acid residues described in SEQ ID NO: 2 '' or ⁇ the second embodiment of the present invention
- labeled monoclonal antibodies prepared using the recombinant soluble CD14 fragment as an antigen are examples of the second binding substance.
- the antibody that specifically binds to the “soluble CD14 antigen of the first embodiment of the present invention” may be a polyclonal antibody or a monoclonal antibody, and is not particularly limited, but specifically binds to the peptide having the amino acid residues described in SEQ ID NO: 2.
- Monoclonal antibodies are preferred in terms of compatibility in sandwich immunoassays using antibodies that bind specifically. It may also be a fragment of the monoclonal antibody. An antibody fragment is Fab, Fab ', or F (ab') 2 of the monoclonal antibody.
- An antibody that specifically binds to the soluble CD14 antigen according to the first aspect of the present invention may specifically bind to the soluble CD14 antigen according to the first aspect of the present invention.
- Antibodies that specifically bind, and antibodies that specifically bind to high molecular weight CD14 are not particularly limited.
- the second binding substance specifically binds to any region of amino acid residues 1 to 52 of human high molecular weight CD14, or an antibody fragment thereof, or human high molecular weight CD14.
- an antibody that competes with or exhibits cross-reactivity with an antibody that specifically binds to any of the amino acid residues at positions 1 to 52, or a fragment of the antibody Particularly preferably, an antibody or a fragment of the antibody, wherein the second binding substance specifically binds to any of the amino acid residues at positions 17 to 26 of the "soluble CD14 antigen of the first embodiment of the present invention" Or an antibody that competes with (cross-reacts with) an antibody that specifically binds to any of amino acid residues 17 to 26 of the ⁇ soluble CD14 antigen of the first embodiment of the present invention, '' It is a fragment.
- the production method is, for example, a mixture or recombinant of high molecular weight CD14, "the soluble CD14 antigen of the first embodiment of the present invention", high molecular weight CD14 and "the soluble CD14 antigen of the first embodiment of the present invention”.
- a polyclonal antibody or a monoclonal antibody may be prepared using CD14 as an antigen in the same manner as in the method described in the first embodiment of the present invention.
- An example of a method for preparing a mixture of high molecular weight CD14 and the “soluble CD14 antigen of the first embodiment of the present invention” and a second antibody using recombinant CD14 as an antigen is shown in Example 3 described below.
- an antibody that specifically binds to the peptide consisting of the amino acid residue set forth in SEQ ID NO: 2 and a candidate antibody for the second antibody are preliminarily prepared in the same manner as in Example 3 described later. It is preferable to select a second antibody by configuring a sandwich method system and confirming the measurement sensitivity.
- Fab, Fab ', and F (ab') which are antibody fragments, can be obtained by a known method ("ultrasensitive enzyme immunoassay").
- the sandwich immunoassay for binding an antibody to an insoluble carrier has been described in detail above, the sandwich immunoassay can be performed in a solution without using an insoluble carrier.
- an antigen is reacted with a labeled antibody and a second labeled second binding substance in a liquid phase, and the interaction between the label and the second label is measured.
- Antibody Antigen This is a method of measuring by competing a labeled antigen or a labeled antigen-like substance with an antigen in a sample in forming an antibody complex.
- the "antibody which specifically binds to the peptide capable of amino acid residue described in SEQ ID NO: 2" or the "recombinant soluble CD of the second embodiment of the present invention” A “monoclonal antibody prepared using the 14 fragment as an antigen” "a soluble CD14 antigen of the first embodiment of the present invention” (or a similar substance thereof) "a second antibody that binds to the soluble CD14 antigen of the first embodiment of the present invention” To form a complex of “binding substances”.
- the configuration of the competition method of the sandwich immunoassay kit of the present invention includes “an antibody that specifically binds to a peptide capable of binding to amino acid residues described in SEQ ID NO: 2” or “the recombinant of the second aspect of the present invention.
- An insoluble carrier bound with a monoclonal antibody prepared using a soluble CD14 fragment as an antigen, a second binding substance, and a labeled ⁇ soluble CD14 antigen of the first embodiment of the present invention '' or a labeled ⁇ soluble CD14 antigen of the present invention.
- a ⁇ antibody that specifically binds to the peptide having the amino acid residue represented by SEQ ID NO: 2 '' or ⁇ the set of the second embodiment of the present invention '' A monoclonal antibody prepared using a recombinant soluble CD14 fragment as an antigen, an insoluble carrier to which a second binding substance is bound, and a labeled “soluble CD14 antigen of the first embodiment of the present invention”. Clause Includes labeled "Soluble CD14 antigen of the first aspect of the invention” analog.
- the analogous substance of the "soluble CD14 antigen of the first embodiment of the present invention” includes, for example, the recombinant soluble CD14 fragment of the second embodiment of the present invention, the N-terminal position 1 to position 285 of human CD14.
- examples thereof include a soluble polypeptide having an amino acid (hereinafter, referred to as rsCD14 (1-285)) and rsCD14 (1-307) S286C.
- the recombinant soluble CD14 fragment of the second embodiment of the present invention is preferably exemplified.
- a method for preparing r sCD14 (1-285) and rsCD14 (1-307) S286C is described in WO01 / 72993.
- the measurement can be performed using the second specific binding.
- Antibody antigen-antibody complex of second specific binding substance or antibody antigen-antibody second specific binding substance specific binding partner of second specific binding substance (hereinafter referred to as second specific binding partner) This is a method of forming a complex and measuring it.
- the "antibody that specifically binds to the peptide having the amino acid residue described in SEQ ID NO: 2" or the "recombinant soluble CD of the second embodiment of the present invention” A "monoclonal antibody prepared using the 14 fragment as an antigen”"the soluble CD14 antigen of the first embodiment of the present invention”-"a second binding substance that binds to the soluble CD14 antigen of the first embodiment of the present invention” Forming a complex of a specific binding substance, an "antibody that specifically binds to a peptide consisting of the amino acid residue set forth in SEQ ID NO: 2" or a "recombinant soluble CD14 fragment of the second embodiment of the present invention” Monoclonal antibody prepared using as an antigen) "Soluble CD14 antigen of the first aspect of the present invention”"Second binding substance that binds to soluble CD14 antigen of the first aspect of the present invention” Second specific binding substance Or a
- the partner of the second specific binding substance may be "a peptide having the amino acid residue represented by SEQ ID NO: 2".
- a binding substance it further includes a labeled second specific binding substance.
- the second specific binding substance include an antibody against the partner of the second specific binding substance.
- the partner of the second specific binding substance is the second specific binding partner
- the peptide having the amino acid residue represented by SEQ ID NO: 2 to which the second specific binding substance is bound An antibody that specifically binds to a monoclonal antibody prepared using the recombinant soluble CD14 fragment of the second aspect of the present invention bound to a second specific binding substance as an antigen, And a second binding agent that binds to the soluble CD14 antigen of the embodiment, and an insoluble carrier to which a second specific binding partner has been bound, or a peptide comprising the amino acid residue represented by SEQ ID NO: 2.
- Second Specific Binding Substances of the combination of the second specific binding partner include an antigen and its antibody, a ligand and its receptor, a sugar chain-containing substance and lectin, a biotin and avidin or a streptavidin, and the like.
- an antibody-antigen-antibody-anti-immunoglobulin antibody complex is formed using an antibody against an antibody, that is, an anti-immunoglobulin antibody.
- the second specific binding substance using the anti-immunoglobulin antibody and the second specific binding to form the second specific binding partner, etc. An example is shown.
- the amino acid described in SEQ ID NO: 2 "An antibody which specifically binds to a peptide having a residue” or "a monoclonal antibody prepared using the recombinant soluble CD14 fragment of the second embodiment of the present invention as an antigen""A soluble CD14 of the first embodiment of the present invention”
- An antigen ''- ⁇ a second binding substance that binds to the soluble CD14 antigen of the first embodiment of the present invention ''-forming an anti-immunoglobulin antibody complex;
- a monoclonal antibody prepared using the recombinant soluble CD14 fragment of the second embodiment of the present invention as an antigen) or a soluble CD14 antigen of the first embodiment of the present invention "A second binding substance that binds to the soluble CD14 antigen according to the first embodiment of the present invention” -forming an anti-immunoglobulin antibody complex, or an anti-immunoglobulin antibody
- CD14 antigen Second binding substance that binds to soluble CD14 antigen according to first embodiment of the present invention
- Second specific binding substance Second specific binding partner Forming second specific binding partner, or anti-immunoglobulin antibody
- Second specific binding substance Second specific binding partner Second specific binding substance Second specific binding partner It is measured such as by causing made.
- an antibody that specifically binds to a peptide consisting of the amino acid residue set forth in SEQ ID NO: 2” or “the recombinant soluble CD14 of the second embodiment of the present invention” A complex comprising a monoclonal antibody prepared using a fragment as an antigen, a soluble CD14 antigen according to the first embodiment of the present invention, and a second binding substance that binds to the soluble CD14 antigen according to the first embodiment of the present invention.
- a labeling substance or the like is produced using the second specific binding, it is included in the measurement method of the present invention.
- any of the sandwich immunoassays as a kit of the sandwich immunoassay, "specifically binds to the amino acid residue capable peptide described in SEQ ID NO: 2" As long as it includes an “antibody” or "a monoclonal antibody prepared using the recombinant soluble CD14 fragment of the second embodiment of the present invention as an antigen", it is included in the kit of the present invention. Similarly, as long as the antibody contains any one of the above a) to d), it is included in the kit of the present invention.
- beads, latex particles, magnetic particles, plates, tubes, membranes or the like may be used as the insoluble carrier used in the sandwich immunoassay kit of the present invention.
- the material of the beads, plates or tubes includes polystyrene, nylon, glass, silicone rubber, stainless steel, plastic and the like.
- the membrane include cellulose, cellulose derivative, nitrocellulose, porous synthetic polymer, glass fiber, cloth, nonwoven fabric, and filter paper.
- beads, latex particles, magnetic particles, or the like can be used as a spherical shape. This is advantageous in securing space during storage. Plates or tubes can be used as wells. This is advantageous in that it can be used with commercially available automated measuring instruments, plate readers, etc.
- the membrane can be used for the immunochromatography method and the flow-through method described later.
- Binding of an antibody, a second binding substance, a second specific binding substance or a partner thereof, or an anti-immunoglobulin antibody to an insoluble carrier, which specifically binds to the amino acid residue strong peptide of SEQ ID NO: 2, is performed by thermal adsorption. Method, a chemical bonding method, or the like.
- a blocking treatment with a substance on the non-adsorption surface where the substance is not bound to the insoluble carrier without affecting the measurement system. It is the power that can increase the specificity or sensitivity of the measurement system.
- the substance that does not affect the measurement system include proteins such as BSA and casein, and surfactants such as Tween20 and NP-40.
- Labels used in the sandwich immunoassay system kit of the present invention include enzymes such as peroxidase, alkaline phosphatase, ⁇ -D-galactosidase, oxidase and pericase, ataridimme or a derivative thereof, or aequorin or a modified product thereof.
- Chemiluminescent substances, fluorescent substances such as FITC or lanthanoids such as pium (Eu) or samarium (Sm), or dyes, colloidal gold, colored latex, or isotopes may be used.
- chromogenic substrates when peroxidase is used as the enzyme, 3,3 ', 5,5-tetrabenzidine or 1,2-phenylenediamine or the like alkaline phosphatase is used as the chromogenic substrate, and when 4-alkoxyphosphatase is used, 4-trophenyl is used as the chromogenic substrate.
- Phosphate Isopotency-When using D-galatatosidase examples include 2-2 trophenyl.
- Enzyme labeling of an antibody, a second binding substance, a second specific binding substance or a partner thereof, or an anti-immunoglobulin antibody that specifically binds to the peptide having the amino acid residue described in SEQ ID NO: 2 is a two-step method. It can be carried out by a talaldehyde method, a periodic acid method, a maleimide method, a pyridyl disulfide method, or the like.
- Labeling other than the enzyme can also be performed using a known technique such as a heat adsorption method or a chemical bonding method.
- a chromogenic substrate as exemplified above can be used to measure the enzyme label using an ordinary absorbance measurement system, and the sensitivity is preferably relatively high.
- a fluorescent substance When a chemiluminescent substance, a fluorescent substance, a colored label or an isotope is used as a label, it can be measured by a measuring device corresponding to the label.
- a fluorescent substance such as Eu, for example, cryptate (Eu 3 + cryptate)
- fluorescence resonance energy transfer can also be measured by using an araphycocyanine derivative such as XL665 as the second label.
- Labels used in a simple measurement kit for example, a kit using an immunochromatography method or a flow-through method described below are preferable because a dye, colloidal gold or colored latex can be visually observed.
- the sandwich immunoassay kit of the present invention is characterized in that it is measured by a sandwich immunoassay, and contains an antibody that specifically binds to the peptide having amino acid residues described in SEQ ID NO: 2.
- sandwich immunoassay known techniques can be used as described above.
- the amino acid residue described in SEQ ID NO: 2 can be used.
- the sandwich immunoassay kit of the present invention as long as it contains an antibody that specifically binds to a basic peptide or a monoclonal antibody prepared using the recombinant soluble CD14 fragment of the second embodiment of the present invention as an antigen. And is not particularly limited.
- a buffer or diluent such as a specimen or a labeled antibody, a coloring substrate suitable for the enzyme when the enzyme is used for the labeled antibody (see above), a blocking agent, a reaction terminator Or a cleaning agent is exemplified.
- the diluent is not particularly limited, but is preferably a diluent containing a substance contained in the specimen.
- the sample is serum and blood collection for obtaining the serum is performed in the presence of EDTA or citric acid
- Standard substances are also exemplified.
- Examples of the standard substance include analogs of “the soluble CD14 antigen of the first embodiment of the present invention” and “the soluble CD14 antigen of the first embodiment of the present invention”.
- the recombinant soluble CD14 fragment of the present invention is preferred as a standard substance.
- the sandwich immunoassay kit of the present invention also includes a kit utilizing an immunochromatography method or a flow-through method based on a sandwich immunoassay method. Furthermore, the sandwich immunoassay kit of the present invention can be used for the measurement by the MED IA method (Japanese Patent Laid-Open No. 5-264552) for electrochemically measuring the signal of the label, and the Imnoassay method using a microchip (“Bioscience and Industry”). 61 449 454 2003), time-resolved fluorescence immunoassay "Analytical biochemistry” (USA), 1984, vol. 137, p.335-343) and homogenous immunoassay. It can also be used for measurement by.
- a measurement kit using these principles is also characterized in that it is measured by a sandwich immunoassay, and it is characterized by "an antibody that specifically binds to a peptide capable of amino acid residue represented by SEQ ID NO: 2" or "the present invention.
- the sandwich immunoassay kit of the present invention as long as it contains the “monoclonal antibody prepared using the recombinant soluble CD14 fragment of the second embodiment as an antigen”.
- the sandwich immunoassay system kit of the present invention comprises "the amino acid residue of SEQ ID NO: 2
- the first aspect of the present invention is characterized in that it includes an antibody that specifically binds to a peptide of the present invention or a monoclonal antibody prepared using the recombinant soluble CD14 fragment of the second aspect of the present invention as an antigen.
- the soluble CD14 antigen of the embodiment can be specifically measured.
- the sample used for the sandwich immunoassay kit of the present invention is preferably an aqueous sample.
- measurement of the soluble CD14 antigen of the first embodiment of the present invention contained in blood components such as blood, serum or plasma, urine, other body fluids, cell culture supernatants, or column eluates is preferred.
- specimens other than human blood components such as human urine or other body fluids, blood components from non-human species, urine or other body fluids, cell culture supernatants, or column eluates, etc. It is possible to measure not only the soluble CD14 antigen of the first embodiment of the invention but also proteins and polypeptides similar to the “soluble CD14 antigen of the first embodiment of the invention”.
- kits for measuring a protein, polypeptide or the like similar to the above-mentioned “soluble CD14 antigen of the first embodiment of the present invention” is also included in the sandwich immunoassay kit of the present invention.
- an antibody that specifically binds to the amino acid residue potent peptide described in SEQ ID NO: 2 or "the recombinant soluble CD14 fragment of the second embodiment of the present invention is used as an antigen A Fab, Fab ', or (Fab'), which is a fragment of an antibody that specifically binds to a peptide capable of amino acid residue described in SEQ ID NO: 2) instead of the monoclonal antibody prepared as The recombinant soluble CD14 fragment of the second aspect of the present invention
- Fab fragment of a monoclonal antibody prepared using
- examples of the principle of measurement include an agglutination method, a solid-phase binding method, and a solution reaction method, and at least one of the "soluble CD14 of the first embodiment of the present invention".
- An antibody that specifically binds to the "antigen” or a fragment of the antibody preferably, a kit corresponding to these methods containing the antibody of the present invention or the fragment of the antibody can be constituted.
- kits when the kit is constituted using a single antibody without using the second binding substance, an antibody or a fragment of the antibody specifically binding to the ⁇ soluble CD14 antigen of the first embodiment of the present invention '' Full-length soluble CD14 protein in human blood (hereinafter sometimes referred to as human high molecular weight CD14) or a soluble polypeptide having amino acids at the N-terminal position 1 to 356 of human CD14 (hereinafter referred to as rsCD14 (1- 356)), it is preferable to use an antibody that does not substantially bind to recombinant high molecular weight CD14.
- human high molecular weight CD14 human high molecular weight CD14
- rsCD14 (1- 356) a soluble polypeptide having amino acids at the N-terminal position 1 to 356 of human CD14
- an antibody is bound to the surface of a particle, and the presence of the antigen causes aggregation of the particle, and the antigen is specifically qualitatively or quantitatively determined using the degree of aggregation of the particle as an index. .
- the agglutination immunoassay kit of the present invention for example, the "antibody specifically binding to the peptide capable of amino acid residue represented by SEQ ID NO: 2" or the “recombinant of the second embodiment of the present invention” Monoclonal antibody prepared using a soluble CD14 fragment as an antigen''The soluble CD14 antigen of the first embodiment of the present invention is formed and measured by agglutination.As a configuration of the agglutination immunoassay kit of the present invention, The antibody of the present invention includes particles bound to its surface.
- particles generally used particles such as latex, red blood cells (for example, sheep red blood cells), gelatin, microbeads or carbon particles can be used.
- the solid phase binding method is a method of measuring by forming a complex of an antibody and an antigen on a solid phase.
- a sample containing an antigen is adsorbed on an insoluble carrier (ie, solid phase).
- an insoluble carrier ie, solid phase.
- a labeled antibody is added and allowed to react, and the amount of complex bound to the solid phase is determined based on the label. Qualitatively or quantitatively.
- a competitive method a method of measuring the amount of a labeled antibody specifically bound to an antigen-like substance by adsorbing the antigen-like substance on an insoluble carrier and competing with the reaction between the labeled antibody and the antigen in the sample.
- the antibody is adsorbed on an insoluble carrier, and the reaction with the antigen in the sample is competed with the labeled antigen-like substance, and the amount of the labeled antigen-like substance specifically bound to the antibody is measured. There is a way to do that.
- the "antibody that specifically binds to the peptide having the amino acid residue described in SEQ ID NO: 2" or “the recombinant of the second embodiment of the present invention” A monoclonal antibody prepared using a soluble CD14 fragment as an antigen '' A complex of the ⁇ soluble CD14 antigen of the first embodiment of the present invention '' and ⁇ specifically binds to the peptide having the amino acid residue described in SEQ ID NO: 2 '' "Antibody” or "monoclonal antibody prepared using recombinant soluble CD14 fragment of the second embodiment of the present invention as an antigen" "Labeled soluble CD14 antigen of the first embodiment of the present invention” (or an analog thereof)
- insoluble carrier the analogous substance of the "soluble CD14 antigen of the first embodiment of the present invention", the label, and the reagent to be adsorbed are as described in the description of the sandwich immunoassay system kit.
- an antigen is reacted with a labeled antibody in a liquid phase, and then the antigen, the antibody and the antigen-antibody complex are separated by an agglutination sedimentation method using an antibody or a physicochemical method. This is a method for specifically qualifying or quantifying the “soluble CD14 antigen of the first embodiment”.
- an antibody that specifically binds to the amino acid residue-enhancing peptide of SEQ ID NO: 2 or "the recombinant soluble CD14 fragment of the second embodiment of the present invention is used as an antigen
- ⁇ a peptide having a continuous 8 to 16 amino acid residue sequence which is also selected as the amino acid sequence sequence described in SEQ ID NO: 2
- an antibody prepared using the peptide having 16 amino acid residues represented by SEQ ID NO: 2 as an antigen
- an antibody prepared using the peptide as an antigen or "Fab, Fab ', or (Fab')" which is a fragment of these antibodies.
- the force described based on the principle of measuring the example of the measurement kit of the present invention is not limited to these principles.
- the soluble CD14 antigen according to the first aspect of the present invention which contains an antibody or a fragment of the antibody specifically binding to at least one "soluble CD14 antigen according to the first aspect of the present invention” and is contained in a sample Is included in the measurement kit of the present invention as long as it can be directly measured.
- Known techniques can be used for the principle of the immunoassay.
- the "soluble CD14 antigen of the first embodiment of the present invention” which can be specifically measured by the kit of the present invention increases in septic patients. Therefore, measurement of the “soluble CD14 antigen of the first embodiment of the present invention” serves as an indicator of sepsis diagnosis, and the kit of the present invention is useful for diagnosis of sepsis.
- an antibody that specifically binds to the peptide having the amino acid residue represented by SEQ ID NO: 2 or "a monoclonal antibody prepared using the recombinant soluble CD14 fragment of the present invention as an antigen” is dissociation constant when expressed as an affinity that pair to "the recombinant soluble CD14 fragment of the present invention” peptide or (KD) is less than 10- 7 M are preferred. More preferred properly is, 10- 8 M or less, more preferably an antibody or less 10- 9 M.
- the peptide serving as the antigen is composed of eight or more consecutive amino acid residues of SEQ ID NO: 2. And preferably 10 or more, more preferably 12 or more, and particularly preferably 16 or more consecutive amino acids.
- the peptide has at least eight consecutive amino acid residues of any of SEQ ID NO: 2. There is no limitation on other amino acid sequences including the above amino acids, but preferably, the entire amino acid sequence of the peptide is derived from the amino acid sequence described in any of SEQ ID NO: 2.
- An antibody is preferably prepared using a peptide containing eight or more consecutive amino acids of the amino acid residues of SEQ ID NO: 2 as an antigen.
- the antibody is preferably an antibody prepared using a peptide containing 10 or more consecutive amino acids, more preferably 12 or more consecutive amino acids, particularly preferably 16 consecutive amino acids.
- the peptide serving as an antigen was described in SEQ ID NO: 2.
- the number of amino acid residues is not particularly limited as long as it is a peptide consisting of consecutive 8 to 16 amino acid residues selected from the amino acid sequence of
- the antibody is prepared using a peptide consisting of 10 or more continuous amino acids, more preferably 12 or more continuous amino acids, and particularly preferably 16 consecutive amino acids. That is, preferably, an "antibody prepared using the peptide consisting of 16 amino acid residues described in SEQ ID NO: 2 as an antigen".
- the "soluble CD14 antigen of the first embodiment of the present invention” has a different molecular weight from the high molecular weight CD14, and has a shorter amino acid sequence than the high molecular weight CD14. Therefore, it is considered that the structure of the “soluble CD14 antigen of the first embodiment of the present invention” in blood is different from that of high-molecular-weight CD14, and the reactivity with the antibody is different.
- the antibodies a) to d) which are preferred examples of the antibodies specifically binding to the ⁇ soluble CD14 antigen of the first embodiment of the present invention '' contained in the measurement kit (hereinafter simply referred to as ⁇ above a) to d) Antibody) may bind more strongly to the "soluble CD14 antigen of the first embodiment of the present invention", that is, have high affinity.
- the antibodies a) to d) above may be polyclonal antibodies or monoclonal antibodies.
- the animal species from which the antibody of the present invention is derived is not particularly limited. From the viewpoint of ease of antibody production, egos and goats are preferred.
- the molecular species is not particularly limited. Immunoglobulins classified into any class, subclass and isotype may be used.
- the method for producing a peptide to be used as an immunogen includes a method using a commonly used peptide synthesizer (Peptide Synthesizer 433A, Perkin-Elma Japan), a gene Recombinant method (New Cancer Engineering Protocol, Shujunsha), edited by Cancer Research Division, Institute of Medical Science, The University of Tokyo.
- a commonly used peptide synthesizer Peptide Synthesizer 433A, Perkin-Elma Japan
- a gene Recombinant method New Cancer Engineering Protocol, Shujunsha
- a peptide consisting of eight or more consecutive amino acid residues of the amino acid residue set forth in SEQ ID NO: 2 can be synthesized by the Fmoc method using a 433A-type peptide synthesizer, and can be protected from deprotection by TFA and resin. After cleavage, the target peptide can be prepared by purification using a C18 HPLC column (Capcel Pak, Shiseido).
- an MAP peptide When the antigen is a protein, a peptide having 8 to 30 amino acid residues or less, which can be used as an immunogen as it is, usually has no immunogenicity due to its small molecular weight.
- an MAP peptide may be prepared by binding to a carrier or by using the Multiple Antigen Peptide (MAP) method to have a molecular weight having immunogenicity and to be used as an immunogen.
- MAP Multiple Antigen Peptide
- the carrier to be bound to the peptide includes a carrier protein and a polymer.
- a carrier protein a heterologous protein such as bovine serum albumin, keyhole limpet hemocyanin (KLH), thyroglobulin or ovalbumin may be used.
- KLH keyhole limpet hemocyanin
- thyroglobulin or ovalbumin may be used.
- These carrier proteins utilize a side chain functional group contained in the peptide or the amino acid of the carrier protein or introduce a maleimide group, N-hydroxysuccinimide (NHS) group or aldehyde group, What is necessary is just to couple
- the polymer include sugars such as mannan and chitosan and polyvinylpyrrolidone (PVA). These polymers may be bonded to the peptide by adsorption or chemical bonding as described above.
- the method for producing the recombinant soluble CD14 fragment of the present invention using an antigen is as described in the description of the second and third embodiments of the present invention.
- the fragment when used as an antigen, it may be used as an immunogen as it is, or may be combined with a carrier or the like as described above to form an immunogen.
- the antibody of the present invention can be prepared by using a known technique (for example, see Immunological Experiment Procedures, edited by the Japanese Society of Immunology, published by the Japan Society of Immunology).
- a polyclonal antibody can be prepared by the following method.
- Various animals can be immunized by mixing 20 to 1000 ⁇ g of the immunogen prepared as described above with adjuvants such as Freund's complete adjuvant, RIBI adjuvant, and ALUM. each Horses, sheep, goats, pigs, egrets, rats, mice, etc. can be used as seed animals. Immunization methods include intramuscular, intradermal, subcutaneous, intraperitoneal, and lymph node administration, and Freund's incomplete adjuvant, RIBI adjuvant, Booster immunization can be performed by similarly administering an immunogen mixed with an adjuvant such as ALUM, or by directly intravenously administering the immunogen.
- adjuvants such as Freund's complete adjuvant, RIBI adjuvant, and ALUM.
- the antiserum can be prepared by collecting blood from the immunized animal in a usual blood sampling method, for example, collecting blood from the carotid artery, ear vein, heart, foot vein and the like, and separating the serum by centrifugation or the like.
- the obtained antiserum precipitates a ⁇ globulin fraction by salting-out method with the addition of ammonium sulfate, sodium sulfate, etc., and after dialysis against an appropriate buffer, specific ⁇ globulins such as protein A, protein G, etc.
- a purified polyclonal antibody of the IgG fraction against the target peptide can be prepared using an affinity matrix that can be purified to a desired degree.
- specific purification can be performed by selecting an antibody that specifically binds to the antigen.
- a monoclonal antibody can be prepared by the following method.
- the present invention provides a hybridoma by fusing immunized mammalian immune cells with myeloma cells to produce a hybridoma, and selecting from these hybridomas a clone that produces an antibody that specifically binds to the peptide.
- a hybridoma by fusing immunized mammalian immune cells with myeloma cells to produce a hybridoma, and selecting from these hybridomas a clone that produces an antibody that specifically binds to the peptide.
- a peptide which has 10 or more consecutive amino acid residues from position 53 to position 68 is used as the immunogen. More preferably, a peptide consisting of 12 or more consecutive amino acids, particularly preferably 16 consecutive amino acids is used as the immunogen.
- the mammal to be immunized is not particularly limited, but is preferably a mouse, rat, hamster, or the like, which is preferably selected in consideration of compatibility with the myeloma cells used for cell fusion.
- myeloma cells various known cells can be used. This includes myeloid cells such as P3, P3U1, SP2Z ⁇ , NS-1, YB2Z0 and Y3-Agl, 2,3.
- Immunization can be performed by a known method.
- the antigen is administered intraperitoneally, subcutaneously, intravenously, or into a footpad. This antigen may be administered in combination with an adjuvant, and is preferably administered more than once.
- the immunocytes are preferably isolated spleen cells or lymph node-derived cells several days after the final administration of the antigen, for example, three days after.
- Immune cells and Mie mouth Fusion with a single cell can be carried out using a known method such as the method of Milstein (Methods in EnzymoL, vol. 73, page 3).
- Milstein Methods in EnzymoL, vol. 73, page 3
- a method using polyethylene glycol (PEG) as a fusion agent, an electrofusion method and the like can be mentioned.
- the mixing ratio of the immunocytes and the myeloma cells is not limited as long as they can be fused, but it is preferable to use an lZio amount or an equal amount of the myeloma cells with respect to the immunocytes.
- the PEG concentration is not particularly limited, but preferably 50%.
- An auxiliary such as dimethyl sulfoxide (DMSO) may be added as a fusion efficiency promoter. Fusion is initiated by adding the PEG solution warmed to 37 ° C. to the mixed cells, and after 1-5 minutes of reaction, ending by adding medium.
- DMSO dimethyl sulfoxide
- the hybridoma and ibridoma formed by the fusion are cultured in a selective medium such as a medium containing hypoxanthine, thymidine and aminopterin (HAT medium) for 1 to 7 days, and separated from unfused cells.
- a selective medium such as a medium containing hypoxanthine, thymidine and aminopterin (HAT medium) for 1 to 7 days, and separated from unfused cells.
- the obtained hybridoma is further selected depending on the antibody produced.
- the selected hybridoma is monocloned according to a known limiting dilution method, and established as a monoclonal antibody-producing hybridoma.
- a known method can be used as a method for detecting the activity of the antibody produced by the hybridoma.
- an ELISA method, an agglutination reaction method, and a radioimmunoassay method can be used.
- the established hybridoma is cultured by a known method, and a monoclonal antibody can be obtained from the culture supernatant.
- the hybridoma can be proliferated by administering it to a mammal having compatibility with the hybridoma, and can be obtained from the ascites.
- the antibody can be purified using a known purification means such as a salting-out method, a gel filtration method, an ion-exchange chromatography method or an affinity chromatography method.
- the stability of the soluble CD14 antigen and the high molecular weight CD14 of the present invention influences and the measured values fluctuate.
- a sixth aspect of the present invention is directed to a soluble CD14 of at least one of the first aspects of the present invention.
- the measurement method according to the sixth embodiment of the present invention does not detect human high molecular weight CD14, and measures at least one of the "soluble CD14 antigens of the first embodiment of the present invention” to measure "the soluble CD14 antigen of the first embodiment of the present invention”.
- An antibody that specifically binds to the ⁇ soluble CD14 antigen of the first embodiment '' is used to directly measure ⁇ the soluble CD14 antigen of the first embodiment of the present invention '' contained in a sample.
- This is an immunological measurement method for “soluble CD14 antigen”.
- a measurement method characterized by using an antibody or a fragment of the antibody described in a) to d) below.
- More preferable is a measurement method characterized by using the antibody of the above a), c) or d) or a fragment of the antibody. More preferably, it is a measurement kit containing the antibody of d) or a fragment of the antibody.
- the antibody fragment is Fab, Fab ', or F (ab') of the monoclonal antibody.
- any one of the above-mentioned a) to d), or a fragment of the antibody using a second binding substance that binds to the "soluble CD14 antigen of the first embodiment of the present invention”
- any one of the above a) to d) can be used as a solid phase antibody, a labeled antibody, or the like. Also, a second specific binding method and a measurement method using an anti-immunoglobulin antibody are included. In this case, any of the above a) to d) is a free antibody, a second specific binding It can also be used as a substance or an antibody bound to a second specific binding partner.
- the measurement method of the present invention can be a non-competitive method or a competitive method of a sandwich immunoassay, and includes a measurement by an immunochromatography method or a flow-through method.
- the principle of the measurement method of the present invention is not limited to the sandwich immunoassay, and other examples include an aggregation method, a solid phase binding method, and a solution reaction method.
- the detailed measuring method is preferably as described in the section of the kit of the fifth aspect of the present invention.
- a seventh aspect of the present invention is an antibody that specifically binds to the soluble CD14 antigen of the first aspect of the present invention.
- the antibody of the following a) to d) is used for the antibody of the second aspect of the present invention. Remove it! ,.
- International Publication WO2004Z44005 is an antibody that binds to the peptide having the amino acid residues described in SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 5, and a continuous antibody selected from the amino acid sequence described in SEQ ID NO: 6.
- Antibodies produced using a peptide having a capacity of up to 30 amino acid residues as an antigen are also described, and the antibody that specifically binds to the recombinant soluble CD14 fragment of the second embodiment of the present invention is one of these antibodies. In order to make a clear distinction even if a part is included, these antibodies may be excluded from the antibody that specifically binds to the recombinant soluble CD14 fragment of the second embodiment of the present invention.
- the seventh embodiment of the present invention "specifically binds to the soluble CD14 antigen of the first embodiment of the present invention.”
- the antibody that does not substantially bind to the full-length soluble CD14 protein or rsCD14 (1-356) in human blood, and the recombinant soluble CD14 fragment according to the second embodiment of the present invention is a recombinant soluble CD14 fragment.
- An antibody that specifically binds to the CD14 fragment is preferred. Further, an antibody that is a monoclonal antibody is preferable.
- the antibody of the present invention can be prepared using the soluble CD14 antigen of the first embodiment of the present invention as an antigen.
- the soluble CD14 antigen of the first aspect of the present invention can be measured, and the ⁇ soluble CD1 antigen of the first aspect of the present invention '' of the fifth aspect of the present invention can be measured. 4 kit for measuring antigens ".
- An eighth aspect of the present invention is an antibody that specifically binds to the recombinant soluble CD14 fragment of the second aspect of the present invention.
- the antibodies of the following a) to d) described in Examples of International Publication WO2004Z44005, which is published after the priority date of the present application are also included and partially overlap. Therefore, the antibody that specifically binds to the recombinant soluble CD14 fragment according to the second embodiment of the present invention may include a part of the following antibodies a) to d).
- International Publication No. WO2004Z44005 is selected from an antibody that binds to a peptide having the amino acid residue described in SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 5, and an amino acid sequence described in SEQ ID NO: 6
- Antibodies prepared using a peptide having 8 to 30 consecutive amino acid residues as an antigen have also been described.
- Antibodies that specifically bind to the recombinant soluble CD14 fragment according to the second embodiment of the present invention include these antibodies. In order to clearly discriminate even if a part of the antibody is contained, these antibodies may be excluded from the antibody specifically binding to the recombinant soluble CD14 fragment of the second embodiment of the present invention. .
- the "antibody that specifically binds to the recombinant soluble CD14 fragment of the second aspect of the present invention” is the full-length soluble CD14 protein or rsCD in human blood.
- the antibody does not substantially bind to 14 (1-356) and specifically binds to the recombinant soluble CD14 fragment of the second embodiment of the present invention.
- an antibody that is a monoclonal antibody is preferable.
- the antibody of the present invention can be prepared using the recombinant soluble CD14 fragment of the second embodiment of the present invention as an antigen.
- a particularly preferred antibody is the F1237-3-4 antibody.
- the hybridoma producing the F1237-3-4 antibody was obtained on April 27, 2005 (receipt number FERM ABP-10330) at 1-1-1 Tsukuba East, Ibaraki, Japan. Laboratory Deposited internationally at the Patent Depositary for Biotechnology.
- the soluble CD14 antigen of the first aspect of the present invention can be measured using the antibody of the eighth aspect of the present invention, and the "first aspect of the present invention" of the fifth aspect of the present invention can be measured. And a kit for measuring soluble CD14 antigen.
- the “kit for measuring soluble CD14 antigen of the first embodiment of the present invention” of the fifth embodiment of the present invention does not measure high molecular weight CD14. This is why antibodies that do not substantially bind to full-length soluble CD14 protein in human blood are preferred. The reason for using a monoclonal antibody in a measurement kit is also preferable. Furthermore, the antibody does not substantially bind to the full-length soluble CD14 protein or rsCD14 (1-356) in human blood, and the antibody can be used alone without using a second binding substance which is different from the sandwich immunoassay. These antibodies can be used, and are particularly useful.
- WO2004Z44005 discloses an antibody that binds to the peptide having the amino acid residues described in SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 5, and the amino acid sequence described in SEQ ID NO: 6
- Antibodies produced using a selected peptide of 8 to 30 amino acid residues as an antigen, and the anti-CD14 antibodies F1031-8-3 antibody and F1106-13-3 antibody are described. Their usefulness is that they can be used in a low-molecular-weight CD14 assay kit useful for diagnosing sepsis.
- the antibody described in International Publication WO2004Z4 4005 is not directly associated with the soluble CD14 antigen of the first embodiment of the present invention. The relationship has not been proven, and the invention is said to be useful for a low-molecular-weight CD14 measurement kit useful for diagnosing sepsis when the peptide or CD14 was prepared as an antigen.
- the antibody of the present invention can be used for the “kit for measuring soluble CD14 antigen of the first embodiment of the present invention” of the fifth embodiment of the present invention.
- the “recombinant soluble CD14 fragment of the second embodiment of the present invention” is an antibody which is similar in immunological properties to the soluble CD14 antigen of the first embodiment of the present invention, and binds to the fragment. If it is not (ie, the antibody of the present invention), it cannot be used in the kit for measuring the “soluble CD14 antigen of the first embodiment of the present invention”.
- Antibodies that have been hitherto known and that can be used in the kit for measuring the "soluble CD14 antigen of the first embodiment of the present invention” include only the above-mentioned antibodies described in International Publication WO2004Z44005.
- the antibodies that bind to the “recombinant soluble CD14 fragment of the second embodiment of the present invention” are only the above-mentioned antibodies, and various anti-CD14 antibodies are “recombinant recombinant CD14 fragments of the second embodiment of the present invention”. It does not bind to the "type soluble CD14 fragment”. That is, the antibody of the present invention exhaustively invents and discloses an antibody that can be used for the “kit for measuring the soluble CD14 antigen of the first embodiment of the present invention”. Furthermore, an antibody prepared using the “recombinant soluble CD14 fragment of the second embodiment of the present invention” as an antigen has immunological reactivity with the “soluble CD14 antigen of the first embodiment of the present invention”. High and especially useful.
- a ninth aspect of the present invention is an antibody that specifically binds to the recombinant soluble CD14 fragment of the third aspect of the present invention.
- the antibody of the ninth aspect of the present invention can be prepared using the recombinant soluble CD14 fragment of the third aspect of the present invention as an antigen.
- Preferred examples of the antibody according to the ninth aspect of the present invention are the same as those described in the section of the eighth aspect of the present invention, and their usefulness and other descriptions are also the same.
- a tenth aspect of the present invention is a method for screening an antibody useful for measuring a soluble CD14 antigen according to the first aspect of the present invention, comprising the following steps.
- the screening method according to the tenth aspect of the present invention is a method for screening an antibody useful for measuring the soluble CD14 antigen according to the first aspect of the present invention, which can be a useful marker for diagnosing sepsis. That is, the method for selecting an antibody useful for measuring the soluble CD14 antigen according to the first aspect of the present invention, which can be a useful marker for diagnosing sepsis.
- the method for selecting an antibody that can be used in the kit according to the fifth aspect of the present invention is also provided.
- the screening method according to the tenth aspect of the present invention is characterized in that the amino acid residue of any of 6 to 20 consecutive amino acids selected from the amino acid sequence of SEQ ID NO: 3 prepared in the step 1) is used.
- a fragment of the antibody may be used as a screening target specimen. (The following description of antibodies also includes descriptions of antibody fragments.)
- the liquid to be measured in 2) is not particularly limited as long as the liquid contains CD14.
- the solution contains at least a high molecular weight CD14.
- the immunoassay system configured in 3) is only required to be able to measure whether the antibody to be screened specifically reacts with CD14 contained in the liquid to be measured.
- an antigen immobilization method, a sandwich method, a biomolecular interaction analysis method and the like can be mentioned.
- the present invention is not particularly limited to any of the immunoassay systems described in the fifth and sixth embodiments of the present invention.
- a substance that specifically binds to the antibody prepared in the step 1) may be measured for the liquid to be measured according to the immunoassay method configured in the step 3).
- step 5 whether or not it is useful for use in an immunoassay useful for diagnosing the antibody-resistant sepsis as a sample to be screened is evaluated based on the results measured in the step 4).
- This is a step of selecting an antibody.
- Indices are not particularly limited
- the screening method according to the sixth aspect of the present invention uses the method described in “Step 6) of preparing the" consecutive 6 to 20 amino acid residues selected from the amino acid sequence of SEQ ID NO: 3 "
- This method is characterized in that an antibody that specifically binds to a specific peptide is used as a sample to be screened, and the other steps are not unnecessarily limited.
- the antibody prepared in the above step 1) is specific to a peptide having a continuous 6 to 20 amino acid residue power which also selects the amino acid sequence power from the N-terminal 1 to 314 of the amino acid sequence described in SEQ ID NO: 3.
- An antibody that binds to the amino acid sequence described in SEQ ID NO: 3 is selected.An antibody prepared using a peptide having 8 to 30 amino acid residues as continuous antigens, or the N-terminal 1 of the amino acid sequence described in SEQ ID NO: 3 It is preferable that the antibody be prepared using a peptide consisting of consecutive 8 to 30 amino acid residues selected from the amino acid sequence from position 314 to position 314 as an antigen.
- step 1) instead of preparing "an antibody that specifically binds to a continuous peptide having 6 to 20 amino acid residues selected from the amino acid sequence described in SEQ ID NO: 3,"
- the following antibodies ⁇ 1> to ⁇ 4> may be prepared and used.
- 1> Synthesize a peptide based on the full-length sequence of CD14 by a standard method, prepare an immunizing antigen, and prepare an antibody.
- ⁇ 2> Purify soluble CD14 in serum and use this as an immunogen to produce antibodies.
- 3> Prepare recombinant CD14 protein using COS cells or Escherichia coli and use this as an immunogen to produce antibodies. 4) Prepare various CD14 antigens by heat denaturation or DNP conversion, etc., and use them as immunogens to produce antibodies.
- a labeled antibody against the antibody prepared in the above step 1) for example, a labeled anti- Further prepare globulin antibody
- the liquid to be measured is preferably a body fluid of a normal human or a sample of human high molecular weight CD14.
- a 3C10 antibody affinity column adsorption fraction of a normal human body fluid may be prepared.
- an immunoassay was performed to form a complex of, for example, "the high molecular weight CD14 in the liquid to be measured”-"the antibody prepared in the step 1)" and "labeled anti-immunoglobulin antibody” on the insoluble carrier.
- the specific binding of the antibody prepared in step (1) to “high molecular weight CD14 in the liquid to be measured” is measured through a label.
- the solution to be measured is bound to an insoluble carrier, and in step 4), the antibody prepared in 1) is added to the dot blotting measurement system configured in 3).
- the “labeled anti-immunoglobulin antibody” may be reacted sequentially. Thereafter, the degree of formation of the complex, that is, the substance that specifically binds to the antibody prepared in 1) in the liquid to be measured may be measured based on the strength of the label.
- the antibody prepared in 1) having low or no labeling strength is compared with the high molecular weight CD14 in the normal human body fluid or the human high molecular weight CD14 preparation. Evaluate that the specific binding is weak or no, and select an antibody that is useful for use in an immunoassay useful for diagnosing sepsis. For example, when an antibody that can be evaluated as having high specific binding to high molecular weight CD14 in blood is used to measure a substance that specifically binds to the antibody in human body fluid, the main protein measured is high. It has a molecular weight of CD14.
- the soluble CD14 antigen of the first embodiment of the present invention which is a protein in a smaller amount than the high molecular weight CD14
- an antibody that does not specifically bind to the high molecular weight CD14 should be selected. That's all.
- the antigen solid phase EIA method is used, and in the case where a membrane is used as the insoluble carrier, the dot blotting method is used.
- sandwich immunoassay is as described in the section of the kit of the fifth aspect of the present invention or the fifth assay of the present invention.
- an antibody or an anti-CD14 antibody that specifically binds to a peptide having a contiguous 6 to 20 amino acid residue strength selected as another amino acid sequence strength described in SEQ ID NO: 3 may be described as a second antibody) Prepare).
- the measurement target liquid prepared in the above step 2) is preferably a body fluid of a normal person and a body fluid of a sepsis patient.
- both body fluids have the same origin. That is, it is more preferable that both body fluids have the same origin, for example, a blood sample of a normal person and a blood sample of a sepsis patient, or a urine sample of a normal person and a urine sample of a sepsis patient.
- it is preferably a blood sample. Particularly, serum is preferred.
- sandwich immunization is performed so that a complex of, for example, the antibody prepared in the step (1), the "soluble CD14 antigen of the first embodiment of the present invention", and the “second antibody” is formed on the insoluble carrier. What is necessary is just to comprise a system.
- one of the “antibody prepared in the step 1” or the “second antibody” is bound to an insoluble carrier, and the other is labeled to constitute a sandwich immune system.
- the solution to be measured and the labeled antibody may be reacted with the sandwich immune system constituted in the step 3) in order, and the measurement may be performed.
- step 5 the measurement result of the body fluid of a normal person is compared with the measurement result of the body fluid of a sepsis patient, and the difference in the compared measurement results indicates that the solubility of the first embodiment of the present invention is useful for diagnosing sepsis.
- the immunoassay composed of 3) is a sandwich assay, it is preferable to select a combination of the antibody prepared in 1) and the antibody of the "second antibody". No. That is, a method for screening a combination of antibodies for use in a sandwich immunoassay useful for diagnosing sepsis, which is used for measuring a blood protein that can be a useful marker for diagnosing sepsis, is preferable.
- the antibody used in the screening method of the present invention can be prepared according to the description of the measurement kit of the fifth embodiment of the present invention.
- the description of the materials and the like is as described in the section of the description.
- the biomolecule interaction analysis method is not particularly limited, but a surface plasmon resonance method is exemplified. For example, it can be performed by using a Biacore apparatus (manufactured by Biacore).
- An eleventh aspect of the present invention is a method for screening an antibody useful for measuring a soluble CD14 antigen according to the first aspect of the present invention, comprising the following steps.
- the screening method according to the ⁇ -aspect of the present invention is a method for screening an antibody useful for measuring the soluble CD14 antigen according to the first aspect of the present invention, which can be a useful marker for diagnosing sepsis. That is, the method for selecting an antibody useful for measuring the soluble CD14 antigen according to the first aspect of the present invention, which can be a useful marker for diagnosing sepsis. The method for selecting an antibody that can be used in the kit according to the fifth aspect of the present invention is also provided.
- the screening method of the ⁇ -th embodiment of the present invention particularly comprises reacting an antibody to be screened with the recombinant soluble CD14 fragment of the second embodiment of the present invention, whereby both are specific. It is characterized by evaluating whether it shows binding, that is, whether it shows an antigen-antibody reaction.
- the recombinant soluble CD14 fragment of the second embodiment of the present invention does not specifically bind to 3C10 and MEM-18, and It specifically binds to an antibody prepared using a peptide having 16 amino acid residues as described as an antigen. This is the same immunological property as the soluble CD14 antigen of the first aspect of the present invention.
- evaluating the reaction between the antibody to be screened and the recombinant soluble CD14 fragment of the second aspect of the present invention is useful for measuring the soluble CD14 antigen of the first aspect of the present invention. Antibodies will be selected.
- the screening target specimen to be prepared is not particularly limited as long as it is an antibody.
- an antibody fragment may be used as a sample to be screened as long as it has a function of causing an antigen-antibody reaction with an antigen. (In the following explanation about antibodies Also includes instructions for fragments of the antibody. )
- the screening target specimen in order to increase the efficiency of the screening, the screening target specimen must be specifically selected from a protein consisting of any of 6 to 356 consecutive amino acid residues selected from the amino acid sequence of SEQ ID NO: 3. It is preferable to prepare an antibody that binds. Further, it is more preferable to prepare an "antibody that specifically binds to a protein containing at least 7 consecutive amino acid residues selected from the 53rd to 68th positions described in SEQ ID NO: 3".
- the prepared recombinant soluble CD14 fragment of the second embodiment of the present invention is particularly preferably a recombinant soluble CD14 fragment described in the section of the description of the second embodiment of the present invention. Not limited!
- the antibody prepared in 1) is reacted with the fragment prepared in 2), and the specific binding between the antibody prepared in 1) and the fragment prepared in 2) is evaluated.
- the method is not particularly limited as long as it is a method capable of evaluating whether a specific binding, ie, an antigen-antibody reaction is exhibited. Examples include an antigen immobilization method, a sandwich measurement method, and a method for analyzing interaction between biomolecules. These methods are as described in the description of the tenth aspect of the present invention. If the specific binding is evaluated by the sandwich immunoassay using the second antibody, the combination of antibodies by the sandwich assay can be evaluated.
- the twelfth aspect of the present invention provides the following steps 1) to 3).
- N-terminus is a shift between positions 1 to 17 of SEQ ID NO: 3
- the C-terminus is any of positions 134 to 356 of SEQ ID NO: 3,
- a step of recovering the N-terminal fragment of the fragment cleaved in 3X2> A method for producing a recombinant soluble CD14 fragment according to the second aspect of the present invention, which has the following sequences 5) to 7).
- the N-terminus is at position 1 to position 17 of SEQ ID NO: 3, and
- the recombinant of the second aspect of the present invention having a predetermined amino acid sequence is provided.
- a soluble CD14 fragment can be produced.
- the detailed production method is as described in the description section of the second embodiment of the present invention.
- the sequence power of the cleavage site in step 4 of ⁇ 1> may be Leu, Glu, Val, Leu, Phe, Gin, Gly, Pro. No.
- the sequence power of the cleavage site in step 4) of step 1> may be SLeu, Val, Pro, Arg, Gly, or Ser.
- the serum of a normal individual and the serum of a sepsis patient used in the following examples were purchased from ProMedDx, Samplex and Sera Care Life Science and used.
- S68 peptide The peptide to be synthesized (hereinafter referred to as S68 peptide) was synthesized by inserting a cysteine at the N-terminus in order to bind to the carrier protein via the SH group at the N-terminus. That is, using a peptide synthesizer ABI433A (Applied), amino acid columns were arranged according to the amino acid sequence, and an amino acid column for cysteine was installed at the N-terminus to perform automatic synthesis.
- the synthesized peptide was cut out from the resin by a conventional method, precipitated with ether, recovered, dissolved again in distilled water, and freeze-dried. After dissolving the resulting crude peptide, elution was performed using C18 reverse-phase HPLC (CAPCELL-PAK, Shiseido) with a linear gradient of 5-70% acetonitrile concentration, and the fraction containing the target peptide was collected. did. The collected fraction was lyophilized to obtain 2-3 mg of a purified peptide.
- the peptide prepared in 1- (1) was dissolved in lOmgZmL with distilled water, and mixed with an equal volume of lOmgZmL of Imject Maleimed Activated keyhole Limpet Hemocyanin (KLH) (PIERCE). After reacting at room temperature for 2 hours, desalting was performed using a NAP-10 column (Amersham Bioscience) equilibrated with physiological saline to obtain 1 mg of an S68 peptide carrier antigen (hereinafter, referred to as S68 peptide-KLH). The protein concentration described in the examples was obtained by dividing the used KLH amount by the liquid amount.
- KLH Imject Maleimed Activated keyhole Limpet Hemocyanin
- each of the S68 peptide-KLH was diluted in 500 ⁇ L of physiological saline, mixed with an equal volume of 500 ⁇ L of Freund's incomplete adjuvant (DIFCO), and then administered subcutaneously on the back.
- DIFCO Freund's incomplete adjuvant
- 100 g of S68 peptide-KLH was diluted in 1 mL of physiological saline and administered into the ear vein.
- the dialysate was applied to a protein A column (Prosep A, Millipore), and the bound IgG fraction was eluted with 0.1 M glycine hydrochloride buffer (PH 3.0) to obtain a purified antibody.
- PH 3.0 0.1 M glycine hydrochloride buffer
- the protein concentration was calculated from the absorbance at 28 Onm (converted value: 0.533 mg / mL). After 0 , the obtained antibody is referred to as S68 peptide polyclonal antibody.
- Example 1 S68 peptide prepared in (2) —20 ⁇ g of KLH was dissolved in 100 ⁇ L of saline, mixed with an equal volume of Freund's complete adjuvant (DIFCO), and each hind footpad of an 8-week-old Wistar rat female was administered in 100 L aliquots. Two weeks later, iliac lymph nodes were removed and cell fusion was performed. Cell fusion was performed in accordance with Tamoe Ando and Takeshi Chiba, "Introduction to Monoclonal Antibody Experimental Procedures," p. 83, 1999, Kodansha.
- DIFCO Freund's complete adjuvant
- lymphocytes were separated from lymph nodes using a cell strainer (Falcon), mixed with myeloma cells (Sp2ZO-Agl4) at 5: 1, and cell fusion was performed using polyethylene glycol.
- the fused cells were suspended in a HAT medium. After selection of hybridomas and hybridomas, hybridomas producing the desired antibody were screened.
- rsCD14 1-307) S286C diluted to 1 ⁇ g / mU with 0.1 M phosphate buffer (pH 7.4) was added to an imnoplate (Maxisorb, NUNC), and 50 ⁇ l of phenol was added thereto. The mixture was allowed to stand at ° C for 1 hour. Next, the plate was washed 5 times with ion-exchanged water, 100 L of PBS (pH 6.4) containing 0.1% BSA was added to each well, and the plate was allowed to stand at room temperature for 1 hour for blocking.
- PBS pH 6.4
- the obtained culture supernatant which was also sampled from the hybridoma power, was added to each well, reacted at 37 ° C for 1 hour, and washed three times with a physiological saline solution containing 0.05% Tween20.
- a solution obtained by diluting a peroxidase-labeled anti-rat immunoglobulin antibody (DAKO) 1000 times with PBS containing 10% heron serum was added to each well in a volume of 50 L. After reacting for 1 hour at 37 ° C, the plate was washed 5 times in the same manner, and a tetramethylbenzidine solution (TMB, BioFix) was added to each well. After the reaction at room temperature for 10 minutes, the reaction was stopped with a 0.5 M sulfuric acid solution.
- DAKO peroxidase-labeled anti-rat immunoglobulin antibody
- the absorbance at 450 nm was measured with a plate spectrophotometer (NJ-2100, Nippon Intermed), and a gel containing an antibody that binds to rsCD14 (1-307) S286C and containing a hybridoma was selected.
- rsCD14 (1-307) S286C was prepared by using the method described in WO01 / 72993 as column f, practice 9.
- Example 2 Using the antibodies described in Example 1 and Example 2, a measurement system by the sandwich EIA method was examined.
- oligomer 8 linkS (5, one agetta gga att t, 3) (SEQ ID NO: 7) and oligomer 8, linkA (5'-ctagaa att cct a-3 ') (SEQ ID NO: 8) were synthesized.
- sense primer A (5, aca tct aga tga cca cgc cag aac ct—3,) (Torigami U number 9) and antisense primer (5′—ttt gga tec tta cta gag ate gag cac tct-3) ') A (IS sequence number 10) was synthesized, and the plasmid pM1659 described in Example 8 of WO01Z72993 was subjected to PCR using Pyrobest DNA polymerase in the form of type ⁇ .
- the obtained amplified product of about 900 bp was double digested with Xbal and BamHI to recover a DNA fragment.
- the vector pM710 described in Example 10 of JP-A-06-025289 was double-digested with Hindlll and BamHI, and then recovered by agarose gel electrophoresis. After ligation of the above-mentioned phosphoric acid-linked linker, PCR-amplified DNA fragment / Xbal + BamHI digested fragment, and vector ZHindlll + BamHI fragment (three-way ligation), E. coli combined cells (JM109 (TOYOBO Transformation was performed in)) to obtain a clone containing the target plasmid. Plasmid DNA was prepared by a standard method.
- Escherichia coli JE7924 (J. Bacteriol 173, p. 4799 (1991)) was recovered from the glycerol stock and cultured at 37 ° C. in LB medium. Further, the cells were re-inoculated into 50 mL of LB medium, cultivation was continued until the absorbance at 600 nm became 0.5 to 0.6, and the whole culture flask was ice-cooled for 30 minutes. Next, Escherichia coli was collected, and twice with ice-cooled sterile distilled water, and ice-cooled 10% After washing once with a glycerol solution, the suspension was suspended in 100 L of an ice-cooled 10% glycerol solution. Aliquots of 50 L each were placed in two tubes, rapidly frozen in liquid nitrogen, and prepared as a competent cell (JE7924) and stored at -80 ° C until use.
- the cells were lysed, treated with a solution (US-3, Iuchi Seieido) for 10 minutes, centrifuged at 10,000 X g at 4 ° C for 20 minutes, and The precipitate was suspended again in 50 mL of Bug Buster, and 1 mL of lOmgZmL of lysozyme (Seikagaku Corporation) was added to the suspension. After leaving at room temperature for 10 minutes, adding 1/10 volume of high-concentration Bug Buster (200 mL) followed by stirring, centrifugation was performed in the same manner, and the supernatant was removed. The Bug Buster was suspended in suspension, centrifuged in the same manner, and this operation was repeated several times, and 100 mL of D-PBS was added to the finally obtained precipitate. ⁇ E, to obtain the inclusion bodies.
- a solution US-3, Iuchi Seieido
- rsCD14 For the preparation of rsCD14 (1-285), first, the inclusion body was treated with a TE buffer solution containing 1% TritonXlOO ( The mixture was thawed three times and centrifuged to collect the precipitate. It was again dissolved in a TE buffer solution (pH 8.0, Futaba Gene) containing 1% TritonXlOO, and after cooling with ice, sonication was performed at 250 A at 10-second intervals for 12 minutes, and the precipitate was collected after centrifugation.
- a TE buffer solution pH 8.0, Futaba Gene
- Monoclonal antibodies were prepared using rsCD14 (1-285) derived from Escherichia coli described above as an administration antigen.
- rsCD14 1-285 derived from Escherichia coli described above as an administration antigen.
- the abdominal cavity purified rsCD14 (l-285) of the ddy mice 6 weeks old female 20 8 of Freund's complete adjuvant (DIFCO) and were then mixed in equal amounts administered 200 mu L.
- DIFCO Freund's complete adjuvant
- 20 ⁇ g of purified rsCD14 (1-285) was mixed with an equal amount of Freund's incomplete adjuvant (DIFCO), and 200 L was intraperitoneally administered.
- 50 g of the antigen was administered to the peritoneal cavity of the mouse.
- rsCD14 (l-285) was diluted to 0.4 gZmL with PBS (pH 6.4), and added to each well of Imunobrate (Maxisorb, NUNC) in a volume of 50 ⁇ L. After the reaction at 4 ° C, the plate was washed 5 times with ion-exchanged water, and 100 L of PBS (pH 6.4) containing 0.5% BSA was added to each well to perform blocking. The sampled culture supernatant was added to each well, reacted at 37 ° C for 1 hour, and washed three times with a physiological saline solution containing 0.05% Tween20.
- a solution obtained by diluting a peroxidase-labeled anti-mouse immunoglobulin antibody (DAKO) 1000 times with PBS containing 10% egos serum was added to each well with 50 / zL. After reacting at 37 ° C for 1 hour, the well was washed 5 times in the same manner, and a tetramethylbenzidine solution (TMB. BioFix) was added to each well. After the reaction at room temperature for 10 minutes, the reaction was stopped with a 0.5 M sulfuric acid solution.
- DAKO peroxidase-labeled anti-mouse immunoglobulin antibody
- the absorbance at 450 nm was measured with a plate spectrophotometer (NJ-2100, Nippon Intermed), and a well containing an rsCD14 (l-285) -producing antibody and containing a hybridoma was selected.
- clawing was performed by the limiting dilution method in accordance with the method of monoclonal antibody experimentation by Tamie Ando and Takez Chiba, p. 83, 1991 (Kodansha) from the selected Pell.
- screening was similarly performed using the reactivity to rsCD14 (l-285) as an index.
- 12 types of anti-rsCD14 (1-285) monoclonal antibody-producing hybridomas were obtained.
- the antibody was produced by culturing in Hybridoma-SFM medium (Invitrogen), and the antibody was purified using protein A (Prosep A, Millipore).
- the subtype of the F1106-13-1-3 antibody which was highly reactive, was determined using the IsoStrip Mouse Monoclonal antibody Isotyping Kit (Roche), and the subtype was IgG2b ⁇ ⁇ .
- the F1031-8-3 antibody was prepared using the method described in Example 7 of WO01Z22085. Briefly, 20 g of CD14 protein in human blood was dissolved in saline, mixed with an equal volume of Freund's complete adjuvant (DIFCO), and the mice were intraperitoneally administered for the first time and two weeks later for the second time1 After one week, the increase in the antibody titer in the serum was confirmed by ELISA for the reactivity with the recombinant human CD14 protein in the same manner as in Example 5 of WO01Z22085. 100 g of the antigen was administered to the abdominal cavity of the mouse for final administration, and three days later, the spleen was removed.
- DIFCO Freund's complete adjuvant
- Lymphocytes were separated from the spleen, mixed with myeloma cells (P3 X 63—Ag. 8. U. 1) at a ratio of 10: 1, and subjected to cell fusion using polyethylene glycol.
- Hybridomas were selected using the HAT medium, and one week later, screening of hybridomas producing antibodies for the purpose was performed by the ELISA method described above. After the reaction with the immobilized soluble CD14 antigen, the hybridomas and hybridomas were cloned by the limiting dilution method. After 10 days, the same screening was carried out to obtain an anti-CD14 protein monoclonal antibody.
- the subtype determined using the IsoStrip Mouse Monoclonal antibody Isotyping Kit is IgG2b' ⁇ 31-8-3 antibodies were obtained.
- a sandwich EIA system was prepared using the antibodies described in Examples 1, 2, 3- (2).
- Peroxidase-labeled antibody was prepared by dissolving 4 mg of peroxidase (Toyobo) in distilled water according to the method of Nakane et al. (J. Histochem. Cytochem., Vol. 22, p. 1084, 1974) and adding 100 mM periodate to the mixture. The reaction was performed at 25 ° C for 20 minutes. After completion of the reaction, 1.5% ethylene glycol was added, and the mixture was reacted at 25 ° C for 10 minutes, and dialyzed against ImM acetate buffer (pH 4.4).
- Each of the purified F1031-8-3 antibody and F1106-13-3 antibody was dialyzed against 10 mM carbonate buffer (PH 9.5), and 70 L of 0.2 M carbonate buffer (pH 9.5) was added to 4 mg. 4 mg of peroxidase, which was added and activated, was mixed with the antibody in an equal amount, and reacted at 25 ° C. for 2 hours. Next, 4 mgZmL of sodium borohydride was added, and the reaction was further performed at 4 ° C for 2 hours.
- the reaction solution is dialyzed against PBS, and a peroxidase-labeled F1031-8-3-3 antibody (hereinafter sometimes referred to as F1031-8-3-HRP) and a peroxidase-labeled F1106-13-3 antibody (hereinafter F1106-13-3) — Sometimes described as HRP).
- F1031-8-3-HRP peroxidase-labeled F1031-8-3-HRP
- F1106-13-3 peroxidase-labeled F1106-13-3 antibody
- a two-step sandwich EIA system was prepared in which the S68 antibody prepared in Example 1 was used as a solid phase antibody and the antibodies prepared in Example 3- (2) [1] and [2] were used as labeled antibodies. That is, the S68 antibody was diluted to 10 g / mL with D-PBS (pH 7.4), and 50 ⁇ L of syrup was added to each well of an immunoplate (Maxisorb, NUNC). After the reaction at 4 ° C, wash with ion-exchanged water 5 times, and add 100 L of D—PBS containing 0.1% StabilGuard (SurModics, Inc) and 0.1% Tween20 to each well. Blocked.
- 3C10 1% of normal human serum (serum from which soluble CD14 antigen was removed using 3C10, hereinafter referred to as CD14-absorbed serum, 3C10 was prepared from ATCC228-TIB hybridoma obtained from AmericanTypeCultureCollection), 0.1 Using PBS (pH 7.4) containing% BSA as a diluent, a diluted sample was prepared by diluting human normal human serum and human sepsis patient serum 20-fold. Dilution sample was applied 50 / zL was added thereto and reacted at 37 ° C for 2 hours.
- the plate was washed three times with a physiological saline solution containing 0.05% Tween 20, and then washed with 76 mM PBS (pH 8.0) containing 5% rat serum, 1% mouse serum, and 0.1% Tween 20. 50 ⁇ L of the diluted F1031-8-3-HRP or F1106-13-3-HRP was added to each well at 6 gZmU. After reacting at 37 ° C for 2 hours, the plate was washed 5 times in the same manner, and a tetramethylbenzidine solution (TMB, BioFix) was added to each well.
- TMB tetramethylbenzidine solution
- a two-step sandwich EIA system was prepared using the F1146-17-2 antibody prepared in Example 2 as the solid phase antibody and the antibody prepared in Example 3- (2) [2] as the labeled antibody. .
- the F1146-17-2 antibody was diluted with PBS (pH 6.4) at 120 / z g / mL and diluted with 50 ⁇ L of iminobrate (Maxisorb, NUNC) in each well. After reacting at 56 ° C for 30 minutes, wash 5 times with ion-exchanged water, and add 100 ⁇ L of PBS containing 0.1% StabilGuard (SurModics, Inc) and 0.1% Tween20 (Wako Pure Chemicals) to each well. I kneaded and blocked.
- a diluted sample was prepared by diluting 10-fold human normal human serum and human sepsis patient serum using PBS containing 1% BSA (pH 6.4) as a diluent.
- the diluted sample was added at 50 L per well and reacted at 25 ° C for 2 hours.
- the plate was washed three times with a physiological saline solution containing 0.05% Tween20, and a 76 mM phosphate buffer (pH 8.0) containing 5% rat serum, 1% mouse serum, and 0.1% Tween20 was used.
- the peroxidase-labeled F1031-8-3 antibody diluted to 0.5 ⁇ g, mL was added to each well with 50 ⁇ L of calo. After reacting at 25 ° C for 2 hours, the wells were washed 5 times in the same manner, and a tetramethylbenzidine solution (TMB, BioFix) was added to each well.
- TMB tetramethylbenzidine solution
- the reaction was stopped with a 0.5 M sulfuric acid solution, and the absorbance at 450 nm was measured with a plate spectrophotometer (NJ-2100, Nippon Intermed).
- a plate spectrophotometer NJ-2100, Nippon Intermed.
- the S68 peptide-specific monoclonal antibody like the S68 antibody, showed a high level in blood serum of sepsis patients, which was almost infrequent in normal human serum. White matter could be measured. That is, it was confirmed that a sandwich measurement system could be used whether the antibody binding to the S68 peptide was a polyclonal antibody or a monoclonal antibody.
- Example 1 In order to confirm the specificity of the S68 antibody prepared in Example 1, it was examined by the same measurement as in Example 3- (3) whether the antibody was blocked by the peptide. That is, the S68 peptide (amino acid sequence positions 53 to 68) and the synthetic peptide prepared in the same manner as in Example 1 (amino acid sequence positions 53 to 58, amino acid sequence) were added to 25 ⁇ L of a 50-fold diluted solution of sepsis patient serum and normal human serum. Sequences 57-62, amino acid sequences 59-64) or a peptide for negative control (Cys Glu Gly Asn Gly Asn Asn Phe Glu Ser Arg Glu Ala Cys) are diluted to 0, 0.1, 1, and 10 gZmU.
- the amount of the soluble protein in the serum of a sepsis patient and the serum of a normal individual bound without being blocked by the S68 antibody was measured.
- the specificity and reaction rate constant of the S68 antibody prepared in Example 1 and the F1146-17-1 antibody prepared in Example 2 were analyzed using Biacore3000 (Biacore).
- the S68 peptide BSA to be immobilized was prepared using maleimide-immobilized BSA (Imject Maleimed Activated BSA, PIERCE) in the same manner as described in Example 1.
- S68 peptide-BSA was immobilized on a sensor chip CM5 (Biacore) using an amine coupling kit (Biacore).
- the measurement was performed using HBS-EP (Biacore) as a running buffer and injecting a dilution series (50, 100, 150, 200, 300 nM) of the F1146-17-2 antibody into the flow cell.
- Data analysis was performed by subtracting the reference cell data from the flow cell measurement data of S68 peptide BSA and using Biaevaluation soft wear version 3.0 (Biacore).
- KD dissociation constant
- the F1146-17-1-2 antibody showed a high affinity of 4.8 ⁇ 10 9 M.
- KD of the measured similarly specifically purified Usagi S68 peptide polyclonal antibody is 2. was 2 X 10- 1Q M.
- the amino acid sequence of CD14 was analyzed using a peptide library membrane (Custom SPOTs, Sigma Genosys) synthesized from the N-terminal side by 10 amino acids. That is, after blocking the membrane according to the manual, the F1106-13-3 antibody was reacted, and after washing, a ⁇ -galactosidase-conjugated anti-mouse antibody was reacted. After washing the membrane, the peptide sequence to which the antibody binds was detected using X-gal.
- peptide sequence of the peptide library membrane 19 peptides were synthesized for the amino acid sequence from the 1st to the 154th position by synthesizing two amino acids at the C-terminus by 10 amino acids.
- the peptide was prepared in the same manner as in Example 1- (1).
- the F1106-13-3 antibody was found to have amino acids 17 to 26 from the N-terminus of high molecular weight CD14. It was found to bind to the region corresponding to the acid sequence (CNFSEPQPDW).
- Example 3- To confirm the specificity of the F1031- 8- 3 antibody in Example 3- (1) derived from E. coli r 5 Ji 014 (1-285) as described and 1 ⁇ ⁇ 001,772,993 of JP Examples 8 and 9 The binding activity was measured using rsCD14 (1-356) and rsCD14 (1-307) S286C prepared by COS cells using the method described.
- rsCD14 (l-356), rsCD14 (1-307) S286C, rsCD14 (1-285) or BSA was immobilized on Hybond-C extra (Amersham Bioscience) at 250 ngZ spot on the membrane. After shading and drying, blocking was performed with 0.05% Tween 20, PBS (pH 6.4) containing 0.05 g ZmL of skim milk (Meiji Dairies). After standing at room temperature for 1 hour, the F1031-8-3 antibody diluted to 3 / z gZmL with 0.05% Tween20 containing 0.5% BSA and PBS (pH 6.4) was added, and reacted at room temperature for 1 hour. The plate was washed with% Tween 20, PBS (pH 6.4).
- the binding region (epitope) of the F1031-8-3 antibody was analyzed. That is, a blocking test was carried out with the F1106-13 antibody using the sandwich EIA system of Example 3- (3) [2] using the S103 antibody as the labeled antibody and the F1031-8-3-HRP as the solid phase. .
- Example 3- (3) [2] the standard product lOOngZmL was added to the S68 antibody solid-phase plate and allowed to react. After washing the plate and before adding F1031—8—3—HRP, add 25 ⁇ L of buffer containing 6 gZmL of F1106—13-3 antibody, mouse IgG antibody or antibody! /, And then add F1031— 8-3-HRP antibody was added in an amount of 25 ⁇ L, and the measurement was carried out in the same manner as in Example 3- (3) [2].
- the mouse IgG antibody-added syrup did not inhibit the binding, whereas the F1106-13-3 antibody inhibited the binding between F1031-8-3 and the standard. From this, it was considered that at least a part of the region recognized by the F1031-8-3 antibody had a region recognized by the F1106-13-3 antibody.
- the “inhibition rate” in Table 3 was calculated from the respective reduced absorbances when the absorbance of the buffer alone was taken as 100%.
- Example 3- (3) shows a configuration example of a soluble protein kit using a combination of a solid phase antibody and a labeled antibody, which showed a high value in the measurement of a sepsis patient and a low value in the measurement of a normal person.
- Solid-phase antibody S68 antibody-immobilized plate
- Table 4 shows an example of the configuration of a sandwich EIA-based measurement kit, prepared as described in 7- (1).
- ⁇ 1> indicates the binding substance immobilized on the plate.
- ⁇ 2> indicates a labeled binding substance.
- the components No. 3> to No. 7> and the measuring device of the reference example No. 8> are the same as 7- (1).
- ⁇ 9> indicates an antibody to which the second specific binding substance has bound. "-" Indicates no description.
- Example 3- (3) measurement was performed in the same manner as in Example 3- (3) [2]. That is, the S68 antibody was diluted to ⁇ g / mL with D-PBS (pH 7.4), and 50 ⁇ L was added to each well of an immunoplate (Maxisorb, NUNC). After incubating at 4 ° C, wash 5 times with ion-exchanged water. Add 100 L of D-PBS containing 0.1% StabilGuard (SurModics, Inc) and 0.1% Tween20 to each well. And blocked.
- soluble CD14 antigen derived from normal human serum at a concentration of 0 to 4 ⁇ g ZmL was added to CD14 (1–307) S286C standard. It was added to the sample and measured in the same manner as in (12). As a result, as shown in FIG. 3, soluble CD14 antigen derived from normal human serum did not affect the measured value even at 4 ⁇ g ZmL. From these results, it was evident that the cross-reactivity with the high molecular weight CD14 in this sandwich EIA system was 0.3% or less. In other words, it is confirmed that this system is specific for soluble protein, which does not detect human serum high molecular weight CD14 and shows a high level in the serum of sepsis patients.
- the reproducibility of the measurement results by the kit of (1) was evaluated. Use three types of specimens as in (12) The coefficient of variation (CV) of the simultaneous reproducibility was 5.8, 3.6, 3.5%, and the reproducibility between measurements was 6.2, 5.2, 5.1%. In addition, the recovery rate of the spiked katsuna recovery test was as good as 88-109%, and no effect of anticoagulants (heparin, citrate, EDTA) was observed. From the above results, it was shown that this kit has sufficient performance for measuring the soluble protein in blood.
- Example 7 In order to analyze the substances in the septic patient serum detected by the measurement kit described in (1), the septic patient serum was subjected to SMART SYSTEM (Amersham Bioscience) using a gel filtration chromatography column Superdex 200PC3.2ZZ30 (Amersham Bioscience). No.Science) and fractionation using D-PBS as a developing solvent, and measure each fraction using the measurement kit described in Example 7- (1) and the CD14-EIA kit (IBL-Hamburg) on the market. did.
- the molecular weight was calculated using the aldolase (158 kDa), BSA (67 kDa), ovovalbumin (43 kDa), and chymotrypsin (25 kDa) of the LMW calibration kit and HMW calibration kit (Amersham Biosciences). I went for a calibration.
- the soluble CD14 antigen with a molecular weight of about 57 kDa was detected in the commercially available CD14-EIA kit, and was determined to be the 49-55 kDa high molecular weight soluble CD14 antigen, which has been reported previously.
- the kit described in Example 7- (1) a peak was detected around 35 to 45 kDa in molecular weight, and no peak was detected in the vicinity of 57 kDa. It was confirmed that the described kit specifically detected only the soluble protein present in blood.
- the serum 501 of a sepsis patient was subjected to gel filtration chromatography column Superdex 75 10/300 GL (Amersham Bioscience) to develop 200 mM ammonium acetate (pH 6.8) as a developing solvent. And measured using each kit.
- the molecular weight was calculated using the LMW calibration kit and the HMW calibration kit (Amersham Bioscience) for BSA (67 kDa), ovoanolebumin (43 kDa), The column was calibrated with trypsinogen (25 kDa) and ribonuclease A (13.7 kDa).
- Figure 5 shows the results.
- a peak derived from the soluble protein was detected around 25 to 35 kDa in molecular weight.
- fraction 12 When the fraction of the peak derived from the soluble protein obtained in ⁇ 2> (for example, fraction 12) is subjected to F1025-3-1 antibody affinity column chromatography, the soluble fraction is obtained. The peak derived from the protein is eluted in the affinity column non-adsorbed fraction.
- the preparation and implementation of the F1025-3-1 antibody affinity column can be performed according to the method described in Example 10 in WO01Z22085.
- WO01Z72993 described in Example 2 as Example 2 and prepared F1024-1-3 antibody (as described above, No. and Ibridomas have been deposited under accession number FERM BP-7511). 55 mg was added to 20 ml of ECH-Sepharose. 4B (Amersham Biosciences) was added to the mixture, and water-soluble carbodiimide (Dohin-Danigaku Kenkyusho Co., Ltd.) was added to a final concentration of 0.1 M, and a coupling reaction was carried out at 4 ° C overnight. Next, after washing with 0.1 M sodium acetate (pH 5.0), unreacted F1024-1-3 antibody was recovered.
- the coupling efficiency was determined by measuring the absorbance at 280 nm of the antibody solution and the washing solution before the coupling reaction (converted value: 0.714 mg ZmL). As a result, the coupling efficiency of the F1024-1-3 antibody was 55%, and it was found that 1.5 mg of the F1024-1-3 antibody was bound per 1 ml of the carrier.
- Example 18 Using a dialysis membrane (Spectrum) having a molecular weight cutoff of 18 mg of the S68 antibody prepared in Example 1- (4), 0.2 M NaHCO containing 2.5 L of 0.5 M NaCl (p H8.3) was dialyzed overnight at 4 ° C as a dialysate. The dialysate was changed three times. Next, 8 mL of Equilibrated with 0.2 M NaHCO (pH 8.3) containing 0.5 M NaCl in advance
- SDS-PAGE was performed using 12.5% gel according to the method of Laemmli (Laemmli UK Cleavage of structural proteins during the assembly or the head of bacteriophage ⁇ 4. Nature. 1970 Aug 15; 227 (259): 680-5.) Performed under non-reducing conditions. That is, 1 volume of Tris-SDS-Separsol (Daiichi Pure Chemicals Co., Ltd.) was added to 2 volumes of the sample, and the mixture was heated at 100 ° C for 5 minutes. And run for 90 minutes at a constant current of 25 mA using Laemmli's discontinuous buffer system.
- Laemmli Laemmli UK Cleavage of structural proteins during the assembly or the head of bacteriophage ⁇ 4. Nature. 1970 Aug 15; 227 (259): 680-5.
- the gel was stained with a silver staining kit 2D silver staining reagent ⁇ “Daiichi” (Daiichi Pure Chemicals, Ltd.).
- a silver staining kit 2D silver staining reagent ⁇ “Daiichi” (Daiichi Pure Chemicals, Ltd.).
- Bio-Rad Bio-Rad
- the filter paper pre-soaked in the same solution was overlapped so as to prevent air bubbles from entering
- the filter paper soaked in 5% methanol Z300 mM Tris was overlapped so as to prevent air bubbles from entering.
- a positive electrode was placed thereon, and transfer was performed at 2 mA / cm 2 for 2 hours at room temperature. After the transfer was completed, the nitrocellulose membrane was immersed in Block Ace (Dainippon Pharmaceutical Co., Ltd.), and a blocking operation was performed at 37 ° C. for one hour.
- the trocellulose membrane was reacted with 10 ml of 6.8871111 antibody 1031-8-3-3 at 37 ° C for 2 hours.After washing with 0.05% Tween20ZPBS, anti-mouse IgG antibody (HRP conjugation HDAKO AZS) and 37 ° C C, reacted for 1 hour. After the reaction was completed, the nitrocellulose membrane was washed with 0.05% Tween20ZPBS. After washing away the unreacted conjugate, the conjugate was immersed in 50 ml of TMB-H (Moss. Inc.) diluted 2-fold with distilled water and emitted light at 4 ° C.
- TMB-H Moss. Inc.
- the serial column was supplied with 18 mL of sepsis patient serum at a flow rate of 0.02 mL Zmin. After washing the protein not adsorbed to the column with D-PBS (pH 7.4) containing 0.05% Tween20, the S68-Sepharose 4FF column was removed, and the protein adsorbed to the S68-Sepharose 4FF column was washed with 0.05%. Elution was carried out with 10 mM HC1 containing% Tween 20 at a flow rate of 0.2 mL Zmin, and 10 2 mL fractions were collected. Each fraction container was preliminarily charged with 200 L of 500 mM ammonium bicarbonate ammonium, and the pH of the eluate was immediately returned to neutral.
- the concentration of the soluble protein in the blood detected by the kit of Example 7- (1) in each fraction was measured, and the fraction containing the protein was pooled and freeze-dried. [0296] After the freeze-drying was completed, 0.2 mL of a 150 mM ammonium acetate solution containing 0.05% Tween 20 was dissolved in the freeze-dried powder, and the solution was centrifuged at 3,500 X g for 10 minutes. The supernatant was subjected to gel filtration using Superdex75 10Z300GL (Amersham-Biosciences).
- each fraction was measured using the kit of Example 7- (1) and a commercially available CD14-EIA kit (IBL-Hamburg).
- the soluble protein in blood detected by the kit of Example 7- (1) was observed in fractions 11 to 13 having a peak in fraction 12, and from 18 ml of serum of septic patient, 1 .: Lg Blood soluble protein was obtained. The peak of the protein was located at 29 ⁇ 5 kDa.
- BSA 67. OkDa
- Ovalbumin 43.0 kDa
- ChymotrypsinogenA 25. OkDa
- RibonucleaseA (13.7 kDa
- Example 9- (1) 20 mL of F1024-1-3-Sepharose 4 B carrier prepared in Example 9- (1) was packed in an XK column 26/20 column (Amersham-Biosciences), and D-PBS containing 0.05% Tween20 was added. (pH 7.4).
- 8 ml of S68-Sephaorse 4FF carrier prepared in Example 9- (2) was applied to an XK column 16/20 column (Amersham-Biosciences Packed in), equilibrated I spoon at Similarly containing 0. 05% T W een20 D- PBS (pH7. 4).
- the container to be separated was preliminarily added with 2 mL of 500 mM ammonium bicarbonate, and the pH of the eluate was immediately returned to neutral.
- the concentration of the soluble protein in the blood detected by the kit of Example 7- (1) in each fraction was measured, and the fraction containing the protein was pooled and freeze-dried.
- the freeze-dried powder was dissolved by adding lmL of a 150mM ammonium acetate solution containing 0.05% Tween20, and the mixture was filtered through a filter having a pore size of 0.22 ⁇ m (Mylex GV13, Millipore). — Biosciences) for gel filtration.
- a 150 mM ammonium acetate solution containing 0.05% Tween 20 as a developing solution, 0.5 mL of the sample was applied to the column, and gel filtration was performed at a flow rate of 0.8 mL Zmin.
- Example 7- (1) Each fraction was measured using the kit of Example 7- (1) and a commercially available CD14-EIA kit (IBL-Hamburg). As a result, the soluble protein in blood detected by the kit of Example 7- (1) was observed in fractions 11 to 13 having a peak in fraction 12. The peak of the protein determined in the same manner as in Example 9- (4) was located at 29 ⁇ 5 kDa.
- the blood soluble protein detected in the kit of Example 7- (1) lyophilized in Example 10- (1) was developed on an acrylamide gel by SDS-PAGE described in Example 9 (3). Thereafter, electroblotting was performed on a polyvinylidene fluoride (hereinafter, PVDF) film. That is, a filter paper immersed in a 20% methanol Z25 mM TrisZ40 mM ⁇ -aminocaproic acid solution is placed on the cathode of a platinum electrode semi-dry transfer (Viocraft Inc.) as a transfer device, and acrylamide gel after electrophoresis and PVD F The membranes (Clear Blot Membrane P (Atoichi Co., Ltd.)) were placed on top of each other.
- PVDF polyvinylidene fluoride
- the PVDF membrane after electroblotting is immersed in 0.1% Coomassie brilliant blue G250 / 10% acetic acid Z30% acetonitrile solution for about 5 minutes, and then appropriately decolorized with 10% acetic acid 30% acetonitrile solution to detect proteins. did.
- the protein band with a molecular weight of 13 ⁇ 2 kDa detected on the PVDF membrane was cut out with a clean cutter knife and transferred to a 1.7 mL microcentrifuge tube.
- the cut-out PVDF membrane fragment was washed three times with a 0.1% trifluoroacetic acid Z50% methanol solution, further washed with methanol, and completely dried.
- a protein sequencer Procise494 cLC (Applied Biosystems Japan) was used. After washing, the PVDF membrane fragment was set on the inlet tin sequencer, the necessary analysis cycle was set, and analyzed.
- Xaa may be Cys, Asn, Ser, Thr or other modified amino acids due to the properties of the protein sequencer.However, considering that it is a protein derived from the protein SCD14, it is Cys. it is conceivable that. In addition, it can be determined that Xaa is Cys in the amino acid analysis by the reduced alkylation method.
- the blood soluble protein detected by the kit of Example 7- (1) has an amino acid sequence Thr Thr Pro Glu Pro Cys Glu Leu Asp Asp Glu at the N-terminus from the first residue of CD14. On SDS-PAGE under non-reducing conditions, the protein was found to be a novel protein having a molecular weight of 13 kDa and 2 kDa. In addition, since it is detected by the kit of Example 7- (1), it is likely that the peptide specifically having 16 amino acid residues described in SEQ ID NO: 2 binds to an antibody prepared using the peptide as an antigen.
- the distribution was 008-0.100 / z g / mU, and the average value was 0.04 g / mL. In sepsis, it was distributed between 0.190 and 7.260 / z g / mL, with an average value of 2.2.0 / z g / mL.
- the soluble protein concentration was higher in septic patients than in normal individuals and patients with various diseases, and no disease showing higher values in patients with various diseases than in normal individuals was found.
- Example 11 The sample of Example 11 was measured using a commercially available CD14-EIA kit (IBL-Hamburg).
- the concentration of soluble CD14 protein in serum is from 5.6 to: L 1.2 gZmL in normal subjects, High cases were observed in patients with sepsis. However, there were many cases in which the soluble CD14 protein was high in the sera of patients with various diseases, and there was no difference from the sera of septic patients.
- Example 7 A comparative study was performed with the measured value of the soluble protein measured in Example 11. As shown in Table 6, the CD14—EIA kit for normal sales showed a maximum difference of about 1.7 times between normal, various diseases, and sepsis, whereas the measurement kit of Example 7— (1) showed normal individuals. There is no difference between the disease and various diseases, but there is a 50-fold difference between the normal person and sepsis, and the measured value of the measurement kit of Example 7- (1) is specifically increased in sepsis It became clear.
- Example X 100 was calculated, and as shown in Table 8, the kit of Example 7- (1) showed that the match rate was 94.3%, the sensitivity was 100.0%, the specificity was 93.8%, and the cutoff value was It has been clarified that setting is useful for differential diagnosis of sepsis. On the other hand, commercially available CD14-EIA did not have the specificity and usefulness to diagnose sepsis in both sensitivity and specificity. [0315] [Table 7] Table 7
- Example 10 The purpose was to express the soluble protein in blood purified in Example 10 (hereinafter, sometimes referred to as a soluble CD14 subtype or its abbreviation as low-molecular-weight sCD14-ST) as a recombinant protein. .
- rsCD14-ST a recombinant soluble CD14 fragment
- CD14 (1-65), the same applies hereinafter
- the molecule at position 106 also lacks the C-terminus (CD14 (1-105)),
- the plasmids expressing pCAG65, pCAG70, pCAG75, pCAG80, pCAG85, pCAG90, pCAG95, pCAG100, pCAG105, and pCAGllO expressing E. coli in Euyu cells were constructed in the following manner.
- Sense primer 1 (5,-TTT CCT ACA GCT CCT GGG-3,) (SEQ ID NO: 11) and antisense primer 1 (5 GG GGT ACC TTA GTC AGC ATA CTG CCG CGG GTC-3,) (SEQ ID NO: 12)
- Antisense primer 2 (5, -GG GGT ACC TTA GAG AGC CTT GAC CGT GTC AGC-3,) (SEQ ID NO: 13)
- antisense primer 3 (5, -GG GGT ACC TTA GAG CCG CCG CAC GCG GAG AGC- 3,) (SEQ ID NO: 14), antisense primer 4 (5, —GG GGT ACC TTA TGC GGC TCC CAC TGT GAG
- antisense primer 5 (5, -GG GGT ACC TTA CTG AGC AGG AAC CTG TGC GGC-3,) (SEQ ID NO: 16)
- antisense primer 6 (5, -GG GGT ACC TTA GGC GCC TAC CAG TAG CTG AGC-3,) (SEQ ID NO: 17)
- antisense primer 7 (5 GG GGT ACC TTA CGC TAG CAC ACG CAG GGC
- antisense primer 8 (5, -GG GGT ACC TTA CTT GAG GCG GGA GTA CGC TAG-3,) (SEQ ID NO: 19), antisense primer 9 (5, -GG GGT ACC TTA CTC GAG CGT CAG TTC CTT GAG-3,) (SEQ ID NO: 20) and And antisense primer 10 (5, -GG GGT ACC TTA GGT TAT CTT TAG GTC CTC GAG-3 ') (SEQ ID NO: 21) were designed.
- pCAG356 was transformed into a type I sense primer 1 and antisense primer 1, sense primer 1 and antisense primer 2, sense primer 1 and antisense primer 3, sense primer 1 and antisense primer 14, and sense primer 1 Antisense primer 5, Sense primer 1 and antisense primer 6, Sense primer 1 and antisense primer 7, Sense primer 1 and antisense primer 8, Sense primer 1 and antisense primer 9, or Sense primer 1 and antisense primer PCR was performed with each of the 10 primer sets.
- the PCR reaction conditions were heating at 90 ° C for 2 minutes, and then a cycle of ⁇ 1> 98 ° C for 10 seconds, ⁇ 2> 50 ° C for 30 seconds, and ⁇ 3> 72 ° C for 1 minute was repeated 30 times.
- pCAG356 is a plasmid in which the CD14 gene derived from the plasmid PUCH14P-4 described in W098Z39438 is inserted into pCGAAS (GENE, vol.15, p269-277 (1989)).
- rsCD14-ST having a ProScision Protease recognition sequence (8 amino acid residues of LEVLFQGP, one-letter code) inserted between Ala at position 64 and Asp at position 65 of human CD14 described in SEQ ID NO: 3 (PSP64Z356)
- Plasmid was constructed by the following method.
- Sense primer 1 (5'—TTT CCT AC A GCT CCT GGG—3,)
- Sense primer 2 (5, one GCT CTG GAA GTT
- the plasmid PCAG356 into which the soluble human CD14 structural gene sequence was inserted was subjected to PCR using type A: sense primer 1 and antisense primer 11; and B: sense primer 2 and antisense primer 12.
- the PCR reaction conditions are: A: Heat at 90 ° C for 2 minutes, then ⁇ 1> 98 ° C for 10 seconds, ⁇ 2> 50 ° C for 30 seconds, 3> 72 ° C for 1 minute 30 times, B: After heating at 90 ° C for 2 minutes, a cycle of ⁇ 1> 98 ° C for 10 seconds, ⁇ 2> 46 ° C for 30 seconds, and ⁇ 3> 72 ° C for 1 minute was repeated 30 times.
- the PCR reaction conditions were the same as in A above.
- the obtained PCR amplification product of about 0.9 kb was recovered and cut with restriction enzymes EcoRI and Xhol. This fragment was ligated with an approximately 5.2 kb fragment obtained by cutting pCAG356 with restriction enzymes EcoRI and Xhol, and E. coli JM109 was transformed according to a standard method.
- the obtained expression plasmid was designated as pCAG356 (PSP64Z356).
- pCAG356 was digested with restriction enzymes EcoRI and Kpnl, and a fragment of about 1.3 kb was recovered. This fragment is ligated with an approximately 4.4 kb fragment obtained by digesting the mammalian cell expression vector pTK-2043 having the human EF-1 ⁇ promoter with EcoRI and Kpnl, and transforming E. coli JM109 according to a standard method. Thereby, pTK356 (PSP64 / 356) was obtained.
- rsCD14-ST (2ST64Z356, and the like) having a Thrombin recognition sequence (6 amino acid residues of LVPRGS) inserted between Ala at position 64 and Asp at position 65 of human CD14 described in SEQ ID NO: 3.
- the plasmid that expresses the gene was constructed by the following method: Sense primer 3 (5, one CTG GTT CCG CGT GGT TCC GAC ACG GTC AAG-3 ') (SEQ ID NO: 25), antisense primer 13 (5, --GA A CCA CGC GGA ACC AGA GCA TAC TGC CGC-3,) (SEQ ID NO: 26), antisense primer 14 (5, — CGG GAT CCT CAA TGA TGA TGA TGA TGA TGG — 3 ′) (SEQ ID NO: 27) were designed and synthesized, and His tag (6 His Xs) was added to the C-terminus of soluble human CD14 of plasmid PCAG356.
- PCAG356-His having the structural gene sequence of the isolated molecule was subjected to PCR using A: sense primer 1 and antisense primer 13, and B: sense primer 3 and antisense primer 14.
- the PCR reaction conditions were as follows: After heating at 96 ° C for 2 minutes, a cycle of ⁇ 1> 96 ° C for 30 seconds, ⁇ 2> 55 ° C for 30 seconds, and ⁇ 3> 72 ° C for 1 minute was repeated 25 times.
- the obtained PCR amplification products A: about 0.5 kb and B: about 0.9 kb were recovered, and the mixture of these two was subjected to PCR using sense primer 1 and antisense primer 4 in the form of ⁇ .
- the PCR reaction conditions were the same as in A above.
- the obtained PCR amplification product of about 1.4 kb was recovered, inserted into a pT7-Blue (T) vector, and after confirming the nucleotide sequence, digested with restriction enzymes EcoRI and BamHI.
- the obtained 1.3 kb fragment was ligated with an approximately 4.4 kb fragment obtained by digesting pTK-2043 with EcoRI and BamHI, and transformed into E. coli JM109 according to a standard method to obtain pTK356H (TB643). ).
- Each plasmid described in (1) was transfected into COS-1 cells (ATCC: CRL-1650) using Fugene6 (Roche). That is, according to the manual, 1. LZmL of the transfection reagent and 4 / z gZmL of plasmid were mixed, added to the medium, added to COS-1 cells, and cultured at 37 ° C. After 72 hours, the culture supernatant was collected. The culture supernatant was centrifuged and then filtered through a 0.22 m filter.
- Plasmids (pTK356 (PSP64 / 356) and pTK356H (TB64)) containing the genes encoding the rsCD14-ST sequences described in (2) -1 and (2) -2 were added to COS-1 cells using Fuge ne6 ( Roche). That is, 1.7 ⁇ L ZmL of the transfection reagent and 4 ⁇ g ZmL of the plasmid were mixed according to the manual and added to the medium. Thereafter, the cells were added to COS-1 cells and cultured at 37 ° C. After 72 hours, the culture supernatant was collected, a new medium was added, and the cells were further cultured for 96 hours. After centrifugation, the culture supernatant was filtered through a 0.22 m filter and used for purification.
- Each culture supernatant produced in step 2 was purified from 5014014-3 to 3 ⁇ 647356) and 5014014-3T (2ST64Z356), cut with proteolytic enzymes, and purified from sCD14-ST. .
- Tris-SDS-Seprasol (Daiichi Pure Chemicals Co., Ltd.) is added to each fraction, and the mixture is heated at 100 ° C for 5 minutes, and then 5-20% e-PAGEL gel (Atoichi Co., Ltd.) ) And electrophoresed at 25 mA for 90 minutes under non-reducing conditions according to the method of Laemmli. After completion of the electrophoresis, the gel was stained with a silver staining kit 2D silver staining reagent ⁇ ⁇ “Daiichi” (Daiichi Pure Chemicals Co., Ltd.). The 2ST64 standard was dialyzed overnight against distilled water to obtain a final purified standard.
- the protein concentration of the final purified sample was measured according to the method described in Example 15- (3) described later.
- 452 g of rsCD14-ST (2ST64) was obtained from 1000 mL of COS-1 culture supernatant.
- the purity of the obtained purified sample was confirmed by SDS-PAGE, it was detected as a single band as shown in FIG.
- the COS-1 culture supernatant obtained in -2 was applied to a 3C10-Separose 4FF column previously equilibrated with PBS at a flow rate of 9 mL Zmin, and the non-adsorbed protein was washed with PBS, and then washed with 10 mM HC1. The adsorbed protein was eluted. The eluted fraction was added with 1Z10 volume of 500 mM ammonium bicarbonate ammonium carbonate to return the pH to neutral, and then lyophilized.
- the 3C10-Sepharose 4FF column was prepared as follows. Using a dialysis membrane with a molecular weight cut-off of 10 kDa, use the 3C10 antibody with 0.2 M NaHCO (pH 8.3) containing 2.5 L of 0.5 M NaCl.
- Dialysis was performed at 4 ° C as a dialysate. The dialysate was changed three times. Next, NHS-Activate previously equilibrated with 0.2 M NaHCO (pH 8.3) containing 0.5 M NaCl
- the carrier was washed.
- the obtained lyophilized sample was dissolved in a 50 mM Tris-HCl (pH 7) buffer containing 1 mM EDTA and 150 mM NaCl, and the protein concentration was determined by the method described in Example 15- (3) below. It measured according to. Then, PreSsion Protease (Amersham Bioscience) was added so that the enzyme: substrate ratio was 1: 3 (U: / z g), and a 4 ° C.- ⁇ cleavage reaction was performed.
- the rsCD14-ST (PSP64) preparation was dialyzed against distilled water overnight to obtain a final purified preparation.
- the protein concentration of the final purified sample was measured according to the method described in Example 15- (3) described later. By the above operation, 13,000 mL of COS-1 culture supernatant was obtained and 368 ⁇ g of PSP64 was obtained. Further, the purity of the obtained purified sample was confirmed by SDS-PAGE, and as a result, it was detected as a single band as shown in FIG.
- Example 14 Concentration measurement using the kit of Example 7- (3) To confirm whether rsC14-ST was produced in the culture supernatant prepared in Example 13- (3) -1 rsCD14-ST in each culture supernatant using the kit of Example 7- (3) The concentration was measured. Table 9 shows the results. Western blotting of each culture supernatant by the method described in Example 9- (4) showed that no band was detected. From this fact, rs C D14- ST was judged to be very small as a force actual ⁇ white amount is detected with a detectable kits with high sensitivity are produced.
- Deletion example: 1-65 is a fragment of positions 1 to 65 of SEQ ID NO: 3 (rs).
- the gel was immersed in a Tris / 40 mM ⁇ -aminocaproic acid solution and placed on a cathode electrode plate of a platinum electrode semi-dry transfer ⁇ 320 (Biocraft), and the gel was immersed in the same solution and overlapped on a filter paper so that air bubbles did not enter. Then, a trocellulose membrane (Trans-Blot Transfer-Medium, Bio-Rad) equilibrated with 5% methanol Z25mM Tris in advance was used. The gel was overlapped so that no air bubbles entered the gel. Further, the filter paper was soaked in advance in the same solution, and the filter paper was layered so as not to cause air bubbles.
- a trocellulose membrane Trans-Blot Transfer-Medium, Bio-Rad
- the filter paper soaked in 5% methanol Z300 mM Tris was stacked so that air bubbles did not enter.
- An anode electrode was placed thereon, and transfer was performed at room temperature for 2 hours at 2 mAZcm 2 .
- the nitrocellulose membrane was immersed in Block Ace (Dainippon Pharmaceutical Co., Ltd.), and a blocking operation was performed at 37 ° C. for 80 minutes.
- the -trocellulose membrane is then reacted with 6.8 / z gZml F1106-13-3 antibody, 6.gZml F1031-8-3 antibody or 6.8 g / ml S68 antibody at 37 ° C for 80 minutes.
- the trocell membrane was made of anti-mouse Igs antibody HRP conjugate (DAKO) and S68.
- the nitrocellulose membrane reacted with the antibody was reacted with an anti-Egret IgG antibody HRP conjugate (DAKO) at 37 ° C for 1 hour each.
- the nitrocellulose membrane was washed with 0.05% Tween20 / PBS. After washing away the unreacted conjugate, add 4 mL of ECL (Plus) (Amersham Bioscience), react at room temperature for 5 minutes, and overlay on HyperfilmTM ECL (Amersham Bioscience). Exposure for seconds.
- rsCD14-ST (2ST64) and rsCD14-ST (PSP64) prepared in Example 13- (3) -3 were analyzed.
- the two fragments are substantially the same as rsCD14-ST, except for the proteolytic enzyme used for cleavage, except for the final purified product.
- N-terminal amino acid sequence analysis was performed using a protein sequencer Procise494cLC (Applied Biosystems Japan). After purification of the purified rsCD14-ST (2ST64) sample, the amino acid sequence of the first residue of CD14 (TTPEPCELDDG) (SEQ ID NO: 1) was confirmed as a main component. No amino acid sequence other than CD14 was identified.
- the sample for mass spectrometry and the matrix solution were mixed at a ratio of 1: 4, and 1 ⁇ L was used for mass spectrometry.
- mass spectrometry a molecular weight peak corresponding to the theoretical molecular weight of 7663.5 of the peptide portion of rsCD14-ST (2ST64) was detected as a main peak.
- N-terminal amino acid sequence analysis it was confirmed that a molecule having a primary structure as designed (a molecule having amino acid sequence power from the 1st to 64th positions of CD14) was obtained.
- the protein concentration was measured using a BRP Atssay kit (Bio-Rad) and a BSA (Bio-Rad) standard according to the attached manual. That is, 5 mL of Dye-Reagen tl. Diluted 5 times with distilled water was added to 30 ⁇ L of a sample diluted to various magnifications with a BSA standard solution and PBS, and the mixture was allowed to stand at room temperature for 15 minutes. The absorbance at 595 nm was measured with a spectrophotometer DU-7400 (Beckman), and the calibration curve force of BSA was also measured for the protein concentration in the sample.
- Example 10- (1) As a purified sample of sCD14-ST having normal human serum ability, the freeze-dried sample obtained in Example 10- (1) was dissolved in 100 1 of distilled water.
- the concentration of rsCD14-ST (2ST64) prepared in Example 13- (3) -3 was measured using the kit of Example 7- (1) and rsCD14 (l-307) S286C standard, and the concentration per protein concentration was measured. Calculated as EIA value. That is, rsCD14-ST (2ST64) was diluted to g ⁇ gZmL with a sample diluent from the kit, and then 50 and 25 pgZmL were prepared and measured with the kit. As a result, the rsCD14 (l-307) S286C conversion value per sC D14-ST (2ST64) lpg was 352 pg, indicating that the kit was extremely reactive with rsCD14-ST (2ST64).
- rsCD14 the ability of ST to bind LPS as well as full-length CD14
- rsCD14-ST (PSP64) has the ability to bind LPS, JBC, Vol.270, No.3 (1995), pp.1382-1387, "Soluble CD14 Truncated at Amino Acid 152 Binds LPS and Enables Cellular Response to LPS" was used as a reference and examined using an endoscope kit (Seikagaku Corporation). That is, LPS (E. Coli 055: B5, DIFCO) was diluted with PBS containing 0.01% BSA (hereinafter referred to as 0.01% BSAZPBS) to prepare a 0.6 ng ZmL LPS solution.
- LPS E. Coli 055: B5, DIFCO
- PBS containing 0.01% BSA hereinafter referred to as 0.01% BSAZPBS
- rhLBP (R & D Systems) is diluted to 100 gZmL with PBS containing 0.1% HSA, mixed with the above LPS solution, and LPSZLBP solution (LPS concentration is about 0.6 ng / mL, LBP concentration is about 0. 3 nM) was prepared.
- LPSZLBP solution LPS concentration is about 0.6 ng / mL, LBP concentration is about 0. 3 nM
- rsCD14-ST PSP64
- rsCD14 l-356
- Endo-C lysate Endo-ES ES-24S set; Seikagaku Corporation
- the reaction was stopped by adding 25% acetic acid, the absorbance was measured at 405 nm, and the LPS concentration in the reaction solution (hereinafter referred to as free LPS concentration) was calculated.
- the calibration curve was prepared by performing the same operation as the above sample after reacting only the LPS diluted solution at 37 ° C for 1 hour.
- the amount of free LPS decreased in rCD14 (l-356) depending on the concentration added, and the force at which the binding of rCD14 (l-356) and LPS was confirmed rsCD14-ST (PSP64) increased to 100 nM.
- the amount of free LPS did not change even after polishing, indicating that rsCD14-ST (PSP64) had no LPS binding ability.
- a standard curve was prepared using rsCD14-ST (2ST64) prepared in Example 13- (3) -3. That is, rsCD14-ST (2ST64) was diluted with the diluent described in Example 7- (12) to prepare a concentration series of 0.06, 0.5, 1.2, 2, and 3 ng / mL.
- Example 7 Measured using the kit of (1). Diluent was used for blanks. As shown in FIG. 11, the absorbance increased in a concentration-dependent manner, confirming that rsCD14-ST (2ST64) can be used as a standard product in the kit.
- sCD14-ST in normal human serum and sCD14-ST in EDT A caroplasma were measured. The degree was about twice as high as that in serum. Since the effect of EDTA on the measurement system was considered as a cause, when EDTA was added to the diluent to a concentration of 0.2 mg / mL, the measured value of serum increased, and there was no difference from EDTA-added plasma. However, it was found that the reactivity of the standard curve prepared using the rsCD14 (1-307) S286C standard decreased, and that the reading was affected by the presence or absence of EDTA. On the other hand, when rsCD14-ST was used as the standard, the standard curve was not affected by the addition of EDTA. Thus, it was judged that rsCD14-ST was better as the standard.
- rsCD14-ST 20 ⁇ g was diluted in 500 ⁇ l of physiological saline, mixed with an equal amount of 5001 incomplete Freund's adjuvant (DIFCO), and administered subcutaneously on the back.
- DIFCO incomplete Freund's adjuvant
- ⁇ 3 ⁇ 14-3 ⁇ ( ⁇ 3 ⁇ 64) 20 / ⁇ was similarly administered.
- blood was collected from the ear vein, antiserum was separated according to a standard method, and the antibody was purified. First, ammonium sulfate was added to the antiserum to a final saturation concentration of 33%, and the mixture was stirred at 4 ° C for 1 hour, and the precipitated precipitate was centrifuged.
- the precipitate was dissolved in Dulbecco's PBS buffer (hereinafter referred to as PBS (pH 7.4)) and dialyzed overnight. After filtration, the dialysate was applied to a protein A column (Prosep A, Millipore), and the bound IgG fraction was eluted with 0.1 M glycine hydrochloride buffer (pH 3.0) to obtain a purified antibody. After dialysis with PBS (pH 7.4), the protein concentration was calculated from the absorbance at 280 nm (extinction coefficient: 0.714 mg / mL). After 0 , the resulting antibody is referred to as an anti-PSP64 polyclonal antibody or an anti-PSP64 antibody.
- PBS Dulbecco's PBS buffer
- DNP-PSP64 antigen 30 ⁇ g of DNP-PSP64 antigen was dissolved in 100 ⁇ L of saline, mixed with an equal amount of Freund's complete adjuvant (DIFCO), and administered to each hind footpad of an 8-week-old Wistar rat female by 100 L.
- DIFCO Freund's complete adjuvant
- lymphocytes were separated from the lymph nodes using a cell strainer (Falcon), mixed with myeloma cells (Sp2ZO-Agl4) in a ratio of 5: 1, and subjected to cell fusion using polyethylene glycol.
- the fused cells were Kendak in HAT medium, hybridomas were selected, and then hybridomas producing the desired antibody were screened.
- rs CD14-ST (PSP64) was directly immobilized on a plate. That is, 014-3 chops (? 3 to 64) diluted with 0.1 M phosphate buffer (pH 7.4) to an imno plate (Maxisorb, NUNC) at a ratio of 2.5 / ⁇ 111 were added to each well at a volume of 50 1 ⁇ . Add the calories and let it stand at 4 ° C overnight. Next, the plate was washed 5 times with ion-exchanged water, 100 L of PBS (pH 7.4) containing 2% StabilGuard (Surmodics) was added to each well, and the plate was allowed to stand at room temperature for 1 hour to perform blocking.
- PBS pH 7.4
- StabilGuard StabilGuard
- the obtained culture supernatant was also added to each well, and the culture was added to each well, reacted at 37 ° C for 1 hour, and washed three times with physiological saline containing 0.05% Tween20.
- 50 L of a solution obtained by diluting a peroxidase-labeled anti-rat immunoglobulin antibody (DAKO) 1000-fold with PBS (pH 7.4) containing 10% heron serum was added to each well.
- DAKO peroxidase-labeled anti-rat immunoglobulin antibody
- PBS pH 7.4
- TMB tetramethylbenzidine solution
- the absorbance at 450 nm was measured with a plate spectrophotometer (Multiscan JX, Thermo Electron), and a well containing a hybridoma producing an antibody that binds to the 2ST64 protein was selected.
- the clone was cloned by the limiting dilution method according to the selected Pell according to Tamoe Ando * Takeshi Chiba, "Introduction to Monoclonal Antibody Experimental Procedures", page 97, 1991 (Kodansha).
- screening was similarly performed using the reactivity to the 2ST64 protein as an index, and six types of hybridomas were selected.
- the antibody was purified.
- the subtypes of the purified F1237-3-4 antibody and F1237-4-4 antibody were determined by a rat typing kit (ZYMED), and the subtypes were rat IgG2a- ⁇ and rat HgG2b, ⁇ , respectively.
- rs CD14-ST prepared in Example 13- (3) 3 was used. ⁇ Immunize the heron. That is, after diluting 20 ⁇ g of rsCD14-ST (PSP64) in 500 ⁇ l of physiological saline and mixing with 500 ⁇ l of Freund's complete adjuvant (DIFCO) in an equal amount, New Zealand White Egret (Kitayama Labes) female 2.0 —2. Inject 4 kg under the back skin.
- DIFCO Freund's complete adjuvant
- rsCD14-ST 20 ⁇ g of rsCD14-ST (PSP64) is diluted in 500 ⁇ l of physiological saline, mixed with an equal volume of 5001 incomplete Freund's adjuvant (DIFCO), and administered subcutaneously on the back.
- DIFCO incomplete Freund's adjuvant
- rsCD14- 3 ⁇ 20 / zeta 8
- the precipitate is dissolved in Dulbecco-phosphate buffer (hereinafter referred to as PBS (pH 7.4)) and dialyzed overnight. After filtration, the dialysate is applied to a protein A column (Prosep A, Millipore), and the bound IgG fraction is eluted with 0.1 M glycine hydrochloride buffer (PH 3.0) to obtain a purified antibody.
- PBS Dulbecco-phosphate buffer
- PH 3.0 0.1 M glycine hydrochloride buffer
- the obtained purified anti-PSP64 polyclonal antibody was prepared using the high molecular weight CD14 prepared in Example 22 or Specific purification is carried out using the rsCD14 (1-356) -bound resin prepared in Example 6 to obtain an antibody that binds only to rsCD14-ST. That is, 5 mg of high molecular weight CD14 or rsCD14 (1-356) is bound to HiTrap NHS-activated HP Columns (Amersham Bioscience) according to a manual to prepare an affinity column for specific purification.
- the antibody purified by the protein A column is applied to a specific purification affinity column, and an antibody that does not bind to high molecular weight CD14 or rsCD14 (1-356) is recovered.
- the obtained antibody is concentrated, dialyzed against PBS (pH 7.4), and the protein concentration is calculated from the absorbance at 280 nm (extinction coefficient: 0. 714 mgZmL;).
- DNP-PSP64 antigen Dissolve 30 ⁇ g of DNP-PSP64 antigen in 100 ⁇ L of saline, mix in equal volume with Freund's complete adjuvant (DIFCO), and add 100 ⁇ L to each hind footpad of an 8-week-old female Wistar rat or ddY mouse Administer each. Two weeks later, iliac lymph nodes are removed and cell fusion is performed. Cell fusion is carried out according to Tamagawa Ando and Takeshi Chiba, “Introduction to Monoclonal Antibody Experimental Procedures,” p. 83, 1991 (Kodansha).
- lymphocytes are separated from the lymph nodes using a cell strainer (Falcon), mixed with myeloma cells (Sp2ZO-Agl4) at 5: 1, and cell fusion is performed using polyethylene glycol. After fusing the fused cells in a HAT medium, selecting the hybridoma, screening the hybridoma producing the desired antibody.
- Falcon cell strainer
- Sp2ZO-Agl4 myeloma cells
- the screening uses an ELISA method in which rsCD14-ST (PSP64), high molecular weight CD14 or rsCD14 (1-356) is directly immobilized on a plate. That is, 50 l of rsCD14-ST (PSP64), high molecular weight CD14 or rsCD14 (l-356) diluted to 2.5 ⁇ g ZmL with PBS (pH 7.4) was added to each well of an immunoplate (Maxisorb NUNC). Cultivate and leave at 4 ° C overnight.
- PBS pH 7.4
- SCD14-ST was measured as the sandwich-labeled antibody described in Example 22 from among the monoclonal antibodies against rsCD14-ST prepared in Example 17- (4), and it had the ability to increase in sepsis patients. After selecting the antibody, measure SCD14-ST in the sample. Measure both the cryopreserved sample and the sample stored at room temperature for 24 hours, and select a combination of antibodies with a small difference in the measured values.
- Example 17- (1) The reactivity of the anti-PSP64 polyclonal antibody prepared in Example 17- (1) was confirmed.
- RsCD14-ST (PSP64) was immobilized in the same manner as in Example 17- (2).
- Example 17-The antiserum containing the anti-PSP64 polyclonal antibody prepared in (1) and the normal mouse serum as a control were diluted 500-fold with PBS (pH 7.4), and then diluted twice to prepare a dilution series up to 32,000-fold. did. Each diluted solution was added to the blocking well, reacted at 37 ° C. for 1 hour, and washed three times with a physiological saline solution containing 0.05% Tween20.
- rsCD14-ST (PSP64) was administered.
- the absorbance of the rabbits increased in a dilution factor-dependent manner, whereas that of the normal rabbits did not, indicating the production of rsCD14-ST (PSP64) protein-specific antibodies.
- the S68 peptide polyclonal antibody was diluted to gZmL with D-PBS (pH 7.4), and 50 ⁇ L was added to each well of an immunoplate (Maxisorb, NUNC). After the reaction at 4 ° C, wash with ion-exchanged water 5 times, and add 100 ⁇ L D-PBS containing 0.1% StabilGuard (SurModics, Inc) and 0.1% Tween20 to each well. And blocked. Next, 76 mM PBS (pH 7.4) containing 1% CD14-absorbed serum and 0.1% BSA was used as a diluent at 0, 0.031, 0.063, 0.125, 0.25, 0.5, and 1.
- a 2 ng ZmL rsCD14-ST (2ST64) protein standard dilution series was prepared. A standard dilution series was added at 50 L per well and reacted at 37 ° C for 2 hours. After completion of the reaction, and washed 3 times with physiological saline containing 0. 05% T W een20, and 50 mu L added pressure to l% ⁇ shea calf serum ZHybridoma- SFM solution containing F 1237- 3-4 antibody.
- Example 11 The difference in the concentration between the standard product and the reference product is as shown in Example 16.
- reaction rate constants of the F1237-3-4 antibody prepared in Example 17- (2) and the 3C10 antibody (ATCC TIB228), which is an anti-CD14 antibody, were prayed using Biacore3000 (Biacore).
- Biacore3000 Biacore3000
- rsCD14-ST (2ST64) and rsCD14 (l-356) were separately fixed to a sensor chip CM5 (Biacore) using an amine coupling kit (Biacore).
- the measurement was performed by using HBS-EP (Biacore) as a running buffer, and injecting a dilution series (1.25 nM to 640 nM, the concentration of which was changed depending on the antibody) of each antibody into the flow cell.
- the reactivity of the F1237-3-4 antibody prepared in Example 17- (2) and the 3C10 antibody, which is an anti-CD14 antibody, with high molecular weight CD14 is measured using an antigen solid phase EIA system. That is, 50 ⁇ L of high molecular weight CD14 diluted to 2.5 ⁇ g ZmL with D-PBS (pH 7.4) was prepared in an immunoplate (Maxisorb, NUNC) in the same manner as in Example 13- (2). Add and leave at 4 ° C overnight. Next, wash the plate 5 times with ion-exchanged water, add 100 L of PBS (pH 7.4) containing 2% StabilGuard (Surmodics) to each well, and allow to stand at room temperature for 1 hour to perform blocking.
- PBS pH 7.4
- StabilGuard StabilGuard
- F1237- 3-4 antibody, 3C10 antibody Dilute to gZmL with PBS (pH 7.4), add to each well, react at 37 ° C for 1 hour, and add 0.05% Tween20. Wash 3 times with saline. Next, 50 L of a solution obtained by diluting a peroxidase-labeled anti-immunoglobulin antibody (DAKO) for each antibody 1000-fold with PBS (pH 7.4) containing 10% serum was added to each well. After reacting at 37 ° C for 1 hour, wash 5 times in the same manner, and add tetramethylbenzidine solution (TMB, BioFix) to each well. After reacting at room temperature for 10 minutes, stop the reaction with 0.5M sulfuric acid solution.
- DAKO peroxidase-labeled anti-immunoglobulin antibody
- the absorbance at 450 nm is measured with a plate spectrophotometer (Multiscan JX, Thermo Electron). As a result, it was confirmed that 3C10 binds strongly to high molecular weight CD14, whereas F1237-3-4 antibody does not substantially bind. Recognized.
- TMB solution BioFix
- Add TMB solution BioFix
- add color stop the reaction with 0.5M aqueous sulfuric acid, and measure the absorbance at 450 nm. Since the absorbance decreases depending on the sCD14-ST concentration in the blood, the measured value reflects the amount of sCD14-ST in the blood, and the sCD14 ST concentration is lower in normal subjects but higher in sepsis patients it can.
- Labels include other enzymes, radioactive compounds, fluorescent materials, chemiluminescent materials, colloidal gold, Dyes and latexes can be used.
- Example 23 A method for screening an antibody for measuring the soluble protein in blood
- an antibody that binds to a peptide having 6 to 20 consecutive amino acid residues selected from the amino acid sequence of SEQ ID NO: 3 is prepared according to the description in Example 1. It can also be prepared as follows. ⁇ 1> A peptide is synthesized by a standard method based on the full-length sequence of CD14, and an immunizing antigen is prepared to prepare an antibody. 2> Purify the purified soluble CD14 antigen in serum and use this as an immunogen to produce antibodies. 3> Prepare recombinant CD14 protein using COS cells and E. coli, and use this as an immunogen to produce antibodies. 4) Prepare various CD14 antigens by heat denaturation or DNP conversion, etc., and use them as immunogens to produce antibodies.
- the P001 antibody an antibody prepared using the peptide having the amino acid residue represented by SEQ ID NO: 4 as an antigen
- the P002 antibody the antibody prepared using the peptide having the amino acid residue represented by SEQ ID NO: 5 as an antigen
- the S68 antibody prepared in Example 1- (4), the F1146-17-2 antibody prepared in Example 2, the F1031-8-3 antibody prepared in Example 3 (2) [2], the Example 3- (2)
- the F1106-13-3 antibody prepared in [1], the F1237-3-4 antibody prepared in Example 17- (2), and the anti-PSP64 antibody prepared in Example 17- (1) were also used.
- a cleaning sample was prepared.
- An antibody screening method for measuring the soluble protein in blood characterized by utilizing the difference in the reactivity of a normal human-derived high molecular weight CD14 protein with an antibody.
- an antibody that does not bind to high molecular weight CD14 present in normal human serum but binds to the soluble protein in blood is screened.
- a high molecular weight CD14 protein was prepared as follows. Human serum (Nihon Biotest) was added to a 3C10 antibody-bound resin column (5 mL), washed with PBS, and eluted with a 6M urea aqueous solution. The eluate was dialyzed against PBS, freeze-dried, and subsequently fractionated on a gel filtration column (Superdex 75 10 / 300GL, Amersham Bioscience). Each of the obtained fractions was assayed with a commercially available soluble CD14 protein measurement kit (IBL-kit), and high-molecular-weight CD14 fractions reacting with the IBL kit were pooled and freeze-dried. The lyophilized product was dissolved and measured again with the IBL-kit to calculate the concentration.
- IBL-kit commercially available soluble CD14 protein measurement kit
- Antigen solid phase EIA was performed as follows. First, high molecular weight CD14 was allowed to stand on a plate at 2.5 / z gZmL at 4 ° C for binding. Next, blocking was performed with 2% StabilGuardZPBS (pH 7.4), each antibody was diluted with 1 ⁇ g ZmL in PBS, and added to a well on which each antigen was immobilized. After reacting at 37 ° C for 1 hour, wash three times with physiological saline containing 0.05% Tween20, and then add peroxidase-labeled anti- ⁇ globulin antibody (Dako) for each antibody to 10% ⁇ sir serum and PBS containing 0.05% Tween20.
- Dako peroxidase-labeled anti- ⁇ globulin antibody
- the antibody can be selected without binding to sCD14-ST.
- dot blotting is performed as follows. First, spot the high molecular weight CD14 on Trans-BlotTransfer Medium (Bio-Rad) at about 400ngZ dots and dry. Next, block with 100% Block Ace (Yuki Brand Milk Products). Two types of immobilized CD14 and various anti-CD14 antibodies diluted with PBS (pH 7.4) containing 10% Block Ace and 0.05% Tween 20 are reacted at room temperature for 1 hour. Then, add 5% with PBS (pH 7.4) containing 0.05% Tween20.
- This is a method for screening an antibody for measuring the soluble protein in the blood, characterized by utilizing the difference between the amounts detected in normal human serum and septic patient serum.
- a sandwich ELISA system is prepared by combining two types of anti-CD14 antibodies, and a normal person and a patient with sepsis are measured.
- the antibody prepared in 12- (1) was used to prepare a peroxidase-labeled antibody according to the description in Example 3- (3).
- Each antibody to be screened was diluted to g / mL with D-PBS (pH 7.4), and then added to each well of an immunoplate (Maxisorb, NUNC) in a volume of 50 ⁇ L. After the reaction at 4 ° C., the plate was washed 5 times with ion-exchanged water, and D-PBS containing 2% StabilGuard (SurModics, Inc.) was added to each well with 100 / z L, and blocked. Next, use 0, 3.12, 6.25, 12.5, 25, 50, 100, and 200 ng ZmL of CD14 (1-307) S286C in PBS containing 0.1% BSA (pH 7.4) as a diluent.
- a protein standard dilution series and a 10-fold diluted sample were prepared. Add 50 L of the standard dilution series and diluted sample per well, incubate at 37 ° C for 1 hour, and after the reaction is completed, wash three times with 0.05% Tween20-containing saline, and add 2% rat serum, Peroxidase-labeled antibody diluted to 1 g / mL with PBS (pH 7.4) containing 1% mouse serum and 0.1% Tween 20 was added to each well at 50 / zL. After reacting at 37 ° C for 1 hour, the plate was washed 5 times in the same manner, and a tetramethylbenzidine solution (TMB, BioFix) was added to each well.
- TMB tetramethylbenzidine solution
- a screening was performed on the combinations which can prepare a standard curve in this system, in terms of their ability to specifically detect the soluble protein in blood.
- the sera of two patients with sepsis and two normal patients should be measured using the measurement system created in [1], and a combination of antibodies in the measurement system that shows a low value for normal people and a high value for sepsis patients should be selected.
- a combination of antibodies that specifically detect sepsis patients was screened.
- the combinations of the antibodies described in Examples 7- (1) to (8) and Example 22 were selected.
- the measurement value of the high molecular weight CD14 of each serum may be obtained in advance using the IBL-kit, and a combination of antibodies in a measurement system in which the high molecular weight CD14 is not measured may be selected.
- Example 17- (2) As a method for screening for an antibody that specifically detects sCD14-ST, the antibody screening method described in Example 17- (2), ie, rsCD14-ST (PSP64) is directly immobilized on a plate This was performed by using an ELISA method.
- Table 13 shows the screening results of various antibodies.
- MY4 Coulter
- MEM18 Monosan
- 61D3 Southern Biotechnology Associate
- various ⁇ -globulins were commercially available.
- Example 23- (2) As a method for screening for an antibody that specifically detects SCD14-ST, the sandwich EIA system described in Example 23- (2) was prepared. In other words, various antibodies to be screened are immobilized on a plate, and sandwiched with rsCD14-ST (PSP64) as an antigen and peroxidase-labeled F1106-13-1-3 antibody or peroxidase-labeled F1031-8-3 antibody This was performed by using an ELISA method. [0376] Table 14 shows the screening results of various antibodies. As the AntiHCG antibody, a commercial product was used.
- sCD14 (1-70) A soluble polypeptide having the N-terminal 1-70 amino acids of human CD14 (hereinafter referred to as sCD14 (1-70)) was chemically synthesized.
- THP-1 cells stimulated with vitamin D3 are suspended in RPMI1640 medium containing 0.1% BSA to a final concentration of numan leukocyte elastase (Elastin Products Company, Inc.) of 1 ⁇ .
- the reaction mixture was added to prepare a final reaction volume of 200 ⁇ L.
- phenylmethylsulfonyl fluoride was added to stop the enzymatic reaction.
- the supernatant of each reaction solution was recovered, and SCD14-ST contained in the supernatant was measured using the kit of Example 7- (1).
- the sCD14-ST concentration increased 3 minutes after elastase addition, and then decreased gradually.
- a novel antigen having the sequence of CD14 present in human blood is provided. Further, a method for diagnosing sepsis or detecting sepsis by measuring the antigen is provided.
- a recombinant soluble fragment having an immunological function similar to that of the antigen is provided.
- a method for producing the recombinant soluble fragment is provided.
- novel antibodies that bind to the fragments are also provided.
- ⁇ an antibody that binds to a peptide having a specific amino acid sequence of human full-length soluble CD14 protein '' ⁇ an antibody prepared using a peptide having a specific amino acid sequence of human full-length soluble CD14 as an antigen '' or A kit and a method for measuring the antigen, which comprise "an antibody that binds to the fragment" or a fragment of the antibody as a component, are provided.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006513045A JP4040666B2 (ja) | 2004-05-11 | 2005-05-11 | 新規可溶性cd14抗原 |
EP05739312A EP1746104B1 (en) | 2004-05-11 | 2005-05-11 | Novel soluble cd14 antigen |
ES05739312T ES2406266T3 (es) | 2004-05-11 | 2005-05-11 | Antígeno CD14 soluble novedoso |
CA2566101A CA2566101C (en) | 2004-05-11 | 2005-05-11 | Novel soluble cd14 antigen |
CN200580019866.6A CN1968962B (zh) | 2004-05-11 | 2005-05-11 | 新型可溶性cd14抗原 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004141600 | 2004-05-11 | ||
JP2004-141600 | 2004-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005108429A1 true WO2005108429A1 (ja) | 2005-11-17 |
Family
ID=35320183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/008635 WO2005108429A1 (ja) | 2004-05-11 | 2005-05-11 | 新規可溶性cd14抗原 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1746104B1 (ja) |
JP (2) | JP4040666B2 (ja) |
CN (1) | CN1968962B (ja) |
CA (1) | CA2566101C (ja) |
ES (1) | ES2406266T3 (ja) |
WO (1) | WO2005108429A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009142303A1 (ja) | 2008-05-23 | 2009-11-26 | 持田製薬株式会社 | 食細胞の機能評価方法 |
WO2012093681A1 (ja) * | 2011-01-06 | 2012-07-12 | 持田製薬株式会社 | 敗血症治療薬を投与する患者を選択する方法 |
WO2012157751A1 (ja) | 2011-05-19 | 2012-11-22 | 持田製薬株式会社 | 尿検体を用いた呼吸器感染症の診断 |
WO2012157750A1 (ja) | 2011-05-19 | 2012-11-22 | 持田製薬株式会社 | 血液検体を用いた呼吸器感染症の診断 |
WO2014104305A1 (ja) * | 2012-12-28 | 2014-07-03 | 持田製薬株式会社 | プレセプシン測定による炎症性腸疾患の診断 |
JP2016060743A (ja) * | 2014-09-17 | 2016-04-25 | 大韓民国 国立水産科学院Republic Of Korea(National Fisheries Research And Development Institute) | 日本ウナギの一本鎖の卵胞刺激ホルモンポリペプチド、これに対する抗体及びこれらの用途 |
JP2016085198A (ja) * | 2014-10-29 | 2016-05-19 | 持田製薬株式会社 | プレセプシン測定による血球貪食症候群の検出 |
KR20170002367A (ko) | 2014-02-26 | 2017-01-06 | 모찌다 세이야쿠 가부시끼가이샤 | 신규 항프레세프신 항체 |
WO2017033281A1 (ja) * | 2015-08-25 | 2017-03-02 | 持田製薬株式会社 | 特異的に精製された抗プレセプシン抗体 |
WO2019167935A1 (ja) * | 2018-02-27 | 2019-09-06 | 持田製薬株式会社 | プレセプシン測定に有用な抗cd14抗体の使用 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120309025A1 (en) | 2010-01-29 | 2012-12-06 | Mochida Pharmaceutical Co., Ltd | METHOD OF ANALYZING HUMAN sCD14-ST |
KR20180118822A (ko) * | 2011-01-11 | 2018-10-31 | 가부시키가이샤 엘에스아이 메디엔스 | 패혈증 예후의 예측 방법 |
ES2578160T3 (es) * | 2011-08-12 | 2016-07-21 | Lsi Medience Corporation | Procedimiento de diagnóstico de infecciones de sitio quirúrgico |
US9910052B2 (en) | 2012-05-07 | 2018-03-06 | Lsi Medience Corporation | Method of diagnosing and treating infectious disseminated intravascular coagulation |
JP6474730B2 (ja) * | 2012-12-28 | 2019-03-06 | 株式会社Lsiメディエンス | sCD14−STの、心血管疾患若しくは状態又はアテローム性動脈硬化症のマーカーとしての使用 |
AU2019264996A1 (en) * | 2018-05-10 | 2020-11-26 | The Methodist Hospital | Methods for prognosis and management of disease |
WO2021097685A1 (zh) * | 2019-11-19 | 2021-05-27 | 深圳迈瑞生物医疗电子股份有限公司 | 混合检测PCT和Presepsin的试剂盒、方法以及应用 |
CN117836629A (zh) | 2021-06-30 | 2024-04-05 | 普和希株式会社 | 用于检测肾小管间质损伤的生物标志物及其用途 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996020956A1 (en) | 1994-12-30 | 1996-07-11 | Amgen Inc. | Anti-inflammatory cd14 peptides |
WO1996020957A1 (en) * | 1994-12-30 | 1996-07-11 | Amgen Inc. | Anti-inflammatory cd14 polypeptides |
WO1998039438A1 (fr) | 1997-03-07 | 1998-09-11 | Mochida Pharmaceutical Co., Ltd. | Composes antisens diriges contre cd14 |
WO2001022085A1 (fr) | 1999-09-17 | 2001-03-29 | Mochida Pharmaceutical Co., Ltd. | Procede de mesure fractionnel de proteine de cd14 soluble |
WO2001072993A1 (fr) | 2000-03-31 | 2001-10-04 | Mochida Pharmaceutical Co., Ltd. | Inhibiteur de liaison entre le recepteur de type toll et cd14 |
US20030114377A1 (en) * | 1998-11-18 | 2003-06-19 | Kirkland Theo N. | Inhibition therapy for septic shock with mutant CD14 |
WO2004044005A1 (ja) | 2002-11-12 | 2004-05-27 | Mochida Pharmaceutical Co., Ltd. | ヒト低分子量cd14測定キットおよび抗体 |
JP2005106694A (ja) * | 2003-09-30 | 2005-04-21 | Mochida Pharmaceut Co Ltd | 敗血症早期検出及び重篤度評価 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID26730A (id) * | 1998-05-27 | 2001-02-01 | Gemma Biotechnology Ltd | Induksi protein-protein dan peptida-peptida antibiotik oleh lait/scd14-protein |
-
2005
- 2005-05-11 CA CA2566101A patent/CA2566101C/en active Active
- 2005-05-11 EP EP05739312A patent/EP1746104B1/en active Active
- 2005-05-11 JP JP2006513045A patent/JP4040666B2/ja active Active
- 2005-05-11 ES ES05739312T patent/ES2406266T3/es active Active
- 2005-05-11 WO PCT/JP2005/008635 patent/WO2005108429A1/ja active Application Filing
- 2005-05-11 CN CN200580019866.6A patent/CN1968962B/zh active Active
-
2007
- 2007-08-06 JP JP2007204668A patent/JP4768685B2/ja active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996020956A1 (en) | 1994-12-30 | 1996-07-11 | Amgen Inc. | Anti-inflammatory cd14 peptides |
WO1996020957A1 (en) * | 1994-12-30 | 1996-07-11 | Amgen Inc. | Anti-inflammatory cd14 polypeptides |
WO1998039438A1 (fr) | 1997-03-07 | 1998-09-11 | Mochida Pharmaceutical Co., Ltd. | Composes antisens diriges contre cd14 |
US20030114377A1 (en) * | 1998-11-18 | 2003-06-19 | Kirkland Theo N. | Inhibition therapy for septic shock with mutant CD14 |
WO2001022085A1 (fr) | 1999-09-17 | 2001-03-29 | Mochida Pharmaceutical Co., Ltd. | Procede de mesure fractionnel de proteine de cd14 soluble |
WO2001072993A1 (fr) | 2000-03-31 | 2001-10-04 | Mochida Pharmaceutical Co., Ltd. | Inhibiteur de liaison entre le recepteur de type toll et cd14 |
WO2004044005A1 (ja) | 2002-11-12 | 2004-05-27 | Mochida Pharmaceutical Co., Ltd. | ヒト低分子量cd14測定キットおよび抗体 |
JP2005106694A (ja) * | 2003-09-30 | 2005-04-21 | Mochida Pharmaceut Co Ltd | 敗血症早期検出及び重篤度評価 |
Non-Patent Citations (14)
Title |
---|
"Introduction to Monoclonal Antibody Experimental Manipulation", 1991, KODANSHA LTD., pages: 97 |
"New Protocols of Cytoengineering Experiments", SHUJUN-SHA |
"Polymerase Chain Reaction, PCR Protocols, A Guide to Methods and Applications", 1990, ACADEMIC PRESS |
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 80, 1996, pages 307 - 310 |
EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 236, 1996, pages 457 - 464 |
EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 25, 1995, pages 604 - 610 |
GENE, vol. 15, 1989, pages 269 - 277 |
MILSTEIN, METHODS IN ENZYMOL., vol. 73, pages 3 |
NATURE, vol. 227, no. 259, 15 August 1970 (1970-08-15), pages 680 - 5 |
RINSHOKENSA, vol. 38, 1994, pages 341 - 344 |
See also references of EP1746104A4 * |
TAMIE ANDO; TAKESHI CHIBA: "Introduction to Monoclonal Antibody Experimental Manipulation", 1991, KODANSHA LTD., pages: 83 |
TAMIE ANDO; TAKESHI CHIBA: "Introduction to Monoclonal Antibody Experimental Manipulation", 1991, KODANSHA LTD., pages: 97 |
THOMAS, E. ET AL., J. MOLECULAR BIOLOGY, vol. 87, 1974, pages 563 - 577 |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10852302B2 (en) | 2008-05-23 | 2020-12-01 | Mochida Pharmaceutical Co., Ltd. | Method for evaluation of function of phagocyte |
US9476872B2 (en) | 2008-05-23 | 2016-10-25 | Mochida Pharmaceutical Co., Ltd | Method for evaluation of function of phagocyte |
WO2009142303A1 (ja) | 2008-05-23 | 2009-11-26 | 持田製薬株式会社 | 食細胞の機能評価方法 |
JP5435587B2 (ja) * | 2008-05-23 | 2014-03-05 | 持田製薬株式会社 | 食細胞の機能評価方法 |
JP2014052387A (ja) * | 2008-05-23 | 2014-03-20 | Mochida Pharmaceut Co Ltd | 食細胞の機能評価方法 |
WO2012093681A1 (ja) * | 2011-01-06 | 2012-07-12 | 持田製薬株式会社 | 敗血症治療薬を投与する患者を選択する方法 |
JPWO2012093681A1 (ja) * | 2011-01-06 | 2014-06-09 | 持田製薬株式会社 | 敗血症治療薬を投与する患者を選択する方法 |
WO2012157750A1 (ja) | 2011-05-19 | 2012-11-22 | 持田製薬株式会社 | 血液検体を用いた呼吸器感染症の診断 |
US9291631B2 (en) | 2011-05-19 | 2016-03-22 | Mochida Pharmaceutical Co., Ltd. | Diagnosis of respiratory tract infectious disease using blood specimens |
US9297802B2 (en) | 2011-05-19 | 2016-03-29 | Mochida Pharmaceutical Co., Ltd. | Diagnosis of respiratory tract infectious diseases using urine specimens |
US10054585B2 (en) | 2011-05-19 | 2018-08-21 | Mochida Pharmaceutical Co., Ltd. | Diagnosis of respiratory tract infectious disease using urine specimens |
US10024869B2 (en) | 2011-05-19 | 2018-07-17 | Mochida Pharmaceutical Co., Ltd. | Diagnosis of respiratory tract infectious disease using blood specimens |
WO2012157751A1 (ja) | 2011-05-19 | 2012-11-22 | 持田製薬株式会社 | 尿検体を用いた呼吸器感染症の診断 |
JPWO2014104305A1 (ja) * | 2012-12-28 | 2017-01-19 | 持田製薬株式会社 | プレセプシン測定による炎症性腸疾患の診断 |
WO2014104305A1 (ja) * | 2012-12-28 | 2014-07-03 | 持田製薬株式会社 | プレセプシン測定による炎症性腸疾患の診断 |
EP3628731A1 (en) | 2014-02-26 | 2020-04-01 | Mochida Pharmaceutical Co., Ltd. | Novel anti-presepsin antibody |
US11685788B2 (en) | 2014-02-26 | 2023-06-27 | Mochida Pharmaceutical Co., Ltd. | Anti-presepsin antibody |
US9951142B2 (en) | 2014-02-26 | 2018-04-24 | Mochida Pharmaceutical Co., Ltd. | Anti-presepsin antibody |
KR20170002367A (ko) | 2014-02-26 | 2017-01-06 | 모찌다 세이야쿠 가부시끼가이샤 | 신규 항프레세프신 항체 |
US10676532B2 (en) | 2014-02-26 | 2020-06-09 | Mochida Pharmaceutical Co., Ltd. | Anti-presepsin antibody |
JP2016060743A (ja) * | 2014-09-17 | 2016-04-25 | 大韓民国 国立水産科学院Republic Of Korea(National Fisheries Research And Development Institute) | 日本ウナギの一本鎖の卵胞刺激ホルモンポリペプチド、これに対する抗体及びこれらの用途 |
JP2016085198A (ja) * | 2014-10-29 | 2016-05-19 | 持田製薬株式会社 | プレセプシン測定による血球貪食症候群の検出 |
JPWO2017033281A1 (ja) * | 2015-08-25 | 2018-06-28 | 持田製薬株式会社 | 特異的に精製された抗プレセプシン抗体 |
EP3342861A4 (en) * | 2015-08-25 | 2019-04-10 | Mochida Pharmaceutical Co., Ltd. | SPECIFICALLY PURIFIED ANTI-PRESEPSIN ANTIBODIES |
US20180237537A1 (en) | 2015-08-25 | 2018-08-23 | Mochida Pharmaceutical Co., Ltd. | Specifically purified anti-presepsin antibody |
US11117974B2 (en) | 2015-08-25 | 2021-09-14 | Mochida Pharmaceutical Co., Ltd. | Specifically purified anti-presepsin antibody |
WO2017033281A1 (ja) * | 2015-08-25 | 2017-03-02 | 持田製薬株式会社 | 特異的に精製された抗プレセプシン抗体 |
WO2019167935A1 (ja) * | 2018-02-27 | 2019-09-06 | 持田製薬株式会社 | プレセプシン測定に有用な抗cd14抗体の使用 |
Also Published As
Publication number | Publication date |
---|---|
JP2008031172A (ja) | 2008-02-14 |
EP1746104A4 (en) | 2008-01-09 |
ES2406266T3 (es) | 2013-06-06 |
JP4768685B2 (ja) | 2011-09-07 |
JP4040666B2 (ja) | 2008-01-30 |
CA2566101A1 (en) | 2005-11-17 |
EP1746104A1 (en) | 2007-01-24 |
EP1746104B1 (en) | 2013-03-20 |
CN1968962A (zh) | 2007-05-23 |
JPWO2005108429A1 (ja) | 2008-04-17 |
CA2566101C (en) | 2013-05-21 |
CN1968962B (zh) | 2013-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005108429A1 (ja) | 新規可溶性cd14抗原 | |
US7608684B2 (en) | Soluble CD14 antigen | |
US7901900B2 (en) | Assay kit and antibody for human low molecular weight CD14 | |
WO2008007804A1 (fr) | ANTICORPS ANTI-INTÉGRINE α-9 HUMAINE ET UTILISATION DE CELUI-CI | |
EP1275713A1 (en) | Tlr/cd14 binding inhibitor | |
KR102360851B1 (ko) | 신규 항프레세프신 항체 | |
WO1999032520A1 (fr) | Dosage de ldl denaturees | |
US20040092712A1 (en) | Tlr/cd14 binding inhibitor | |
US6916628B1 (en) | Method for the measurement of soluble CD14 proteins separately | |
US20160151405A1 (en) | Pappalysin Regulator | |
EP1439223A1 (en) | Novel class ii cytokine receptor | |
JP4059404B2 (ja) | 甲状腺機能を刺激する活性を持つ抗体 | |
AU755574B2 (en) | Synthetic peptide immunogens and antibodies thereto | |
JP2010536715A (ja) | Nesfatin−1特異的抗体およびその用途、ならびにNesfatin特異的抗体およびその用途 | |
JPH06189786A (ja) | 抗オキシトシン受容体抗体およびその製法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006513045 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2566101 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005739312 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580019866.6 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005739312 Country of ref document: EP |